Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 2 of 164 Sponsor Declarations  
 
This confidential d ocument is the property of Symphogen A/S. No unpublished information 
contained herein may be passed on, reproduced, published or used without prior written approval 
from Symphogen A/S. Access to this document must be restricted to relevant parties.  
 
The tr ial will be conducted in compliance with this clinical trial protocol, International Council 
for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use 
E6(R2): Guideline for Good Clinical Practice (GCP) (EMA/CHMP/ICH/135/1995), the  
Declaration of Helsinki, and applicable regulations.  
 
The Sponsor has appointed a Coordinating Investigator for the trial. This Coordinating 
Investigator will provide input to the trial design and act as overall coordinator for Investigators 
across all si tes. The Coordinating Investigator will furthermore sign off the Clinical Trial Report 
on behalf of all Investigators.  
 
Lists of Investigators responsible for conducting the trial, medically qualified physicians 
responsible for all site -related medical dec isions (if other than the Investigators), monitors, 
clinical laboratories, and other medical and/or technical departments and/or institutions involved 
in the trial are provided as separate documents . 
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 3 of 164 Principal Investigator  Signature Page  
 
I, the undersig ned, am responsible for the conduct of the trial at this site and agree : 
 To assume responsibility for the proper conduct of the clinical trial at this Investigational 
Site. 
 Not to implement any changes to the clinical trial protocol without agreement from the 
Sponsor and prior review and written approval from the appropriate Healthy  Authority (as 
indicated) and the Institutional Review Board/ Ethics Committee, except where necessary to 
eliminate an immediate hazard to the patients . 
 That I am aware of, and wi ll comply with “Good Clinical Practice” (ICH E6(R2)  GCP ) 
(EMA/ CHMP/ICH/135/ 1995), the Declaration of Helsinki,  and all applicable regulatory 
requirements . 
 That all site staff to which I have delegated tasks for this clinical trial are appropriately 
selecte d and adequately informed about the investigational product(s) and of their trial -
related duties and functions as described in the clinical trial protocol . 
 
________________________________   ____________________  
Signature       Date of Signature  
 
 
Name : ________________________________________  
 
 
Academic Degree : ______________________________  
 
 
Function: _____________________________________  
 
 
Institution : ____________________________________  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 4 of 164 TABLE OF CONTENTS  
1. SYNOPSIS  ................................ ................................ ................................ .............................. 9 
2. LIST OF ABBREVIATIONS AND EXPANDED TERMS  ................................ ................ 19 
3. BACKGROUND AND RATIONALE  ................................ ................................ ................. 23 
3.1 Disease and Treatment  ................................ ................................ ................................ .......23 
3.1.1  Solid Tumor Malignancies  ................................ ................................ ............................... 23 
3.1.2  MET -Amplified Solid Tumor Malignancies  ................................ ................................ ....23 
3.1.3  Current Treatment of MET -Amplified Solid Tumor Malignancies  ................................ .25 
3.2 Investigational Medicinal Product  ................................ ................................ ..................... 26 
3.2.1  Sym015  ................................ ................................ ................................ ............................. 26 
3.2.2  Mechanism of Action  ................................ ................................ ................................ .......26 
3.2.3  Summary o f Non -Clinical Findings  ................................ ................................ ................. 27 
3.2.4  Summary of Clinical Findings  ................................ ................................ ......................... 28 
3.2.4.1  Protocol Sym015 -01 ................................ ................................ ................................ ......28 
3.2.4.2  Other Monoclonal Antibodies Targeting MET  ................................ ............................. 29 
3.3 Trial Rationale  ................................ ................................ ................................ ................... 29 
3.4 Dose Rationale  ................................ ................................ ................................ ................... 30 
3.4.1  Rationale for Starting Dose  ................................ ................................ .............................. 30 
3.4.2  Rationale for Recommended Phase 2 Dose  ................................ ................................ .....30 
3.5 Overall Benefits/Risk  ................................ ................................ ................................ ......... 31 
4. TRIAL OBJECTIVES  ................................ ................................ ................................ .......... 33 
4.1 Objectives of Part 1, Dose -Escalation  ................................ ................................ ............... 33 
4.1.1  Primary Objective  ................................ ................................ ................................ ............. 33 
4.1.2  Secondary Objectives  ................................ ................................ ................................ .......33 
4.2 Objectives o f Part 2  ................................ ................................ ................................ ............ 33 
4.2.1  Primary Objective  ................................ ................................ ................................ ............. 33 
4.2.2  Secondary Objectives  ................................ ................................ ................................ .......33 
5. TRIAL DESIGN  ................................ ................................ ................................ ................... 35 
5.1 Overall Design and Plan  ................................ ................................ ................................ ....35 
5.2 Discussion of Trial Design ................................ ................................ ................................ .37 
5.2.1  Rationale for Trial Design  ................................ ................................ ................................ 37 
5.2.2  Rationale for Trial Population  ................................ ................................ .......................... 38 
5.3 Schedule of Events  ................................ ................................ ................................ ............. 38 
5.3.1  Prescreening for MET -amplification and METEx14Del Status  ................................ ............ 39 
5.3.2  Screening  ................................ ................................ ................................ .......................... 40 
5.3.3  Screening Failures  ................................ ................................ ................................ ............ 41 
5.3.4  Treatment  ................................ ................................ ................................ .......................... 42 
5.3.5  End of Treatment and Follow -up Visits  ................................ ................................ ........... 42 
5.3.6  Flow Chart – Schedule of Assessments  ................................ ................................ ........... 43 
5.4 Recruitment Period  ................................ ................................ ................................ ............ 48 
5.5 Number of Patients  ................................ ................................ ................................ ............ 48 
5.6 End of Trial  ................................ ................................ ................................ ........................ 49 
6. PATIENT SELECTION AND WITHDRAWAL  ................................ ................................ 50 
6.1 Inclusion Criteria  ................................ ................................ ................................ ............... 50 
6.2 Exclusion Criteria  ................................ ................................ ................................ .............. 52 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 5 of 164 6.3 Withdrawal  ................................ ................................ ................................ ......................... 55 
6.3.1  Withdrawal from Treatment with Sym015  ................................ ................................ ......55 
6.3.2  Withdrawal from Trial  ................................ ................................ ................................ ......56 
6.4 Replacement of Patients  ................................ ................................ ................................ .....57 
6.4.1  Part 1, Dose -Escalation  ................................ ................................ ................................ ....57 
6.4.2  Part 2  ................................ ................................ ................................ ................................ .57 
7. TREATMENT  ................................ ................................ ................................ ...................... 58 
7.1 Investigational Medicinal Product/Sym015  ................................ ................................ .......58 
7.1.1  Packaging and Labeling of Sym015  ................................ ................................ ................. 58 
7.1.2  Handling, Storage and Preparation of Sym015  ................................ ................................ 58 
7.1.3  Administration of Sym015  ................................ ................................ ............................... 59 
7.1.3.1  Treatment Schedule  ................................ ................................ ................................ .......59 
7.1.3.2  Part 1, Dose -Escalation  ................................ ................................ ................................ .59 
7.1.3.3  Part 2  ................................ ................................ ................................ .............................. 61 
7.1.3.4  Duration of Infusion for Administration of Sym015  ................................ ..................... 61 
7.1.3.5  Patient Monitoring During and After Infusion of Sym015  ................................ ........... 61 
7.1.3.6  Infusion -Related Reactions to Sym015  ................................ ................................ ......... 62 
7.1.3.7  Handling of Infusion -Related Reactions to Sym015  ................................ ..................... 62 
7.1.4  Dose -Adjustment and Delays of Sym015  ................................ ................................ ........ 63 
7.1.4.1  Dose -Adjustment for Body Weight  ................................ ................................ ............... 64 
7.1.4.2  Dose -Delays for Sym015 -Related or Disease -Related Toxicities  ................................ 64 
7.1.4.3  Dose -Reduction for Sym015 -Related Toxicities  ................................ .......................... 64 
7.2 Other Drugs to be Used in the Trial  ................................ ................................ ................... 65 
7.2.1  Premedication for Sym015 Infusions  ................................ ................................ ............... 65 
7.2.2  Prophylactic and Therapeutic Treatment  ................................ ................................ ......... 66 
7.2.2.1  Mandatory Prophylactic Treatment  ................................ ................................ ............... 66 
7.3 Blinding ................................ ................................ ................................ .............................. 66 
7.4 Drug Accountability and Compliance Check  ................................ ................................ ....66 
7.5 Concomitant Medication/Therapy  ................................ ................................ ..................... 67 
7.5.1  Allowed Medication/Therapy and Procedures During the Trial  ................................ ......67 
7.5.2  Prohibited Medication/Therapy and Procedures During the Trial  ................................ ...67 
7.6 Medical Care of Patients after End of Trial Participation ................................ .................. 69 
8. TRIAL ASSESSMENTS  ................................ ................................ ................................ ......70 
8.1 Baseline Characteristics / Eligibility Assessments  ................................ ............................ 70 
8.1.1  Signing of Informed Consent  ................................ ................................ ........................... 70 
8.1.2  Demographics  ................................ ................................ ................................ ................... 70 
8.1.3  Medical History  ................................ ................................ ................................ ................ 70 
8.1.4  Tumor Characteristics and Extent of Disease  ................................ ................................ ..70 
8.1.5  Prior Cancer Treatments  ................................ ................................ ................................ ...70 
8.2 Safety Assessmen ts ................................ ................................ ................................ ............ 71 
8.2.1  Medication/Procedure Survey  ................................ ................................ .......................... 71 
8.2.2  Adverse Events Survey  ................................ ................................ ................................ ....71 
8.2.3  Dose -Limiting Toxicities Evaluation (Part 1 Only)  ................................ ......................... 71 
8.2.4  Vital Signs and Body Weight  ................................ ................................ ........................... 71 
8.2.5  Performance Stat us ................................ ................................ ................................ ........... 72 
8.2.6  Physical Examination  ................................ ................................ ................................ .......72 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 6 of 164 8.2.7  Electrocardiogram  ................................ ................................ ................................ ............ 72 
8.2.8 Echocardiogram or Multi -Gated Acquisition Scan  ................................ .......................... 73 
8.2.9  Laboratory Assessments and Pregnancy Test  ................................ ................................ ..73 
8.2.9.1  Hematology Pan el ................................ ................................ ................................ ......... 74 
8.2.9.2  Biochemistry Panel  ................................ ................................ ................................ ........ 74 
8.2.9.3  Coagulation Panel  ................................ ................................ ................................ .......... 75 
8.2.9.4  Urinalysis  ................................ ................................ ................................ ....................... 75 
8.2.9.5  Pregnancy Test  ................................ ................................ ................................ .............. 76 
8.3 Disease Assessments  ................................ ................................ ................................ .......... 76 
8.3.1  Disease Status Evaluation by CT or MRI  ................................ ................................ ........ 76 
8.3.2  Tumor Marker Evaluation (Part 1 and Part 2 Basket Cohort)  ................................ .......... 77 
8.3.3 Archival Tumor Tissue for MET  and KRAS  Assessment (Part 1 and Part 2 Basket 
Cohort)   ................................ ................................ ................................ ................................ .......... 77 
8.3.4  Tumor Biopsy for Eligibility Assessment and Biomarker Analysis (Part 1 and Part 2 
Basket Coho rt) ................................ ................................ ................................ ............................... 78 
8.3.5  Tumor Biopsy for MET  Status and Biomarker Analysis (Part 2 NSCLC MET -Amplified 
Cohort and NSCLC METEx14Del Cohort)  ................................ ................................ ........................ 79 
8.4 Pharmacokinetic Assessments  ................................ ................................ ........................... 80 
8.5 Anti-Drug Antibody Testing  ................................ ................................ .............................. 81 
8.6 Skin Biopsy (Part 1 only)  ................................ ................................ ................................ ...82 
8.7 Blood Sample for Genomic and Biomarker Analyses  ................................ ....................... 82 
8.8 Handling of Biological Samples  ................................ ................................ ........................ 83 
8.9 Follow -up Assessments  ................................ ................................ ................................ .....83 
8.10  Appropriateness of Measurements  ................................ ................................ ..................... 84 
9. ADVERSE EVENTS  ................................ ................................ ................................ ............ 85 
9.1 Definitions of Adverse Events  ................................ ................................ ........................... 85 
9.1.1  Adverse Event  ................................ ................................ ................................ .................. 85 
9.1.2  Events Not to be Considered as  Adverse Events  ................................ ............................. 85 
9.1.3  Adverse Events of Medical Interest  ................................ ................................ ................. 86 
9.1.4  Serious Adverse Events  ................................ ................................ ................................ ....86 
9.1.5  Events that Do Not Meet the Definition of Serious Adverse Events  ............................... 86 
9.2 Adverse Event Recording and Reporting Instructions ................................ ....................... 87 
9.2.1  Adverse Event Recording Period  ................................ ................................ ..................... 87 
9.2.2  Diagnosis  ................................ ................................ ................................ .......................... 87 
9.2.3  Severity  ................................ ................................ ................................ ............................. 87 
9.2.4  Relationship to Investigational Medicinal Product/Sym015  ................................ ............ 88 
9.2.5  Outcome  ................................ ................................ ................................ ........................... 89 
9.2.6  Follow -up of Adverse Events  ................................ ................................ ........................... 89 
9.3 Serious Adverse Event Recording and Reporting  ................................ ............................. 90 
9.4 Safety Reporting to Health Auth orities, Institutional Review Boards/Ethics Committees, 
and Investigators  ................................ ................................ ................................ ............................ 90 
9.5 Dose -Limiting Toxicities (Part 1 Only)  ................................ ................................ ............. 91 
9.5.1  Definition of Dose -Limiting Toxicities  ................................ ................................ ............ 91 
9.5.2  Observation Period for Dose -Limiting Toxicities  ................................ ............................ 92 
9.5.3  Reporting of Dose -Limi ting Toxicities  ................................ ................................ ............ 92 
9.6 Reporting of Infusion -Related Reactions ................................ ................................ ........... 92 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 7 of 164 9.7 Pregnancy  ................................ ................................ ................................ ........................... 92 
10. STATISTICS  ................................ ................................ ................................ ........................ 94 
10.1  Statistical Considerations and Analysis Plan  ................................ ................................ .....94 
10.2  Sample Size Determination ................................ ................................ ................................ 94 
10.3  Analysis Population  ................................ ................................ ................................ ........... 96 
10.4  Primary Endpoint and Analysis  ................................ ................................ ......................... 96 
10.4.1 Part 1, Dose -Escalation  ................................ ................................ ................................ ....96 
10.4.2  Part 2  ................................ ................................ ................................ ................................ .96 
10.5  Secondary Endpoint and Analysis  ................................ ................................ ..................... 97 
10.5.1  Efficacy Endpoints and Analyses  ................................ ................................ ..................... 97 
10.5.2  Other Efficacy Assessments  ................................ ................................ ............................. 97 
10.5.3  Safety Endpoints and Analyses  ................................ ................................ ........................ 98 
10.5.3.1  Adverse Events  ................................ ................................ ................................ .............. 98 
10.5.3.2  Clinical Laboratory Values  ................................ ................................ ........................... 99 
10.5.3.3  Other Safety Assessments  ................................ ................................ ............................. 99 
10.5.4  Pharmacokinetic Endpoints and Analyses  ................................ ................................ .......99 
10.5.5  Additional Endpoi nts and Analyses  ................................ ................................ ............... 100 
10.6  Interim Analysis  ................................ ................................ ................................ ............... 101 
10.7  Deviations from the Statistical Plan  ................................ ................................ ................. 101 
11. ETHICS ................................ ................................ ................................ ............................... 102 
11.1  Institutional Review Board/Ethics Committee  ................................ ................................ 102 
11.2  Patient Information and In formed Consent ................................ ................................ ......102 
12. SAFETY SURVEILLANCE SET -UP ................................ ................................ ................ 103 
12.1  Safety Review  ................................ ................................ ................................ .................. 103 
12.2  Other Safety Surveillance Activities  ................................ ................................ ................ 104 
13. MONITORING AND QUALITY ASSURANCE ................................ .............................. 105 
13.1  Compliance with Good Cl inical Practice  ................................ ................................ ......... 105 
13.2  Source Documents  ................................ ................................ ................................ ........... 105 
13.3  Monitoring  ................................ ................................ ................................ ....................... 105 
14. DATA HANDLING AND RECORD KEEPING  ................................ .............................. 107 
14.1  Data Protection ................................ ................................ ................................ ................. 107 
14.2  Data Transactions and Access  ................................ ................................ ......................... 107 
14.3  Data Processing  ................................ ................................ ................................ ................ 107 
14.4  Clinical Trial Report  ................................ ................................ ................................ ........ 108 
14.5  Compliance with the Gener al Data Protection Regulation  ................................ .............. 108 
14.6  Retention of Trial Documents at Site ................................ ................................ ............... 108 
15. REGISTRATION AND COMMUNICATION OF RESULTS  ................................ ......... 109 
15.1  Use of Information  ................................ ................................ ................................ ........... 109 
15.2  Registration and Publication  ................................ ................................ ............................ 109 
16. INSURANCE AND LIABILITY  ................................ ................................ ....................... 110 
17. CHANGES TO THE FINAL CLINICAL TRIAL PROTOCOL  ................................ .......111 
18. PREMATURE TERMINATION OF THE TRIAL OR A TRIAL SITE  ........................... 112 
18.1  Premature Termination of the Trial  ................................ ................................ ................. 112 
18.2  Premature Termination of a Trial Site  ................................ ................................ ............. 112 
19. REFERENCES  ................................ ................................ ................................ ................... 113 
20. APPENDICES  ................................ ................................ ................................ .................... 117 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 8 of 164 Appendix 1: Summary of Response Evaluation Criteria in Solid Tumors (RECIST v1.1)  ........ 117 
21. SUMMARY OF CHANGES  ................................ ................................ .............................. 123 
21.1  Protocol Amendment 1 dated 17 -Feb-2016  ................................ ................................ .....123 
21.2  Protocol Amendment 2 dated 22 -Feb-2016  ................................ ................................ .....124 
21.3  Protocol Amendment 3 dated 02 -May-2016 ................................ ................................ ....125 
21.4  Protocol Amendment 4 dated 04 -Nov-2016  ................................ ................................ ....128 
21.5  Protocol Amendment 5 dated 11 -May-2017 ................................ ................................ ....137 
21.6  Proto col Amendment 6 dated 20 -Nov-2017  ................................ ................................ ....140 
21.7  Protocol Amendment 7 dated 07 -Dec-2018  ................................ ................................ ....152 
 
LIST OF FIGURES  
Figure 1  Overall Trial Design  ................................ ................................ ................................ ... 37 
 
LIST OF TABLES  
Table 1  Preliminary Sym015 Geometric Mean PK Parameters  ................................ ..............  31 
Table 2  Overall Trial Plan  ................................ ................................ ................................ ....... 39 
Table 3  Flow Chart: Schedule of Assessments (Part 1 and Part 2 Basket Cohort)  .................  44 
Table 4  Flow Chart: Schedule of Assessments (Part 2 NSCLC Cohorts)  ...............................  46 
Table 5  Description of Investigational Medicinal Product/Sym015  ................................ ....... 58 
Table 6  Infusion -Related Reactions Management Guidelines  ................................ ................  63 
Table 7  Sym015 Dose -Reduction Schedule  ................................ ................................ ............  65 
Table 8  Schedule of Safety B lood and Urine Samples  ................................ ............................  73 
Table 9  Schedule of Pharmacokinetic Assessments  ................................ ................................  81 
Table 10  90% Confidence Intervals for Observed Resp onse Rates for N=20 and N=25 ..........  95 
Table 11  PK Endpoints Definitions and Derivations  ................................ ..............................  100 
Table 12  Response Criteria for Evaluation of Target Lesions  ................................ ................  120 
Table 13  Response Criteria for Evaluation of Non -Target Lesions  ................................ ........  120 
Table 14  Overall Response Status for P atients with Baseline Measurable Disease  ................  121 
Table 15  Best Overall Response when Confirmation of CR and PR Required  .......................  122 
Table 16  Protocol Amendment 1  ................................ ................................ .............................  123 
Table 17  Protocol Amendment 2  ................................ ................................ .............................  124 
Table 18  Protocol Amendment 3  ................................ ................................ .............................  126 
Table 19  Protocol Amendment 4  ................................ ................................ .............................  129 
Table 20  Protocol Amendment 5  ................................ ................................ .............................  138 
Table 21  Protocol Amendment 6  ................................ ................................ .............................  141 
Table 22  Protocol Amendment 7  ................................ ................................ .............................  153 
 
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 9 of 164 1. SYNOPSIS  
Item  Summary  
Trial Title  An Open-label, Multicenter P hase 1a/2a Trial Investigating the Safety, Tolerability 
and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody 
Mixture Targeting MET, in Patients with Advanced Solid Tumor Malignancies  
Trial ID  Sym015 -01 
Trial Phases  This is an open -label, multicenter  trial composed of 2 parts:  
 Part 1 is a Phase 1a dose -escalation in patients with KRAS  proto -oncogene  
(KRAS ) wild -type (WT) advanced solid tumor malignancies withou t available 
therapeutic options  
 Part 2 is a Phase 2a dose -expansion  in which dosing will be at the 
recommended Phase 2 dose (RP2D) o n an every second week (Q2W) 
schedule. Three cohorts will be included:  
o Basket * Cohort : A cohort of approximately 25 patient s with KRAS  
WT advanced  solid tumor malignancies  with MET -amplification, and 
without  available  therapeutic options.   Included in this  group will be a 
subset of approximately 6 patients who have received prior therapy 
with a MET -targeting tyrosine kinase inhibitor ( TKI). 
Note:  Effective with protocol  version 8.0 ( December  2018), accrual to the 
Basket Cohort is suspended . 
o NSCLC MET -Ampli fied Cohort : A cohort of approximately 20 
patients with advanced non-small cell lung carcinoma ( NSCLC ) with 
MET -amplification, and without  available  therapeutic options.  
Patients may have received prior therapy with MET -targeting and /or 
epidermal growth f actor receptor (EGFR) -targeting agents . 
o NSCLC METEx14Del Cohort : A cohort of approximately 6-12 patients  
with advanced NSCLC  with MET  exon 14 skipping alteration      
(METEx14Del), and without available therapeutic options.  Tumors need 
not be MET -amplifie d, and patients may have received prior therapy 
with MET -targeting  and/or EGFR -targeting agents . 
*A basket cohort is designed to evaluate the potential antitumor effects of a targeted 
therapy by enriching for patients with a defined genetic alteration (e.g., mutations in or 
overexpression of a specific gene(s)) regardless of the histotype of the enrolled patients ’ 
tumors.  
Trial Sites and 
Countries  Part 1, Dose -Escalation: 2 to 3 investigational trial sites , located within the United 
States ( USA ). 
Part 2: 1 5 to 27 investigational trial sites, located within  the USA , Asia Pacific , 
and Europe .  
Planned Trial 
Period  Part 1 of the trial  is expected to begin Q1 2016.  
Patients will be enrolled in dose-escalation cohorts until establishment of a 
maximum tolerated  dose (MTD) or until 24 mg/kg has been evaluated , whichever 
comes first,  expected by  Q1 2017.  
Enrollment to Part 2 of the trial will commence upon establishment of the Q2W  
RP2D. Enrollment is ex pected  to complete by Q4 2019 .  
The end of trial will be reach ed at the latest 1 month ( 30 +7 days) after the last 
patient has been withdrawn from Sym015. Patients will continue to be followed to 
assess duration of disease stabilization , response , and overall survival (OS) . 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 10 of 164 Primary 
Objectives  Primary objective of Pa rt 1, Dose -Escalation: To assess the safety and tolerability 
of Sym015 when administered by intravenous (IV) infusion  on a Q2W schedule  to 
patients with KRAS WT advanced solid tumor malignancies without available 
therapeutic  options . 
Primary objective of P art 2: To evaluate the antitumor activity of Sym015 when 
administered at the Q2W RP2D to patients in the following cohorts :  
 Basket Cohort : MET -amplified, KRAS  WT solid tumor malignancies 
without a vailable therapeutic options .   
 NSCLC MET -Amplified Cohort:  MET -amplified advanced NSCLC 
without available therapeutic options . 
 NSCLC METEx14Del Cohort : METEx14Del advanced NSCLC without 
available therapeutic options . 
Primary 
Endpoints  Primary Endpoint of Part 1, Dose -Escalation: The occurrence of dose -limiting 
toxicities (DLT) measured during Cycle 1 of Sym015 administration on a  Q2W  
(28 days equals 1 cycle) dosing schedule . 
Primary Endpoint of Part 2: Documented , confirmed  objective response ( OR) 
(defined as partial response [ PR] or complete response [ CR]), asse ssed by the 
Response Evaluation Criteria in Solid Tumors (Version 1.1) (RECIST v1.1 ) at any 
time during trial participation by Investigator assessment . 
Overall Trial 
Design  During Part 1  of the trial , patients with  KRAS WT advanced  solid tumor 
malignanci es will receive increasing doses of Sym015  on a Q2W schedule  until 
establishment of  the MTD or until 24 mg/kg has been evaluated . Dose -escalation 
will follow a standard 3+3 design with dos e-escalation guided by DLTs . Patients 
in Part 1 will receive infusio ns of Sym015 on a Q2W  schedule  at the specified 
dose level until the highest planned dose has been evaluated and/or a n MTD is 
identified .  
A safety monitoring committee (SMC)  will be established  and will include 
Investigator(s) , Medical Monitor(s) , and Sponsor’s medical r epresentatives . The 
SMC  will review clinical and laboratory safety data regularly  throughout the trial . 
The SMC  will select the Q2W RP2D to be used in Part 2 based on safety data  and 
available pharmacokinetic ( PK) results.  
During Part 2 , three cohorts will receive Sym015 at the  RP2D on a Q2W dosing 
schedule : 
 Basket Cohort : A basket cohort of KRAS  WT, advanced solid tumor 
malignancy patients with  MET -amplification  will be evaluated . Patients must 
be MET -targeting TKI-naïve; a n exception will be a subset of approximately 
6 patients who have received prior therapy with a MET -targeting TKI.  
Note:  Effective with protocol  version 8.0 ( December  2018), accrual to the Basket 
Cohort is suspended.  
 NSCLC MET -Amplified Cohort : A cohort of advanced NSCLC patients with 
MET -amplification will be evaluated.  Patients may have received prior 
therapy with MET -targeting and/or EGFR -targeting agents . 
 NSCLC METEx14Del Cohort :  A cohort of advanced NSCLC patients with  
METEx14Del will be evaluated . Tumors need not b e MET -amplified , and 
patients may have received prior therapy with MET -targeting and/or EGFR -
targeting agents . 
Trial Periods  Prescreening : Site s may choose to prescreen patients utilizing genomic analysis 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 11 of 164 (e.g., Guardant360 or other similar liquid biopsy methodology) or tumor tissue 
(archival, or recently obtained if acquired outside of the screening process as part 
of the site’s usual practice ) to assess MET -amplification status and METEx14Del 
status before entering patients into screening for the treatme nt portion of the trial. 
In this case, the site will use a separate pre -screening informed consent form.  
Screening Period : After providing informed consent, the eligibility of patients will 
be established according to the protocol -defined inclusion and exc lusion criteria.  
Treatment Period : Patients in the trial will receive IV infusions of Sym015 on a 
Q2W schedule until occurrence of any of the following: Unacceptable toxicity or 
other conditions preventing further administration, progressive disease (PD), 
termination of the trial, or patient’s decision to withdraw.  
End of Treatment/Follow -up: Once Sym015 has been discontinued, an End of 
Treatment (EOT) Visit will be performed within 10 days following the decision to 
withdraw treatment. A follow -up visit wi ll be performed 1 month after the last 
administration of Sym015.  
After the 1-Month Follow -up (1M FUP ) Visit, the Investigator will make every 
effort to obtain follow -up information on response assessment and/or OS, about 
once every 2 months. Response asse ssment follow -up is required in the event of an 
ongoing stable disease ( SD), PR, or CR at the 1M FUP Visit, until PD or another 
therapeutic intervention is initiated. Survival follow -up is required until death, 
withdrawal of consent, trial site closure, or termination /end of the trial.  Occurrence 
of one of these events constitutes the end of trial for the patient.  
Number of 
Patients  It is planned to enroll approximately 63-72 patients in total.    
Approximately 12-15 patients will receive increasi ng doses of Sym015 during Part 
1.  
Approximately 51-57 patients will receive Sym015 at the RP2D on a Q2W 
schedule during Part 2.  Three cohorts will be included:  
 Basket Cohort : Approximately 25 patients with KRAS  WT, advanced solid 
tumor malignancies with document ed MET -amplifi cation  will be enrolled 
and treated .  A subset of approximately 6 patients will have received prior 
therapy with a MET -targeting TKI . 
Note:  Effective with protocol  version 8.0 ( December  2018), accrual to the Basket 
Cohort is suspended.    
NSC LC MET -Amplified patients entered to the Basket Cohort will be counted 
toward the NSCLC MET -Amplified Cohort; NSCLC METEx14Del patients entered to 
the Basket Cohort will be counted toward the NSCLC METEx14Del Cohort ; patients 
with both will be counted as MET-Amplified.   
 NSCLC MET -Amplified Cohort : approximately 20 patients with advanced 
NSCLC with documented  MET -amplification will be enrolled and treated. 
Patients may have received prior therapy with MET -targeting and/or EGFR -
targeting agents . 
 NSCLC METEx14Del Cohort : approximately 6-12 patients with advanced 
NSCLC with documented  METEx14Del will be enrolled and treated . Tumors  
need not be MET -amplified , and patients may have received prior therapy 
with MET -targeting and/or EGFR -targeting agents . 
Note:  NSC LC patients with tumors identified as both MET -Amplified and  
METEx14Del will be enrolled to the MET -Amplified cohort . 
Main Inclusion Main inclusion criteria all patients, Part 1 and Part 2:  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 12 of 164 and Exclusion 
Criteria   Male or female, at least 18 years of age a t the time of informed consent  
 Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 
or 1 
 Life expectancy > 3 months assessed during Screening  
 Documented (histologically - or cytologically -proven) solid tumor 
malignancy that is locally advan ced or metastatic, and that is refractory to 
standard therapy or for which no standard therapy is available  or accessible  
(i.e., patients must have recurrent and/or progressive disease and be without 
available therapeutic options)  
Additional main inclusion  criteria applicable to Part 1 patients  ONLY : 
 Tumor documented to be KRAS WT by local assessment according to 
institutional standards . If KRAS  WT is not previously documented and if 
archival tissue is not available for pretrial assessment, patient must be willing 
to undergo a tumor biopsy to confirm eligibility   
 
Additional m ain inclusion criteria applicable to Part 2  patients ONLY : 
 Measurable disease according to RECIST v1.1 that has been confirmed by 
computed tomography ( CT) or magnetic resonance imaging (MRI) within 4 
weeks prior to Cycle 1 /Day 1  (C1/D1 ) 
Note : Measurable disease is defined as 1 or more target lesions assessed by CT or MRI. A 
tumor lesion situated in a previously irradiated area is considered measurable only if 
subsequent PD has been docum ented in the lesion    
 Basket Cohort ONLY : 
o Confirmed MET -amplification by local assessment; i.e. , MET  gene 
copy number  to control probe ratio [G:CN] >2.2 scored in 50 tumor 
nuclei by fluorescence in situ  hybridization ( FISH ), chromogenic in situ  
hybridizati on (CISH ), silver in situ  hybridization (SISH)  or similar , or a 
copy number >5 by next -generation sequencing (NGS) or quantitative 
polymerase chain reaction  (qPCR)  
Note:  Peripheral blood collection for MET -amplification assessment in ctDNA  
will be allowed  as a local pre -screening metho dology provided results are 3+ 
by Guardant360 * analysis  (or equivalent to 3+ by Guardant360 if an 
alternative Sponsor -approved methodology is used ), and provided subsequent 
required confirmatory tumor tissue evaluation meets the above inclusion 
criterion .  
*http://guardanthealth.com/  
o Tumor documented to be KRAS  WT by local assessment according to 
institutional standards. If KRAS  WT is not previously documented and 
if archival tissue is not available for pretrial assessment, patient must be 
willing to undergo a tumor biopsy to confirm eligibility  
Note:  Peripheral blood collection for KRAS -mutation assessment in circulating 
tumor deoxyribonucleic acid (ctDNA) (also referred to as “liqu id biopsy”) will 
be allowed as a local pre -screening methodology by Guardant360* analysis. 
Other liquid biopsy methodologies, except if used to detect METEx14Del, will 
only be allowed if previously approved by the Sponsor.  
o No prior therapy with MET -targeti ng agents  
Note:  An exception will be a subset of approximately 6 patients entered to the 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 13 of 164 Basket Cohort after having received prior therapy with a MET -targeting TKI.  
o Willingness to undergo a pre - and post -dosing biopsy (maximum of 2 
biopsies) from primary or metastatic tumor site(s) considered safely 
accessible for biopsy  
 NSCLC MET -Amplified Cohort ONLY : 
o Documented NSCLC meeting disease criteria as defined above  
o Documented MET -amplification by either:  
 Local assessment in a recent* tumor biopsy; i.e. ,  G:CN ≥3.0 
scored in 50 tumor nuclei by FISH, CISH, SISH or similar assay, 
or a copy number >5 by NGS or qPCR (subsequent central 
confirmation required ; however , patient may be enrolled and 
treated based on local assessment, before central confirmation 
results h ave been obtained)  
*Tissue for local assessment may be from a recent tumor biopsy, defined 
as one performed since last documented disease progression as part of the 
site’s usual practice, and  where no intervening antineoplastic therapy has 
been administere d; otherwise tissue from a newly performed biopsy must 
be obtained and submitted.       
 Central confirmation ** in a newly performed pre -dosing tumor 
biopsy; i.e. ,  G:CN ≥3.0 scored in 50 tumor nuclei by FISH  
**If central confirmation of MET -amplification status cannot be assessed 
in tumor due to assay failure/technical error, the Sponsor may decide to 
enroll based on MET -amplification detected by Guardant360 on a c ase 
per case basis (see Note below regarding Guardant360 analysis).  
o May have received prior therapy with MET -targeting and/or EGFR -
targeting agents  (antibodies or TKIs)  
o Willingness to undergo a pre -dosing biopsy (mandatory  unless a 
recent* tumor biopsy as defined above is available ), and potentially a 
biopsy at the E nd of Cycle 2 (EOC2) (optional), from a primary or 
metastatic tumor site considered safely accessible for biopsy  
Note: Peripheral blood for ctDNA analysis by Guardant360 will be obtained for 
assessment of MET -amplification status.  As data are acquired on concordance 
between findings in tumor tissue versus ctDNA, the Sponsor may decide to 
transition to screening for MET -amplification using Guardant360 analysis only 
(e.g., 2+ or 3+ amplification s core) without requiring confirmation in a recent or 
newly performed tumor biopsy.  
 NSCLC METEx14Del Cohort  ONLY :  
o Documented NSCLC meeting disease criteria as defined above  
o Documented  METEx14Del (tumors need not be MET -amplified)  
Note:  METEx14Del status to  be documented according to local institutional 
standards.  Assessment in ctDNA by Guardant360 technology or equivalent is 
allowed.  Tissue from a recent* or newly performed pre -dosing tumor biopsy 
must be submitted for central assessment . 
*Recent tumor bi opsy, defined as one performed since last documented disease 
progression as part of the site’s usual practice, and where no intervening 
antineoplastic therapy has been administered; otherwise  tissue from a newly 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 14 of 164 performed biopsy must be obtained and submit ted. 
o May have received prior therapy with MET -targeting agents and/or 
EGFR -targeting agents  (antibodies or TKIs)  
o Willingness to undergo a pre -dosing biopsy (mandatory  unless a 
recent* tumor biopsy as defined above is available ), and potentially a 
biopsy a t the EOC2 (optional), from a primary or metastatic tumor site 
considered safely accessible for biopsy  
Note: Peripheral blood for ctDNA analysis by Guardant360 will be obtained for 
assessment of METEX14Del status.  
Main exclusion criteria  all patients, Part  1 and Part 2 : 
 Any antineoplastic agent for the primary malignancy (standard or 
investigational) without delayed toxicity within 4 weeks or 5 plasma half -
lives, whichever is shortest, prior to C1/D1 , except:  
o Nitrosoureas and mitomycin C within 6 weeks  prior to C1/D1   
 Immunosuppressive or systemic hormonal therapy within 2 weeks prior to 
C1/D1 with specified allowed exceptions  
 Use of hemat opoietic growth factors within 2  week s prior to C1/D1  
 Active second malignancy or history of anot her malignancy within t he last 3  
years, with specified allowed exceptions  
 Central nervous system (CNS)  malignancy  including primary malignancies 
of the CNS and/ or known , untreated  CNS or leptomeningeal metastases , or 
spinal cord compression; patients with any of these  not contro lled by pri or 
surgery or radiotherapy, or symptoms suggesting CNS involvement for 
which treatment is required  
 Inadequate recovery from an acute toxicity associated with any prior 
antineoplastic therapy  
 Major surgical procedure within 4 weeks prior to C1/D1  or inadequate 
recovery from any prior surgical procedure  
 Active thrombosis, or a history of deep vein thrombosis or pulmonary 
embolism, within 1 month prior to C1/D1, unless adequately treated and 
stable  
 Active uncontrolled bleeding or a known bleeding di athesis  
 Significant cardiovascular disease or condition  
 Abnormal hematologic, renal or hepatic function as defined by the following 
criteria:  
o Absolute neutrophil count (ANC) < 1.5 ×109/L (1500/mm3) 
o Hemoglobin ≤ 9 g/dL  
o Platelet count < 75 ×109/L (75 ,000/mm3)  
o Serum creatinine > 1.5 × upper limit of normal (ULN) for the institution  
o Aspartate aminotransferase (AST) >3.5 × ULN for the institution or 
AST >5 × ULN for the institution in case of known liver met astases  
o Alanine aminotransferase (ALT) >3.5 × ULN for the institution or ALT 
>5 × ULN for the institution in case of known liver metastases  
o Total bilirubin > 1.5 × ULN for the institution  
o Prothrombin time as assessed by International N ormalized Ratio (INR)  
>1.5 × ULN for the institution * 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 15 of 164 o Partial thromboplastin time (PTT) > 1.5 × ULN for the institution * 
*Unless on a stable dose of anticoagulant therapy for a prior thrombotic 
event  
 Any of the following within 2 weeks prior to C1/D1:  
o Any serious or uncontrolle d infection  
o Any infection requiring parenteral antibiotics  
o Unexplained fever > 38.0 °C  
Additional main exclusion criteria applicable to Part 2 patients ONLY : 
 Basket Cohort  ONLY :  
o Prior therapy with MET -inhibiting agents  
Note:  Exception s will be a subset of  approximately 6 patients entered to the 
Basket Cohort after having received prior therapy with a MET -target ing TKI.  
o Prior therapy with antibody to hepatocyte growth factor (HGF)  
 Basket Cohort and NSCLC  MET -Amplified Cohort  ONLY : Tumor status 
demonstrating  MET -polysomy in the absence of MET -amplification, as 
specified  
Note: Patients in the NSCLC  METEx14Del Cohort  with polysomy are eligible  
 Radiotherapy against target lesions within 4 weeks prior to C1/D1 , unless 
there is documented progression of the lesion  following the radiotherapy  
Investigational 
Medicinal 
Product, Dose(s) 
and Treatment 
Schedule  The Investigational Medicinal Product (IMP) is Sym015.  
Sym015 is a recombinant antibody mixture containing 2 humanized  
immunoglobulin G1 ( IgG1 ) monoclonal antibo dies ( mAbs ), designated Hu9006 
and Hu9338, which bind specifically to MET, the receptor for HGF. Preclinical 
studies have shown that Sym015 effectively down -regulates the target and has a 
superior tumor growth i nhibitory activity compared to  other antibodi es targeting 
this receptor. Sym015 is intended f or the treatment of solid tumor malignancies  
with amplification of the gene encoding MET.  
 
Sym015 will be administered on  a Q2W schedule by IV infusion.  
 Q2W dosing: Day 1 and Day 15 of each 28 -day cycle (± 2  days)  
Sym015 will be administered over a 1 .5-hour (+10 minutes) period  for doses ≥18 
mg/kg and over a 1-hour (+10 minutes) period for doses <18 mg/kg , following 
delivery of premedication prior to each infusion.  In Part 2, i f the patient is without 
evidenc e of infusion related reactions (IRRs) after Cycle 1 , the Investigator may 
opt to withdraw premedication on a patient -by-patient basis with subsequent 
dosing.  
 
Part 1/Dose -Escalation  
During the dose -escalation part of the trial, the following dose levels o f Sym015 
administered Q2W will potentially be evaluated in a standard 3+3 dose -escalation 
design:  
 Dose Level 1: 6 mg/kg  
 Dose Level 2: 12 mg/kg  
 Dose Level 3: 1 8 mg/kg  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 16 of 164  Dose Level 4: 24 mg/kg  
A substitute or additional dose level, within the dose levels l isted above, could 
potentially be evaluated.  
Enrollment will be staggered between the first and second patient in each new 
higher dose level tested. The first patient must have completed and tolerated the 
first dose of Sym015, including follow -up until Day 8 of Cycle 1 (C1/D8) , in order 
to allow for review of clinical and laboratory assessments. Thereafter patients 
within a cohort may be added concurrently.  
 
Part 2  
Once the Q2W RP2D has been established during dose -escalation, the enrollment 
into Part 2  will commence.  
Note:   Effective with protocol  version 5.0 (November 2016), following review of available 
safety and PK data, the decision has been made to choose  the following  as the Q2W  RP2D 
of Sym015: Loading dose of 18 mg/kg  infused  over 1.5 hours on C1/ D1, followed by Q2W 
maintenance doses of 12 mg/kg  infused  over 1 hour beginning on C1/D15. As the MTD 
has not yet been reached, dose -escalation will continue in Part 1 of the trial to 24 mg/kg.  
Trial 
Assessments  All assessments will be  repeated throughout  the trial at protocol -specified 
intervals, unless otherwise stated.  
 
Safety Assessments  
 Medication /Procedure  survey  
 (Serious) Adverse Event ([S]AE) survey  
 DLT evaluation (Part 1, dose -escalation only) during Cycle 1  with a final 
assessment 14 (±2) days after the last  dose of Cycle 1 or prior to dosing on 
Cycle 2 /Day 1 (C2/D1)  
 Vital signs and body weight  
 ECOG  PS 
 Physical e xamination  
 Electrocardiogram (ECG)  at screening, EOT and as clinically indicated  
during trial participation  
 Transthoracic echocardiogram (ECHO) or multi -gated a cquisition (MUGA) 
scan at screening an d in the event of cardiac symptoms and as otherwise 
clinically indicated during trial participation  
 Safety blood samples  
 Urinalysis  
 Pregnancy test  at screening, EOT , and if clinically indicated d uring trial 
participation  
 
Disease Assessments  
 Disease  status eva luation by CT  or MRI at screening, at the EOC 2 and every 
second cycle thereafter . Further potential  timepoints are in the event of 
suspected PD, in the event of CR/PR and at EOT/1M FU P 
 Tumor marker evaluation  as indicated by tumor type , if applicable   
 Archival tumor tissue  for MET  and KRAS  assessment  (Part 1 and Part 2 
Basket Cohort) :  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 17 of 164 o For patients in Part 1, local eligibility assessment for KRAS  mutational 
status will be done  using archival t issue , whenever possible . If archival 
tissue is not available , a tumor biopsy will be performed for eligibility 
assessment. Assessment of MET -amplification status is n ot required 
for patients in Part 1, but tissue should be assessed if available  
o For patien ts in Part 2, local eligibility assessment for KRAS  mutational 
status may be done using archival tumor tissue. If archival tissue is not 
available, tissue from the tumor biopsy performed during screening 
will be used . 
 It is preferred that the eligibility a ssessment for MET -amplification 
will be done using tissue from a tumor biopsy performed during 
screening, however archival tumor tissue may be used at the 
Investigator’s discretion . 
Note:  During Part 2 ONLY, peripheral blood collection for KRAS -
mutation a ssessment and for MET -amplification assessment  in ctDNA is 
allowed as a local pre -screening methodology by Guardant360 analysis .  
Other liquid biopsy methodologies , except if used to detect METEx14Del, 
will only be allowed  if previously approved by the Spo nsor. Subsequent 
required tumor tissue evaluation to confirm MET -amplification must 
meet the protocol -specified inclusion criteria.  
 NSCLC METEx14Del Cohort  (pre-protocol  v8.0) : Eligibility 
assessment for METEx14Del status will be done according to local 
institutional standards.  Assessment in ctDNA by Guardant360 
technology or equivalent is allowed.  Subsequent confirmation in 
tumor tissue is preferred but not required, however, archival tissue 
to be submitted for central testing, if available  (applies only  to 
patients with METEx14Del tumors entered prior to suspension of the 
Basket Cohort and establishment of NSCLC METEx14Del Cohort).  
 Tumor biopsy  for MET  status and biomarker analysis  (Part 2 NSCLC MET -
Amplified Cohort and NSCLC  METEx14Del Cohort) :  
o Screeni ng (Mandatory)  
 NSCLC MET -Amplified Cohort : Required; tissue from a newly 
performed pre -dosing tumor biopsy must be submitted for central 
confirmation of MET -amplification  
(Patient s may be entered and treated based on local assessment of 
a recent tumor bio psy [if available  and performed outside of the 
screening process as part of the site’s usual practice ] provided no 
intervening antineoplastic  therapy has been administered; 
otherwise tissue from a newly performed pre -dosing biopsy must 
be obtained and subm itted) 
 NSCLC METEx14Del Cohort : Required; tissue from a  recent or  
newly performed pre -dosing tumor biopsy must be submitted for 
central assessment of METEx14Del  
(Patient s may be entered and treated based on local institutional 
standards; alternatively, as sessment in ctDNA by Guardant360 
technology or equivalent is allowed; a recent [as defined above] or 
newly performed pre -dosing biopsy must still be submitted ) 
o Post-Dosing (Optional)  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 18 of 164 EOC 2 (i.e. , coinciding with time of first response assessment) or upon 
PD, whichever occurs first . 
Additional Assessments  
 PK sampling  with extended PK -profiling after the first infusion  
 Anti-drug antibody (ADA) t esting  
 Part 1 only : Skin biopsy  for biomarker analysis  at screening, at the EOC 2 or 
upon P D, whichever comes first  
 Blood sample for genomic/ biomarker  analy ses at screening , at the EOC 2 or 
upon PD , whichever comes first , and at EOT  
Statistical 
Methods and 
Sample Size 
Calculation  The primary endpoint of Part 1 of the trial is the occurrence of DLTs measured 
during Cycle 1  of Sym015 administration . The number of enrolled patients will 
depend on the extent of observed DLTs independently in each cohort. Based on a 
3+3 design, it is planned to enroll between 12 and 15 patients during dose -
escalation.  
All DLT events will be lis ted by dose cohort and patient. A summary table of 
DLTs by System Organ Class (SOC) and Preferred Term will be presented for 
each dose cohort, if applicable. The summaries will include number of DLTs and 
number and per centages of patients experiencing  a DL T.  
The MTD is defined as the highest dose with a maximum of 1 out of 6 patients 
experiencing a DLT. The MTD may or may not be found within the dose levels 
tested. Based on an overall evaluation of the dose -escala tion part, the Q2W RP2D 
and highest safe do se tested will be selected.  
In Part 2 of the trial, the primary endpoint is documented , confirmed OR, assessed 
by RECIST v1.1 at any time during trial participation by Investigator assessment . 
It is planned to include approximately 25 patients with  advanc ed solid tumor 
malignancies,  documented and confirmed as MET -amplified in the Basket C ohort , 
20 patients in the NSCLC MET -Amplified Cohort , and 6 -12 patients in the 
NSCLC METEx14Del Cohort , for a total of approximately 51 -57 patients in Part 2 .  
The expect ed (target) range of OR  in any of the three cohorts  is in the range of 
20%-50%, depending on histology, previous therapies , and other prognostic 
factors defining the enrolled patient population.   
Number and percentages of patients with documented OR will b e presented 
including corresponding 9 0% exact Confidence Intervals (CI) . 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 19 of 164 2. LIST OF ABBREVIATION S AND EXPANDED TERMS  
1M FUP  1-Month Follow -up 
ADA  Anti-Drug Antibody  
ADCC  Antibody -Dependent Cellular Cytotoxicity  
AE Adverse Event  
ALP  Alkaline Phosphatase  
ALT  Alanine Aminotransferase  
ANC  Absolute Neutrophil Count  
ASCO  American Society of Clinical Oncology  
AST  Aspartate Aminotransferase  
BOR  Best Overall Response  
BUN  Blood Urea Nitrogen  
C#/D#  Cycle # / Day #  
CAP  College of American Pathologists  
CEC  Central Ethi cal Committee  
CI Confidence Interval  
CISH  Chromogenic In Situ  Hybridization  
CNS  Central Nervous System  
CR Complete Response  
CRF  Case Report Form  
CT Computed Tomography  
ctDNA  Circulating Tumor Deoxyribonucleic Acid  
CTCAE v4.03  Common Terminology Criteria fo r Adverse Events (Version 4.03)  
CTR  Clinical Trial Report  
DLT  Dose -Limiting Toxicity  
DMP  Data Management Plan  
DR Duration of Response  
DSUR  Development Safety Update Report  
EC Ethics Committee  
ECG  Electrocardiogram  
ECHO  Echocardiogram  
ECOG  Eastern Cooperati ve Oncology Group  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 20 of 164 EDC  Electronic Data Capture  
EEA  European Economic Area  
EGFR  Epidermal Growth Factor Receptor  
EOC  End of Cycle  
EOI End of Infusion  
EOS  End of Study  
EOT  End of Treatment  
FAS Full Analysis Set  
FISH  Fluorescence In Situ  Hybridization  
FUP Follow-up 
G:CN  Gene Copy Number to Control Probe Ratio  
GCP  Good Clinical Practice  
GDPR  General Data Protection Regulation  
GTP  Gamma -Glutamyl Transpeptidase  
hCG  Human Chorionic Gonadotropin  
HGF  Hepatocyte Growth Factor  
HIV Human Immunodeficiency Virus  
HRT  Hormo ne Replacement Therapy  
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use  
ICMJE  International Committee of Medical Journal Editors  
IgG1  Immunoglobulin G1  
IHC Immunohistochemistry  
IMP Investigational Medi cinal Product  
INR International Normalized Ratio  
IRB Institutional Review Board  
IRR Infusion -Related Reaction  
ISF Investigator Site File  
IV Intravenous  
KRAS  KRAS  proto -oncogene  
mAb  Monoclonal Antibody  
MedDRA  Medical Dictionary for Regulatory Activities  
MET  MET proto -oncogene tyrosine kinase, hepatocyte growth factor receptor  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 21 of 164 MET  MET  proto -oncogene, hepatocyte growth factor receptor gene  
METEx14Del MET  exon 14 skipping alteration  
MRI  Magnetic Resonance Image/Imaging  
MTD  Maximum Tolerated Dose  
MUGA  Multi -Gate d Acquisition  
NE Not Evaluable  
NGS  Next -Generation Sequencing  
NOAEL  No Observed Adverse Effect Level  
NSAID  Nonsteroidal Anti -Inflammatory Drug  
NSCLC  Non-Small Cell Lung Cancer  
NYHA  New York Heart Association  
OR Objective Response  
OS Overall Survival  
PD Progressive Disease  
PDF Portable Document Format  
PDX  Patient -Derived Xenograft  
PFS Progression -free Survival  
PK Pharmacokinetic(s)  
PO Orally, by mouth  
PR Partial Response  
PS Performance Status  
PSA Prostate -Specific Antigen  
PTT Partial Thromboplastin Time  
qPCR  Quantitative Polymerase Chain Reaction  
Q2W  Every Second Week  
RECIST v1.1  Response Evaluation Criteria in Solid Tumors (Version 1.1)  
RP2D  Recommended Phase 2 Dose  
RTK  Receptor Tyrosine Kinase  
TKI Tyrosine Kinase Inhibitor  
SAE  Serious Adverse Event  
SD Stabl e Disease  
SISH  Silver In Situ  Hybridization  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 22 of 164 SMC  Safety Monitoring Committee  
SOC  System Organ Class  
SOI Start of Infusion  
SOP Standard Operating Procedure(s)  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
TEAE  Treatment Emergent Adverse Event  
TTP Time to Progression  
ULN  Upper Limit of Normal  
USA  United States  
WHO  World Health Organization  
WT Wild -Type  
 
PHARMACOKINETIC TERMS  
AUC τ Area under the concentration -time curve in a dosing interval  
AUC Norm, τ  Dose -normalized area under the concentration -time curve in a dosing interval  
CL Clearance  
Cmax Maximum Concentration  
Ctrough Trough Concentration  
Cz Last Quantifiable Concentration  
T½ Elimination Half -Life 
Tmax Time of Maximum Concentration  
Vz Volume of Distribution  
λz Terminal Rate Constant
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 23 of 164 3. BACKGROUND AND RATIONALE   
3.1 Disease and Treatment  
3.1.1 Solid Tumor Malignancies  
Cancers are malignant tumors formed by an abnormal growth of cells and t issue leading to organ 
failure. They fall into two categories: solid and hematological cancers. Solid tumors are formed 
by an abnormal growth of body tissue cells other than blood, bone marrow or lymphatic cells. A 
solid tumor consists of an abnormal mass of cells, which may stem from different tissue types 
such as lung, breast, colon, prostate, stomach and liver, and which initially grows in the organ of 
its cellular origin. In advanced stages of the disease, solid tumors may spread to other organs 
through  metastatic tumor growth.   
Cancer is the second -leading cause of death and disability in the world, only surpassed by heart 
disease. In 2012, 14.1 million people were diagnosed with cancer worldwide. An estimated 8.2 
million people died from the disease. The World Health Organization (WHO) projected that by 
2035, these figures could increase to 24 million new cases and 14.6 million cancer deaths 
worldwide. Lung, breast, colorectal, prostate and stomach cancer are the most common 
malignancies  (1). Non-small cell lung cancer (NSCLC) is the leading cause of death due to 
malignancy  globally  (31).  
3.1.2 MET -Amplified Solid Tumor Malignancies  
MET ( MET proto -oncogene tyrosine kinase, hepatocyte g rowth factor receptor, also known as c -
MET) is a receptor tyrosine kinase (RTK) containing an extracellular ligand -binding domain, a 
transmembrane domain, and an intracellular domain with tyrosine kinase activity. The 
hepatocyte growth factor (HGF), also k nown as scatter factor, is the only known ligand for MET. 
Binding of HGF to MET leads to receptor dimerization and autophosphorylation, which activates 
downstream signaling pathways and ultimately leads to increased cell proliferation, survival, and 
motili ty (2).   
Dysregulation of MET or HGF activity may occur through overexpression, gene -amplification, 
mutation, or alternative splicing of MET, or through HGF ligand -induced autocrine/paracrine 
loop signaling. Su ch dysregulation plays a role in many cancers by facilitating cancer 
invasiveness, angiogenesis, metastasis, and tumor growth, thus leading to a more aggressive 
cancer phenotype and a poorer prognosis. Recent preclinical and clinical results have indicated  
that MET  (MET proto -oncogene, hepatocyte growth factor receptor gene) -amplification confers 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 24 of 164 addiction to this receptor in cancer cells and make them susceptible to treatment with MET -
targeted therapeutics  (3,4). 
Depending on the methodology used for detection, varying frequencies of MET  amplification 
have been reported in solid tumor malignancies over the past few years. Fluorescence in situ  
hybridization (FISH) is cu rrently considered the gold st andard for detection of MET -
amplification, as this methodology makes it possible to distinguish between polysomy and true 
gene -amplification  (3). In accordance with the American Soc iety of Clinical Oncology (ASCO) 
and the College of American Pathologists ( CAP ) guidelines for testing of HER2 amplification  
(5), MET -amplification may be defined as positive with a MET/CEP7 ratio  (CEP7 being th e 
centromeric region of chromosome 7 ) of >2.2 (occasionally 2.0), equivocal with a ratio between 
1.8 and 2.2 , and negative with a ratio of <1.8 . Polysomy tends to yield a ratio in the equivocal 
range.  
In a recent study, MET -amplification (MET/CEP7 ratio >2  by FISH) was detected in 29 out of 
1,115 (2.6%) patients with advanced solid tumor malignancies (6). Tumor types where MET -
amplification was detected include d adrenocortical, renal cell, gastro -esophageal, brea st, ovaria n, 
colorectal , biliary, bladder, salivary gland  and lung carcinomas , as well as malignant  melanoma. 
This study also reported MET -amplification frequencies above 10% for certain tumors , albeit 
based on a limited number of patients. Based on FISH a nalysis in larger cohorts of patients, 
MET -amplification has been shown to occur in 3 %-4% of NSCLC (7,8,9,10) and in 4 %-6% of 
gastric cancers (11,12,13). A number of studies have also demonstrated a correlation between 
MET -expression by immunohistochemistry ( IHC) and MET -amplification by FISH (10,11). 
Mutations leading to skipping of MET exon 14 (METEx14Del) result in the deletion of the 
juxtamembrane domain of MET, which stabilizes and accumulates receptor on the cell surface 
and leads to enhanced signaling through the MET receptor pathway ( 13). MET  alterations that 
result in exon 14 skipping are found in 3 %-4% of lung adenocarcinomas, both in the presence 
and absence of MET -amplification and studies have demonstrated clinical benefit of targeting 
patients with tumors harboring METEx14Del (14-17). Over 100 mutations in MET -mutated cancers 
resulting in exon 14 skipping have been described ( 15). KRAS  proto -oncogene  (KRAS ) mutation 
appears  to be a cause of resistance to MET inhibition both in preclinical models  (19) and in the 
clinic  (20). According to the single study published to date that deals with  the prevalence of 
KRAS  mutation in MET -amplified tumors, 25% (4/16) of MET -amplified lung adenocarcinomas 
were found to harbor KRAS  mutations , and alterations of both MET  and KRAS  were found in 
0.8% (4/519) of treatment -naïve lung adenocarcinomas  (10). Because  these two  molecular 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 25 of 164 alteration s are rare in NSCLC patients , testing of KRAS  status in clinical trials involving anti -
MET therapy may not be warranted (10,19). 
NSCLC patients with either MET -amplification or METEx14Del have been documented to have a 
poor prognosis ( 32). MET -amplification was observed in 0.7% of all patients with NSCLC and 
MET mutations were observed in 2.6% of patients in this population.  
3.1.3 Current Treatment of MET -Amplified Solid Tumor Malignancies  
There are currently no approved therapeutics for targeted treatment of MET -amplified solid 
tumor malignancies. However, m ultiple c ompounds targeting the MET/HGF pathway are being 
evaluated in the clinic. These include both small -molecule tyrosine -kinase inhibitors, such as 
crizotinib, cabozantinib , tivantinib, tepotinib, and capmatinib as well as single monoclonal 
antibodies ( mAbs ). The small -molecul e inhibitors are generally promiscuous in their target 
specificity and may have activity on additional RTKs besides MET. The activity of MET 
inhibitors in patients with NSCLC has recently been reviewed ( 33), and more recent data are 
cited below with respect to additional inhibitors.  
Crizotinib is an inhibitor of MET, ALK, and ROS1 . Crizotinib has been approved for treatment 
of advanced NSCLC harbori ng ALK translocations and  has shown promising results in an 
ongo ing Phase 1 clinical trial in MET -amplified NSCLC patients  (21). The degree of MET -
amplification , determined by  FISH,  correlated closely with the observed response rate; there 
were no responses in patients with tumors classed as low -level amplified, and response rates of 
20% and 50% were observed in tumors  classed as having medium or high  levels of MET -
amplification , respectively.  
Tepotinib is another MET tyrosine kinase inhibitor (TKI) that has been studied in P hase 1 and 
Phase 2 clinical studies.  A recent study was reported showing evidence of antitumor activity in 
patients with METEx14Del. The preliminary data documented that 60% of patients treated with 
tepotinib in this study had confirmed partial responses (PR) ( 34). 
Capmatinib (INC280), a MET TKI, is also in Phase 2 studies enrolling NSCLC patients with 
METEx14Del as well as in combination with gefitinib in patients with epidermal growth factor 
receptor ( EGFR )-mutated MET  dysreg ulated NSCLC. An overall response rate of 72% was 
observed in treatment -naïve patients compared to a 39% objective response rate  in previously 
treated patients with advanced METEx14Del-positive NSCLC ( 35). 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 26 of 164 AMG 337 is an investi gational selective MET inhibitor that has shown promising clinical 
activity . An objective response (OR) was observed in 8 out of 13 patients with MET -amplified 
gastroesophageal junction, gastric, or esophageal cancer (22). 
LY2875358 (emibetuzumab) is a humanized IgG4  anti-MET mAb  that is reported to block 
ligand binding and induce target internalization. LY2875358 has demonstrated preliminary 
evidence of antitumor activity  (durable PR in 2 of 13 patients) in comb ination with erlotinib in 
patients with tumors positive for MET -expression and is currently being evaluated in Phase 2 
trials (23).  
ABT -700 is a humanized immunoglobulin G1 ( IgG1 ) mAb with an engineered hinge r egion that 
inhibits MET receptor dimerization and induces receptor internalization and antibody -dependent 
cellular cytotoxicity (ADCC)  in tumor cell lines  in vitro . ABT -700 has demonstrated potent 
activity as a single agent in patients with MET -amplified t umors (tumor regression in 5/8 
patients)  (24).  
ARGX -111 is a  third mAb that has rec ently entered clinical trials. ARGX -111 is  a human IgG1  
mAb , which has been glyco -engineered to enhance ADCC activity. In  the Phase 1 dose -
escalation trial , the only patient with a MET -amplified tumor maintained stable disease during 6 
months of treatment  (25).  
3.2 Investigational Medicinal Product  
3.2.1 Sym015  
The investigational medicinal prod uct (IMP) tested in this trial is Sym015.  
Sym015 is a recombinant antibody mixture containing 2 humanized IgG1 mAbs, designated 
Hu9006 and Hu9338, which bind specifically to MET, the receptor for HGF. Preclinical studies 
have shown that Sym015 effectively  down -regulates the target and has superior tumor growth 
inhibitory activity compared to other antibodies targeting this receptor. Sym015 is intended for 
the treatment of solid tumor  malignancies  with amplification of the gene encoding MET.  
Sym015 is a clear to opalescent, colorless to slightly yellow  liquid to be administered as an 
intravenous (IV) infusion through a peripheral line or indwelling catheter.  
3.2.2 Mechanism of Action  
The two antibodies of Sym015 bin d to non -overlapping epitopes on the SEMA -α domain of 
MET. This allows the antibodies to bind simultaneously to the receptor and effectively induce 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 27 of 164 receptor  internalization and degradation. Through this mechanism, Sym015 effectively inhibits 
cell-prolifera tion and tumor growth in models where MET is constitutively activated. Moreover, 
Sym015 blocks HGF -binding to the receptor and is thus also capable of inhibiting HGF -induced 
MET phosphorylation and cell -proliferation. In addition, Sym015 induces effector f unctions, 
including ADCC, which may contribute to the activity  observed  in vivo . 
3.2.3 Summary of Non -Clinical Findings  
Sym015 demonstrates potent antitumor activity in a number of MET -dependent cell line and 
patient -derived xenograft (PDX) tumor models, includi ng esophagogastric and NSCLC models.  
Response to Sym015 was observed in models with MET -amplifi cation , METEx14Del, and 
autocrine HGF -expressi on. Sym015 also retains full efficacy in  MET -amplified models in human 
HGF transgenic mice . Sym015 is in many cases  superior to a LY2875358 (emibetuzumab) 
analogue and is also active in tumor models that escape treatment with this antibody. Based on 
the preclinical models, KRAS  mutation appears to predict resistance to Sym015 treatment  
(25,26).  
In vivo  safety and pharmacokinetics (PK) of Sym015 w ere evaluated in non -human primates. 
MET is evolutionarily conserved between cynomolgus monkeys and humans and Sym015 
recognizes both hum an and cynomolgus MET with the same, high affinity . Thus, the 
cynomolgus monkey is considered a pharmacologically relevant model in which to study toxicity 
and PK . 
In the pivotal repeat -dose toxicity study , the toxicity of Sym015  was determined following 
weekly IV infusion s (30 minutes  infusion time ) at 15  mg/kg , 50 mg/kg , or 100 mg/kg  to 
cynomolgus monkey s for 4 weeks  followed by a 6-week treatment -free period  in the high dose 
group . 
No unscheduled deaths occurred during the course of the study . Sym015 did  not exert effects on 
cardiovascular functions  and was overall well tolerated in the monkeys . However, soft, liquid,  or 
loose feces  were observed in treated animals, with a higher incidence in high dose males.  At the 
end of the recovery period, there was n o evidence of delayed onset toxicity in previously treated 
animals.  
No in vivo  agonistic activity of Sym015 was observed as judged by Ki67 expression 
(proliferation marker) in liver, kidney, duodenum,  and heart  at study termination . Toxicokinetic 
profiles showed that all treated animals were exposed to Sym015 throughout the entire duration 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 28 of 164 of the study . Target engagement, documented by reduced MET expression in tissue s, was 
observed for all dose levels tested.  
In the initial elimination phase, the serum  half-life (T ½) of Sym015 after a single dose of 15 
mg/kg ranged from 8 -23 days, while in the terminal elimination phase the T ½ ranged from 5 -8 
days. Upon repeat, once -weekly dosing of Sym015 at 15  mg/kg , 50 mg/kg , or 100 mg/kg 
produced a 2-fold accumulation o f Sym015 over a period of four weeks.  
In conclusion, the 100 mg/kg dose level is considered the no observed adverse effect level  
(NOAEL) of Sym015 in monkeys.  
For further information, refer to the Investigator’s Brochure.  
3.2.4 Summary of Clinical Findings  
3.2.4.1  Proto col Sym015 -01 
This is the first clinical trial to study Sym015.  As of Amendment 5 , a total of 12 patients were  
enrolled in the completed Part 1 of this trial : 3 patients at each of 4 dose levels (6  mg/kg , 12 
mg/kg , 18 mg/kg , and 24  mg/kg , dosed every secon d week  [Q2W ]). All 4 dose levels were  
considered well tolerated, no DLTs or trial drug-associated serious adverse events (SAEs) were  
reported. A total of 2 of 3 patients entered to the 18 mg/kg cohort experienced infusion -related 
reactions (IRRs) with the first dose of trial drug.  Reactions were  characterized in one patient by 
nausea, a “cotton -mouth”  sensation , and wheezing, and characterized in the second patient by 
cough, shortness of breath, and a transient oxygen saturation decrease to 87% that did no t require 
delivery of supplemental  oxygen .  In each case, the infusion was interrupted for approximately 
30 minutes while the patient was treated with a glucocorticoid and an antihistamine; upon 
resolution of symptoms, the infusion was restarted at a slowe r rate and completed without further 
incident.  As a result of these two events, the duration of Sym015 infusion was extended from 1 
hour to 2 hours for the affected patients, and the duration of Sy m015 infusion was extended per 
protocol  from 1 hour to 1.5  hours for subsequent patients entered at this dose and higher doses.  
No additional IRRs were  reported with the longer duration of infusion  in the remaining patients 
treated during Part 1 of the trial.  While data in this ongoing clinical trial have not b een fully 
monitored, other observed trial drug -associated adverse events ( AEs) noted have included fatigue 
in 2 patients, and single episodes of nausea, dyspepsia, vomiting, diarrhea, peripheral edema, 
weight decrease, and hypokalemia ; all AEs were Grade 1  or Grade 2 in severity .  Part 2 of the 
study is open to accrual.    
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 29 of 164 As of September 2018 , a total of 21 MET -amplified patients and 2 METEx14Del patients have been 
enrolled in the ongoing Part 2 portion  of this trial to receive Sym015 at a loading dose of 1 8 
mg/kg delivered over 1.5 hours, followed by Q2W maintenance doses of 12 mg/kg delivered 
over 1 hour.  In a single  patient,  the SAEs of Grade 3 colitis which resulted in Grade 3 septic 
shock (both possibly -related) have been reported ; these 2 events occur red in a patient with 
metastatic gastric carcinoma and a history of total gastrectomy with esophagojejunostomy  whose 
diarrhea present at baseline worsened  after administration of 3 doses  of Sym015 .  In another 
patient, the SAEs of Grade 3 anasarca  and Grad e 3 hypoalbuminemia (both possibly related ) 
have been reported . Other study drug -related AEs have been limited to Grade 2 fatigue and 
mouth sores, and Grade 1 asthenia, anorexia, gastric pain, abdominal cramping, abdominal gas, 
nausea, diarrhea, constipati on, xerosis , pruritus, and voice change.  In addition to the Grade 3 
hypoalbuminemia noted, other laboratory abnormalities reported as study drug -related AEs have 
been Grade 1 in severity and have included: anemia; prolongations in prothrombin time  and 
international normalized ratio ( INR); and elevations in aspartate aminotransferase  (AST ), alanine 
aminotransferase (ALT ), gamma -glutamyl transpeptidase (GTP ), and blood bilirubin .  Accrual to 
the Part 2 portion of the trial continues.  
Note:   Effective with protocol  version 8.0 ( December  2018), accrual to the Part 2 Basket Cohort comprised of 
patients with MET -amplified solid tumor malignancies is suspended; accrual will continue to cohorts of patients 
with MET -amplified NSCLC or METEx14Del NSCLC.  
3.2.4.2  Other Monoclo nal Antibodies Targeting MET  
Based on available literature/reports, mAbs  targeting  MET appear to be generally well tolerated. 
No dose -limiting toxicities (DLTs) or SAEs were  observed in the Phase 1 trials with LY2875358 
or ABT -700. The most frequent treatm ent-related AEs were nause a, vomiting, and diarrhea for 
LY2875358 and constipation, fatigue and decreased appetite for ABT -700 (23,24). Two DLTs  of 
infusion -related r eactions (IRRs)  have been reported  with the glyco -engineered ARGX -111. 
IRRs  were the overall most common adverse event with this drug (likely a class effect  of glyco -
engineered antibodies ), followed by fatigue and nausea  (25). Based on nonclinical results, 
Sym015 appears to have a safety profile similar to that of LY2875358 and ABT -700. 
3.3 Trial Rationale  
As outlined in the sections above, recent  results suggest that MET -amplification and METEx14Del 
identify small b ut clinical ly important subgroup s of patients who are likely to respond to MET 
target ed therapies . The potent tumor inhibitory activity, observed in preclinical studies in  models 
with MET -amplification and/or METEx14Del, suggests that Sym015 may provide a clinically 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 30 of 164 relevant effect in these patient population s. Based on the nonclinical pharmacology and toxicity 
testing,  Sym015 is expected to continue to be well  tolerated and the benefit -risk ratio for patients  
enrolled  is considered to be favorable.  
3.4 Dose Ra tionale  
3.4.1 Rationale for Starting Dose  
The starting dose of 6 mg/kg Sym015 has been selected based on demonstrated safety of 
Sym015 in nonclinical studies in cynomolgus monkeys  (refer to Section 3.2.3 ). In these st udies, 
dose levels that are multiples (2.5 - to 17-fold) of the anticipated clinical starting dose of 6 mg/kg 
were  tested to provide a safety margin. All dose levels resulted in high levels of exposure to 
Sym015 . The NOAEL was determined as 100 mg/kg in cyn omolgus monkeys. In addition, the 
results of nonclinical pharmacology, pharmacodynamic, PK, and toxicology studies provide 
guidance with respect to potential target serum levels of Sym015 to down -regulate MET in 
tissues and that correlate with efficacy in animal models.  
The dosing schedule to be explored in this clinical trial is based on nonclinical data documenting 
the concentrations of Sym015 required for downregulation of MET, inhibition of cancer cell 
lines in vitro , and in vivo  activity in murine mode ls. PK data (long terminal T ½ and accumulation 
with weekly dosing) support the selection of the dosing schedule, dosing every second week 
(Q2W),  to be evaluated in this trial.  
IV dosing is being pursued to maximize exposure to Sym015 while minimizing the p otential for 
adverse effects and immunogenicity. Based on the anticipated doses required , neither 
subcutaneous nor intramuscular dosing have been  considered for initial evaluation of Sym015.  
3.4.2 Rationale for Recommended Phase 2 Dose  
As of Amendment 4 , followi ng review of available safety (refer to Section  3.2.4.1 ) and PK data, 
the decision has been made to choose the following as the recommended Phase 2 dose (RP2D) 
on a Q2W schedule of Sym015  (referenced as the Q2W RP2D) :   
 Loading dose of 18 mg/kg  infused over 1.5 hours on Cycle 1/Day 1 (C1/D1)  
 Followed by Q2W maintenance doses of 12 mg/kg infused over 1 hour beginning on 
Cycle 1/Day 15 ( C1/D15) 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 31 of 164 The rational for this choice is based upon preliminary PK data from the  initial 6 mg/kg Q2W 
(N=3, 2 -3 cycles) and 12 mg/kg Q2W (N=3, up to Cycle 2/Day 1) cohorts treated in the dose -
escalation phase of this trial.  These data were used to establish a population PK model.  
The summary PK parameters for these data, based on non -compartmental analysis, are listed in 
Table 1. 
Table 1 Preliminary Sym015 Geometric Mean PK Parameters  
Dose  
Q2W  N AUC 0-336h  
1st dose  
(h x μg/mL)  Cmax 
1st dose  
(μg/mL)  Ctrough  
2nd dose 
(μg/mL) Cmax 
3rd dose  
(μg/mL)  t½ 
1st dose  
(h) 
6 mg/kg  3 19400  146 35.9 196 158 
12 mg/kg  3 40000  294 119 396 213 (n=1)  
Abbreviations: AUC , area under the concentration -time curve in a dosing interval;  Cmax, maximum concentration ; C trough, trough 
concentration ; h, hour; N, number of patients;  Q2W, dosing every second week; t ½, elimination half -life 
 
The model was used to simulate average and 90% confidence intervals for Sym015 PK profiles 
for the 18+12 mg/kg Q2 W regimen, and demonstrated that pre -dose serum concentrations, 
Ctrough, are likely to be above 100 μg/mL for the vast majority of patients for all dose 
administrations. The serum concentration of 100 μg/mL has been defined as an approximate 
threshold for clinical efficacy. This has been  deduced from the 750 mg Q2W dose regim en of 
another anti -MET monoclonal antibody, emibetuzumab, which has shown signs of efficacy in 
patients with MET -amplified tumors (23,28).  It is assumed that similar  serum concentrations of 
Sym015 and emibetuzumab will result in similar clinical efficacy because similar potencies 
between the two compounds have been observed in preclinical in vitro  and in vivo  studies (refer 
to Investigator’s Brochure) . In vivo  studies  also support that efficacy can be expected at 
concentrations above 100 μg/mL for both compounds.   
3.5 Overall Benefits/Risk  
It is not possible to quantify the potential benefit to individual patients entering this Phase 1 trial. 
Definite, but sometimes limite d, antitumor activity has been reported  in many Phase 1 trials , 
including other trials of MET -targeted agents.   
In this trial there will be an ongoing assessment of the risks with periodic evaluation of safety 
data. The trial will be discontinued in the e vent of any new finding  indicating a risk that would 
render continuation of the trial unjustifiable.  
In order to mitigate potential risks, the trial is designed to detect DLTs , if any, and to define a 
maximum tolerated dose (MTD), if this is observed in th e range of doses planned for the trial. 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 32 of 164 Enrollment will be staggered between the first and second patient in each new higher dose level 
tested in order to ensure safety, before allowing concurrent enrollment of further patients at the 
given dose level. If the dose administered in a cohort is safe and well -tolerated, dose -escalation 
may proceed , and enrollment of subsequent cohorts may occur in order to establish a Q2W 
RP2D  and to define an MTD or highest safe dose . The potential to slow infusions, interrupt  
dosing, decrease the dose administered, and discontinue administration of Sym015 in the even t 
of specific AEs is outlined. In addition, steps to prev ent IRRs, and measures to intervene in the 
event of their occurrence are specified.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 33 of 164 4. TRIAL OBJECTIVES  
4.1 Objectives of Part 1, Dose -Escalation  
4.1.1 Primary Objective  
To assess the safety and tolerability of Sym015 when administered by IV infusion  on a Q2W 
schedule  to patients with KRAS wild-type (WT) advanced solid tumor malignancies without 
available therapeutic  options.   
4.1.2 Secondary Objectives  
1. To determine a Q2W RP2D of Sym015  
2. To evaluate the PK profile of Sym015  
3. To evaluate target -engagement in skin biopsy tissue  
4. To evaluate the immunogenicity of Sym015  
5. To evaluate potential pharmacodynamic biomarkers of Sym015 act ion, and estimate, if 
feasible, the magnitude of biological activity  
6. To make a preliminary evaluation of the antitumor activity of Sym015  
4.2 Objectives of Part 2  
4.2.1 Primary Objective  
To evaluate the antitumor activity of Sym015 wh en administered at  the Q2W RP2D  to patients  
in the following cohorts:  
1. Basket Cohort : MET -amplified, KRAS  WT solid tumor malignancies without available 
therapeutic  options ; patients may not have received prior therapy with a MET -targeting 
TKI  
2. NSCLC MET -Amplified Cohort : MET -amplified  advanced NSCLC without available 
therapeutic options ; patients may have received prior therapy with MET -targeting and/or 
EGFR -targeting agents    
3. NSCLC METEx14Del Cohort : METEx14Del advanced NSCLC  without available therapeutic 
options ; patients may have rece ived prior therapy with MET -targeting and/or EGFR -
targeting agents  
4.2.2 Secondary Objectives  
1. To further evaluate the safety and tolerability of Sym015  when administered at the Q2W 
RP2D  
2. To further evaluate the PK profile of Sym015 when administered at the Q2W R P2D 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 34 of 164 3. To further evaluate the immunogenicity of Sym015  when administered at the Q2W RP2D  
4. To further  evaluate potential pharmacodynamic biomarkers of Sym015 action, and 
estimate, if feasible, the magnitude of biological activity  when administered at the Q2W 
RP2D 
5. Basket Cohort : To make a preliminary assessment of the antitumor activity of Sym015, 
and to evaluate all of the above secondary objectives, in a subset of approximately 6 
patients with solid tumor malignancies administered Sym015 at the Q2W RP2D after 
having received prior therapy with a MET -targeting TKI  
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 35 of 164 5. TRIAL DESIGN  
5.1 Overall Design and Plan  
This is an open -label, multicenter  trial composed of 2 parts : 
 Part 1 is a Phase 1a dose -escalation in patients with KRAS WT advanced solid tumor 
malignancies with out available therapeutic options.  
 Part 2 is a Phase 2a dose -expansion  in which dosing will be at the RP2D on an every 
second week (Q2W) schedule .  Three cohorts will be included:  
o Basket* Cohort:  A cohort  of approximately 25 patients  with KRAS  WT advanced 
solid tumor malignancies with MET -amplifi cation , and without available 
therapeutic options. Included in this group will be a subset of approximately 6 
patients who have received prior therapy with a MET -targeting TKI.   
Note:   Effective with protocol  versi on 8.0 ( December  2018), accrual to the Basket Cohort is 
suspended.   
o NSCLC MET -Amplified Cohort : A cohort of approximately 20 patients with 
advanced NSCLC with MET -amplification, and without  available therapeutic 
options.  Patients may have received prior t herapy with MET -targeting and/or 
EGFR -targeting agents . 
o NSCLC METEx14Del Cohort : A cohort of approximately 6-12 patients with advanced 
NSCLC with METEx14Del, and without  available  therapeutic options.  Tumors need 
not be MET -amplified , and patients may hav e received prior therapy with MET -
targeting  and/or EGFR -targeting agents . 
*A basket cohort is designed to evaluate the potential antitumor effects of a targeted 
therapy by enriching for patients with a defined genetic alteration (e.g. , mutations in or 
overexpression of a specific gene(s)) regardless of the histotype of the enrolled 
patients’ tumors.  
During Part 1 , dose-escalation , cohorts of patients with KRAS WT advanced  solid tumor 
malignancies will receive increasing doses of Sym015 on a Q2W schedule until establishment of 
the MTD or until 24 mg/kg has been evaluated.  Dose -escalation will follow a standard 3+3 
design with escalation dependent upon the occurrence of DLTs. The following dose levels of 
Sym015 will potentially be evaluated:  
 Dose Level 1: 6 m g/kg  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 36 of 164  Dose Level 2: 12 mg/kg  
 Dose Level 3: 18 mg/kg  
 Dose Level 4: 24 mg/kg  
An MTD may or may not be reached in the range of doses tested.  
A safety monitoring committee (SMC) will be established  and will include Investigator(s), 
Medical Monitor(s), and S ponsor’ s medical representatives. The SMC  will review clinical and 
laboratory safety data regularly  throughout the trial . The SMC will select the Q2W RP2D to be 
used in Part 2 based on safety data  and available PK results.   
Note:  Effective with protocol  version 5.0 ( November 2016), follow ing review of available safety and PK 
data, the decision has been made to choose the following as the Q2W RP2D of Sym015:  Loading dose of 
18 mg/kg infused over 1.5 hours on C1 /D1, followed by Q2W maintenance doses of 12 m g/kg infused 
over 1 hour  beginning on C1/D15 . As the MTD has not yet been reached, dose -escalation will continue in 
Part 1 of the trial to 24 mg/kg.  
During Part 2 , three cohorts will receive Sym015 at the RP2D on a Q2W dosing schedule : 
 Basket Cohort : A basket cohort of KRAS  WT, advanced solid tumor malignancy patients 
with MET -amplifi cation  will be evaluated . Patients must be MET -targeting TKI -naïve; an 
exception will be a subset of approximately 6 patients entered who have received prior 
therapy with a MET -targeting TKI . 
Note:  Effective with protocol  version 8.0 ( December 2018), accrual to the Basket Cohort is suspended.  
 NSCLC MET -Amplified Cohort : A cohort of advanced NSCLC patients with MET -
amplification  will be evaluated.  Patients may have received pri or therapy with MET -
targeting and/or EGFR -targeting agents . 
 NSCLC METEx14Del Cohort : A cohort of advanced NSCLC patients with METEx14Del will 
be evaluated. Tumors need not be MET -amplified , and patients may have received prior 
therapy with MET -targeting and/or EGFR -targeting agents .  
The trial design is shown in  Figure 1. 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 37 of 164 Figure 1 Overall Trial Design   
 
 
Abbreviations: EGFR , epidermal growth factor receptor; Dec , December; KRAS , KRAS  proto -oncogene ; MET , MET  proto -oncogene ; 
METEx14Del, MET  exon 14 skipping  alteration ; N, number of patients; NSCLC, non -small cell lung carcinoma; Q2W, dosing every second 
week ; RP2D, recommended Phase 2 dose; TKI, tyrosine kinase inhibitor; WT, wild -type 
 
Part 1 will be conducted in the United States ( USA ). Part 2 will be conducted in the USA and 
countries within the Asia Pacific and European region s. The number of investigational trial sites, 
hereafter called “trial sites”, expected to participate , will be approximately 2 to 3 in Part 1 and 15 
to 27 in Part 2.   
5.2 Discussion of Trial Design  
5.2.1 Rationale for Trial Design  
Part 1 of this trial utilizes a standard dose -cohort escalation with groups of a minimum of three 
patients evaluated for safety and tolera bility of Sym015 in each cohort.  In the event of a DLT , a 
cohort will be expanded to six patients.  If tolerability is demonstrated (0/3 DLT, 1/6 DLT) in 
any cohort , escalation to the  next dose level will be permitted. This part of the  trial is designed t o 
select a safe and well -tolerated dose of Sym015 on a Q2W  schedule . Part 2 of this trial is 

Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 38 of 164 designed to evaluate  the antitumor activity of Sym015 administered at  the selected RP2D  on a 
Q2W  schedule.  
The choice of a basket cohort (i.e., patients with MET -amplified, KRAS  WT, advanced  solid 
tumor malignancies of any tissue origin ) for Part 2 is expected to allow for effective recruitment 
of patients with this relatively rare molecular alteration within a reasonable period of time. 
Emerging literature allow ed for the identification of specific tumor types that are more likely to 
respond  to Sym015 treatment  (e.g., NSCLC) .  
Note:   Effective with protocol  version 8.0 ( December  2018), accrual to the Basket Cohort is suspended.  
5.2.2 Rationale for Trial Population  
In Par t 1, patients with KRAS  WT advanced solid tumor malignancies without other treatment 
options will be entered in order to evaluate the safety and tolerability of Sym015.  
In Part 2,  patients with MET -amplified , KRAS  WT, advanced solid tumor malignancies of any 
tissue origin will be entered to evaluate the antitumor activity of Sym015  in the Basket Cohort . 
In addition, a cohort of NSCLC patients  with MET -amplification  and a cohort  of NSCLC 
patients  with METEx14Del will be entered to evaluate the antitumor act ivity of Sym015  in these 
populations .  
Nonclinical studies have documented that the activity of Sym015 is greater in tumors with MET -
amplifi cation and/or METEx14Del, suggesting that Sym015 may provide a clinically relevant effect 
in these patient populatio ns.  S imilar findings have been observed in preliminary studies in 
patients with MET -amplified tumors with other anti -MET mAbs  in early clinical trials . 
5.3 Schedule of Events  
The overall trial plan is introduced in Table 2 and further defined in the following sections.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 39 of 164 Table 2 Overall Trial Plan  
Screening Period  
Screening  Within 14 days prior to the first dose of Sym015  
Treatment Period  
Treatment Allocation  The allocated dose and dosing sche dule of Sym015 will depend upon cohort 
assignment and will be confirmed in writing by the Sponsor or designee on 
the Screening and Allocation Form.  
Sym015  Sym015 will be initiated on C1/D1 and will be administered by IV infusion 
in cycles of treatment:  
 Q2W dosing  
o Day 1 and Day 15 of each 28 -day cycle (± 2 days)  
Sym015 will be administered following delivery of premedication prior to 
each infusion.  In Part 2, i f the patient is without evidence of IRRs after 
Cycle 1 , the Investigator may opt to withdraw prem edication  on a patient -
by-patient basis  with subsequent dosing.  
Discontinuation of Sym015  Treatment will continue until unacceptable toxicity or other conditions 
preventing further treatment, PD, termination of the trial , or patient’s 
decision to withdraw . 
End of Treatment  
End of Treatment Visit  Within 10 days following the decision to discontinue Sym015 , an EOT Visit 
must be performed.  
Follow -up 
1-Month Follow -up Visit  Follow -up continues until 1  month ( 30 + 7 days) after the last dose of 
Sym015. At t hat time, a 1M FUP Visit must be performed .  
Continued follow -up for 
response and/or  for OS  After the 1M FUP Visit, the Investigator will make every effort to obtain 
follow -up information on response assessment and /or OS about once every 2 
months . Respons e assessment follow -up is required in the event of an 
ongoing SD, PR or CR at the 1M FUP Visit, until PD or another therapeutic 
intervention is initiated.  Survival follow -up is required until death, 
withdrawal of consent, trial site closure, or termination /end of the trial.   
Occurrence of one of these events constitutes the end of study (EOS) for the 
patient.  
The continued follow -up does not require an in -person v isit at the trial site, 
but may be obtained by collection of data/documentation.  
Abbreviations  (in alphabetical order): C1/D1, Cycle 1/ Day 1;  CR, complete response;  EOS, End of Study; EOT, End of Treatment Visit; 
IRR, infusion -related r eaction; 1M FUP, 1-Month Follow -up Visit; OS, overall survival; PD, progressive disease, PR, partial response; Q2W , 
every second week; SD, stable disease  
 
5.3.1 Prescreening for MET -amplification  and METEx14Del Status  
The trial site may choose to prescreen patients utilizing genomic analysis (e.g., Guardant360 or 
other similar liquid biopsy methodology) or tumor tissue (archival , or recently obtained  if 
acquired outside of the screening process as part of the site’s usual practice ) to assess  MET -
amplification status  and METEx14Del status  before entering patients into screening  for the 
treatment portion of the trial . In this case, the site will use a separate pre -screening informed 
consent form.   
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 40 of 164 Peripheral blood collection for assessment in circulating tumor deoxyribonucleic acid  (ctDNA ) 
(also referred to as “liquid biopsy”) may be used as a local pre -screening methodology by 
Guardant360 analysis  (http://guardanthealth.com ).  Other liquid biopsy methodologies , if used to 
detect METEx14Del, are acceptable alternatives .     
All patients giving informe d consent for prescreening will re ceive a unique prescreening number. 
This number is composed of the prefix “PS”, followed by a three -digit number, allocated 
sequentially starting from 001, i.e. . PS001, PS002, PS003 , etc. The trial site must maintain a 
prescreening log detailing the result s for prescreened patients. This log will list the patient’ s 
prescreening number , and if the patient continues into full screening, the patient’s unique patient 
number as defined in the following section.  
5.3.2 Screening  
When the trial site identifies a patient  suitable for screening, the Sponsor or designee should be 
contacted to ensure that a cohort is open for inclusion  (applies to Part 1 only) . With this 
assurance , the patient may be approached for informed consent. Screening activities may begin 
only once w ritten informed consent has been obtained.  
All patients giving informed consent to participate in the trial will receive a unique patient 
number. This number will identify the patient throughout the trial and  will be  composed of : a 
five-digit prefix, which  identifies the country and site; a three -digit number, allocated 
sequentially starting from 001 for the first patient screened at the site, 002 for the second patient 
screened , etc. 
The trial site staff must complete a Screening and Allocation Form , stati ng the allocated patient 
number along with the planned dates of screening and the day of first scheduled Sym015 
administration (C1/D1). The planned date of C1/D1 will be agreed upon in collaboration with 
Sponsor or designee for the dose -escalation cohorts in order to ensure adequate time between 
dosing of the first patient and dosing of subsequent patients within each cohort  (applies to Part 1 
only) . The completed Screening and Allocation Form  will then be sent to the Sponsor or 
designee prior to or on the day of Screening.  
Once eligibility has been confirmed in accordance with the inclusion and exclusion criteria, the 
Screening and Allocation Form  will be fully completed and signed by the Investigator and resent 
to the Sponsor or designee. Sponsor or design ee will approve each patient for start of treatment. 
A copy of the fully executed Screening and Allocation Form  will be returned to the trial site for 
archiving. This form documents the allocated dose and dosing schedule of Sym015.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 41 of 164  Part 1 : Patients in Part  1 with known MET -amplification who consent to optional biopsies 
will have a biopsy performed  for biomarker analysis  (archival tissue or tissue from a 
biopsy performed  during screening as part of eligibility assessment  may be submitted ) 
 Basket Cohort : All patients in the Part 2  Basket Cohort will have a tumor biopsy 
performed  for biomarker analysis ( tissue from a biopsy performed during screening as 
part of eligibility assessment  is preferred, however archival tissue may be submitted  at 
the Investigator’s d iscretion ).   
 NSCLC MET -Amplified Cohort : All patients in the Part 2 NSCLC MET -Amplified 
Cohort will have a tumor biopsy performed and submitted for central confirmation of 
MET -amplification status,  and for biomarker analysis .   
Note: Peripheral blood for ctDNA analysis by Guardant 360 will be obtained for assessment of 
MET -amplification status. If central confirmation of MET -amplification status cannot be assessed 
in tumor due to assay failure/technical error, the Sponsor may decide to enroll based on MET -
amplification detected by Guardant360 on a case per case basis. As data are acquired on 
concordance between findings in tumor  tissue versus ctDNA, the Sponsor may decide to 
transition to screening for MET -amplification using Guardant360 analysis only (e.g. , 2+ or 3+ 
amplification score) without requiring confirmation in a recent or newly performed tumor biopsy.  
 NSCLC METEx14Del Cohort : All patients in the Part 2 NSCLC METEx14Del Cohort  will 
have a tumor biopsy performed and submitted for central assessment  of METEx14Del 
status, and for biomarker analysis.   
 All patients in Part 1 will have a skin biopsy performed for biomarker analysis  
 All patients in Part 1 and Part 2 will have a blood sample taken for biomarker analysis  
All safety screening activities must  be performed within 14 days prior to C1/D1, unless 
otherwise specified. Individual safety screening assessments may be repeated prior to C1/D1, if 
justified and documented by the Investigator.  
5.3.3 Screening Failures  
A patient found not eligible after giving i nformed consent to the trial is considered a screening  
failure. The Screening and Allocation Form  must be completed and sent to the Sponsor or 
designee to confirm the outcome of the screening process.  
Re-screening of a patient will be allowed, if justified  and documented by the Investigator.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 42 of 164 5.3.4 Treatment  
On the day of the first scheduled Sym015 infusion  (C1/D1 ) and prior to the start of infusion 
(SOI), the Investigator must assess whether any changes have occurred in the clinical state of the 
patient , which wo uld exclude the patient from the trial.  
Sym015 will be administered o n a Q2W schedule by IV infusion:  
 Q2W dosing: Day 1 and Day 15 of each 28 -day cycle (± 2 days)  
There will be no intra -patient dose -escalation.  
For all patients, the dose to be administer ed and the dosing schedule will be documented on the 
Screening and Allocation Form.  
In the event of toxicity due to Sym015, dosing may be delayed , and/or the dose may be reduced, 
as described in Section 7.1.4 . 
Treatment will continue until unacceptable toxicity or other conditions preventing further 
treatment, progressive disease ( PD), termination of the trial, or patient’s decision to withdraw.  
5.3.5 End of Treatment and Follow -up Visit s 
An End of Treatment  (EOT ) Visit will be performed for all patients within 10 days following the 
decision to discontinue treatment.  
The patient will return for a 1-Month F ollow -up Visit (1M FUP) 30 (+7) days after the last dose 
of Sym015 .  
After the 1M FUP Visit, the Investigator will make every effort to obtain follow -up information 
on response assessment and/or overall survival ( OS) about once every 2 months. Response 
assessment follow -up is required i n the event of an ongoing stable disease (SD) or objective  
response (OR, defined as PR or complete response [ CR]), as per the Response Evaluation 
Criteria in Solid Tumors  (Version 1.1) (RECIST  v1.1) (29) at the 1M FUP Visit, until PD or 
another therapeutic intervention is initiated. Survival fo llow-up is required until death, 
withdrawal of consent, trial site closure, or termination /end of the trial.   Occurrence of one of 
these events constitutes the EOS for the patient.  This continued follow -up does not require an 
in-person v isit at the trial site, but may be obtained by collection of data/documentation.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 43 of 164 5.3.6 Flow Chart – Schedule of Assessments  
Schedules of assessments are provided in the trial flow chart s in Table 3 (Part 1 and Part 2 
Basket Cohort ) and Table 4 (Part 2 NSCLC Cohorts) . 
All efforts should be made to perform assessments as close as possible to the scheduled time 
points. Visit windows are included in the flow chart.  
The projection of visit days within  each cycle must be made from Day 1 of the respective cycle. 
Furthermore, each  new cycle must  be initiated as soon as possible after completion of the 
previous cycle in order to achieve the Q2W dosing schedule.
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8 .0 
Confidential     Page 44 of 164 Table 3 Flow Chart: Sc hedule of Assessments  (Part 1 and Part 2 Basket Cohort)  
Pre-Treatment P eriod  Treatment P eriod1 Post-Treatment P eriod2 
 Screening  Cycle 1  Cycle 2, 4, 6 etc.  Cycle 3, 5, 7 
etc. EOT  1M FUP2 
Day within Cycle  
Visit Window ( ± days)  D-14 to D -1 D1 D3 D8 
(±2) D15 
(±2) D22 
(±2) D1 
(±2) D15 
(±2)  
End of 
Cycle  D1 
(±2) D15 
(±2) ≤ 10 d 
following the 
decision of trial 
treatment  
withdrawal  1 month after last 
dose of trial 
treatment 
(30+7d)  
Informed Consent  X             
Baseline Characteristics/Eligibility3 X X            
Safety Assessments  
Medication /Procedure  Survey  X X   X  X X  X X X X 
(S)AE Survey and Reporting  X X X X X X X X X X X X X 
DLT Evaluation4 
Part 1/ Dose -Escalation only   X X X X X C2 only        
Vital Signs and Body Weight  X X   X  X X  X X X X 
ECOG PS5 X X5     X   X  X X 
Physical Examination5 X X5     X   X  X X 
ECG6 X           X  
ECHO or MUGA scan7 X             
Safety blood samples5,8 X X5 X X X X X X  X X X X 
Urinalysis5,8 X X5   X  X   X  X X 
Pregnancy Test  X           X  
Disease Assessments  
Disease Status Evaluation by CT/ MRI9 X        X   X10 X10 
Tumor Marker Evaluation11 X        X   X X 
Archival Tumor Tissue  (may include pre -
screening by  liquid  bx)12 X             
Tumor Biopsy13 X13        C2 only13     
Additional Assessments  
PK Samples14  X X X X  X X  X X X X 
ADA Sample15  X     C2 
only15   X  X X 
Skin Biopsy16 
Part 1/Dose -Escalation only X        C2 only16     
Biomarker Blood Sample17 X        C2 only17   X  
Trial Treatment  
Sym015 Premedication18  X   X  X X  X X   
Sym015 Infusion   X   X  X X  X X   
Post-Infusion Monitoring   X   X  X X  X X   
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8 .0 
Confidential     Page 45 of 164 Abbreviations  (in alphabetical order): ADA, anti -drug antibody; Bx, biopsy; C, Cycle; CT, computed tomography scan; D/d, day(s); DLT, dose -limiting toxicity; EOT, End of Treatment Visit; ECG, 
electrocardiogram ; ECHO, transthoracic echocardiog ram; ECOG PS, Eastern Cooperative Oncology Group performance status; MRI, magnetic resonance imaging; MUGA, multi -gated acquisition  scan; 
1M FUP, 1-Month Follow -up Visit; PK, pharmacokinetic; Q2W, every second week; (S)AE, (serious) adverse event; TX, ther apy 
 
1) The treatment period  continues until the patient is withdrawn from Sym015 . 
2) After the 1M FUP Visit, the Investigator will make every effort to obtain follow -up information on response assessment and/or OS about once every 2 months. Response assessment follow -up is 
required in the event of an ongoing SD, PR or CR at the 1M FUP Visit, until PD or another therapeutic intervention is initiated. Survival follow -up is required until death, withdrawal of consent, 
trial site closure,  or termination /end of the t rial. This continued follow -up does not require an in -person visit at the trial site, but may  be obtained by collection of data/documentation . 
3) Screening assessments include demographics, medical history, tumor histology, mutation status, extent of disease,  prior anti -cancer treatment , etc. 
4) DLT evaluation, applicable for Part 1/ dose -escalation cohorts only : DLTs are reported during Cycle 1 with a final assessment 14 (±2) days after the last dose of Cycle 1 or prior to dosing on 
C2/D1 .  
5) Does not n eed to be performed  prior to C1/D1 if performed during screening ≤ 7 days from C1/D1 . 
6) In addition to the scheduled timepoints, an ECG should be performed if clinically indicated .  
7) In addition to the scheduled timepoint, an ECHO/MUGA should be performed in the event of  cardiac symptoms  and as otherwise clinically indicated . 
8) Local laboratory results must be available and assessed prior to each Sym015 infusion. Refer to Section 8.2.9  for details . 
9) CT or MRI imaging schedule and conditions, applying to all cohorts:  
 A CT/MRI performed within 28 days prior to C1/D1 can be used for evaluation of eligibility and as baseline scan, provided tha t the CT/MRI has been performed according to the protocol 
requirements . 
 The first CT/MRI asses sment for response is done at the end of Cycle 2 and thereafter repe ated at the end of every second cycle (in the week prior to Day 1 of the next cycle)  
 In the event of suspected PD, a CT/MRI is to be performed as soon as possible .  
 In the event of CR/PR, a confirmatory CT/MRI is to be performed no earlier than 28 days after the first assessment of CR/PR .   
10) A CT/MRI at EOT should only be performed if the previ ous CT/MRI has been performed > 3 weeks before. A CT/MRI scan at 1M FUP should only be performed if no CT/MRI documents PD 
before or at EOT . 
11) Tumor maker evaluation  to include tumor markers that are part of the trial site s tandard practices  as indicated by tumor type , if applicable.  
12) Archival tumor tissue:  To be assessed locally . Does not need to be repeat ed if MET -amplification and KRAS  mutational status ha ve been assessed previously and the pathology report is available to 
document findings .   
For Part 2 -Basket Cohort : It is preferred that the local eligibility assessment for MET -amplification will be don e using tissue from a tumor biopsy performed during screening, however archival 
tumor tissue may be used at the Investigator’s discretion . If archival tissue is not available, tissue from a tumor biopsy performed during screening will be used.   Peripheral blood collection for 
KRAS -mutation assessment and for MET -amplification assessment in ctDNA  (liquid biopsy) is allowed as a local pre -screening methodology by Guardant360 analysis . Other liquid biopsy 
methodologies , except if used to detect MET ex14 mutatio n, will only be allowed  if previously approved by the Sponsor.  
For Part 2 -NSCLC Cohort: Archival tissue to be submitted, if available        
13) Tumor biopsy: To be assessed locally as part of eligibility assessment  in Part 1 and Part 2 , if applicable . Optional  for patients with known MET -amplification enrolled in Part 1  
For Part 2 -Basket Cohort: Required , to be assessed centrally . Tissue from a tumor  biopsy performed during screening is preferred, however a rchival tissue may be submitted for central analysis 
at the Investigator’s discretion , provided the archival tissue is  suitable for central analysis. Sampling  for central analysis  to be  repeated at the end of Cycle 2 or upon PD , whichever occurs first. 
Refer to Section 8.3.4  for d etails . 
For Part 2 -NSCLC Cohort:  Biopsies are optional  at the timepoints specified  
14) Extended PK sampling for PK profiling will be done starting C1/D1. Refer to  Table 9 for details.   
15) Only applicable f or Part 2 : ADA sample on first day of Cycle 2, prior to dosing . 
16) Only applicable for Part 1 : Skin biopsy is obtained  during screening after patient eligibility has been confirmed. Sampling is repeated at the end of Cycle 2 or upon PD , whichever occurs first .  
17) Biomarker blood sample is taken during screening after patient eligibility has been confirmed. Sampling is repeated at the end  of Cycle 2 or upon PD , whichever occurs first, and at EOT . If a tumor 
biopsy is collected at the same time point as the biomar ker blood sample, the biomarker blood sample should be collected prior to collecting the tumor biopsy.  
18) For Part 1 of the trial, premedication is mandatory prior to each dose of Sym015.  For Part 2 of the trial, premedication is mandatory prior to each dos e of Sym015 during Cycle 1. In Part 2, 
premedication may be withdrawn after Cycle 1  on a patient -by-patient basis if the patient is without evidence of infusion related reactions. Refer to Section 7.2.1  for deta ils. 
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8 .0 
Confidential     Page 46 of 164 Table 4 Flow Chart: Schedule of Assessments (Part 2 NSCLC Cohorts)  
Pre-Treatment Period  Treatment Period1 Post-Treatment Period2 
 Screening  Cycle 1  Cycle 2, 4, 6 etc.  Cycle 3, 5, 7 etc.  EOT  1M FUP 
Day within Cycle  
Visit Wind ow (± days)  D-14 to D -1 D1 D3 D8 
(±2) D15 
(±2) D22 
(±2) D1 
(±2) D15 
(±2)  
 
EOC  D1 
(±2) D15 
(±2) ≤ 10 d 
following the 
decision of trial 
treatment  
withdrawal  1 month after last 
dose of trial 
treatment 
(30+7d)  
Informed Consent  X             
Baseline Characteristics/Eligibility3 X X            
Safety Assessments  
Medication/Procedure Survey  X X   X  X X  X X X X 
(S)AE Survey and Reporting  X X X X X X X X X X X X X 
Vital Signs and Body Weight  X X   X  X X  X X X X 
ECOG PS4 X X4     X   X  X X 
Physical Examination4 X X4     X   X  X X 
ECG5 X           X  
ECHO or MUGA scan6 X             
Safety blo od samples4,7 X X4 X X X X X X  X X X X 
Urinalysis4,7 X X4   X  X   X  X X 
Pregnancy Test  X           X  
Disease Assessments  
Disease Status Evaluation by CT/MRI8 X        X   X X 
Tumor Biopsy9 X        EOC2 only 
optional      
Additional Assessments  
PK Samples10  X X X X  X X  X X X X 
ADA Sample  X     C2 only   X  X X 
Genomic/Biomarker Blood Sample11 X        EOC2 only    X  
Trial Treatment  
Sym015 Premedication12  X   X  X X  X X   
Sym015 Infusion   X   X  X X  X X   
Post-Infusion Monitoring   X   X  X X  X X   
Abbreviations  (in alphabetical order): ADA, anti -drug antibody; Bx, biopsy; C, Cycle; CT, computed tomography scan; D/d, day(s); DLT, dose -limiting toxicity; EOC, End of Cycle; EOT, End of 
Treatment Visit; ECG, electrocardiogram; ECHO, trans thoracic echocardiogram; ECOG PS, Eastern Cooperative Oncology Group performance status; MRI, magnetic resonance imaging; MUG A, 
multi -gated acquisition scan; 1M FUP, 1 -Month Follow -up Visit; PK, pharmacokinetic; Q2W, every second week; (S)AE, (serious) adv erse event; TX, therapy  
 
1) Treatment Period : The treatment period continues until the patient is withdrawn from Sym015.  
2) Post-treatment Period : After the 1M FUP Visit, the Investigator will make every effort to obtain follow -up information on response assessm ent and/or OS about once every 2 months. Response 
assessment follow -up is required in the event of an ongoing SD, PR or CR at the 1M FUP Visit, until PD or another therapeutic intervention is i nitiated. Survival follow -up is required until death, 
withdrawa l of consent, trial site closure, or termination/end of the trial. This continued follow -up does not require an in -person visit at the trial site, but may be obtained by collection of 
data/documentation.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8 .0 
Confidential     Page 47 of 164 3) Baseline Characteristics/Eligibility : Screening asse ssments include demographics, medical history, tumor histology, mutation status, extent of disease, prior anti -cancer treatment, etc.  
4) Safety Assessments : Does not need to be performed prior to C1/D1 if performed during screening ≤ 7 days from C1/D1.  
5) ECG : In addition to the scheduled timepoints, an ECG should be performed if clinically indicated.  
6) ECHO/M UGA : In addition to the scheduled timepoint, an ECHO/MUGA should be performed in the event of cardiac symptoms and as otherwise clinically indicated.  
7) Blood S afety Samples/Urinalysis : Local laboratory results must be available and assessed prior to each Sym015 infusion. Refer to Section 8.2.9  for details.  
8) Disease Status Evaluation : CT or MRI imaging schedule and cond itions:  
 A CT/MRI performed within 28 days prior to C1/D1 can be used for evaluation of eligibility and as baseline scan, provided tha t the CT/MRI has been performed according to the protocol 
requirements.  
 The first CT/MRI assessment for response is done at  the EOC2 and thereafter repeated at the end of every second cycle (EOC assessments may be performed at any time during the we ek 
prior to Day 1 of the next cycle, including Day 1 of the next cycle prior to dosing, provided results are available prior to study drug administration)  
 In the event of suspected PD, a CT/MRI is to be performed as soon as possible.  
 In the event of CR/PR, a confirmatory CT/MRI is to be performed no earlier than 28 days after the first assessment of CR/PR.   
 A CT/MRI at EOT should o nly be performed if the previous CT/MRI has been performed >3 weeks before. A CT/MRI scan at 1M FUP should only be performed if no CT/MRI documents 
PD before or at EOT.  
9) Tumor Biopsy : Recent or newly performed  biopsies  are mandatory at screening ; it is perm issible to perform the screening  procedure outs ide the 14 -day screening period  provided informed consent 
for the trial has been obtained .  EOC2 tumor biopsies (coinciding with time of first response assessment ) or upon PD, whichever occurs first , are optio nal.   
10) PK Samples : Extended PK sampling for PK profiling will be done starting C1/D1. Refer to Table 9 for details . 
11) Genomic/Biomarker Blood Sample : It is permissible to obtain the screening sample  outside the 14 -day screening period provided informed consent for the trial has been obtained . Subsequent 
samples to be obtained: EOC2 (coinciding with time of first response assessment ) or upon PD, whichever occurs first ; EOT (if after EOC2; need not repeat if patient is discontinuing at the EOC2 
or if a sample was obtained upon PD) .  If a tumor biopsy is collected at the same time point as the biomarker blood sample, the biomarker blood sample should be coll ected prior to collecting the 
tumor biopsy .  
12) Premedication : Manda tory prior to each dose of Sym015 during Cycle 1; may be withdrawn after Cycle 1 on a patient -by-patient basis if the patient is without evidence of infusion related 
reactions. Refer to Section 7.2.1  for details . 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 48 of 164 5.4 Recruitment Period  
Part 1 of the trial is expected to begin Q1 2016.  
Patients will be sequentially enrolled to dose -escalation cohorts until completion of Dose Level 4 
or establishment of an MTD, whichever comes first, expected  by Q1 2017.  
Enrollment t o Part 2 of the trial will commence upon establishment of the  Q2W RP2D . 
Enrollment is expected to complete by Q 4 2019. 
5.5 Number of Patients  
In total , approximately 63-72 patients will be included in this trial.  
It is estimated that approximately 12-15 patien ts will be enrolled to receive increasing doses of 
Sym015 during Part 1. The exact number of patients will depend upon the observed tolerability 
of Sym015 and the potential for adding additional patients to a cohort to assure a sufficient 
number of evaluab le patients per cohort. For details, refer to Section 7.1.3.2 . 
It is estimated that approximately 51 -57 patients will be enrolled to receive Sym015 at the RP2D 
on a Q2W schedule during Part 2. Three cohorts will  be included:  
 Basket Cohort : Approximately 25 patients with KRAS  WT, advanced solid tumor 
malignancies with documented MET -amplifi cation  will be enrolled and treated. A subset 
of approximately 6 patients will have received prior therapy with a MET -targetin g TKI .  
Note:  Effective with protocol  version 8.0 ( December 2018), accrual to the Basket Cohort is 
suspended.  
NSCLC MET -Amplified patients entered to the Basket Cohort will be counted toward the 
NSCLC MET -Amplified Cohort; NSCLC METEx14Del patients entere d to the Basket Cohort will be 
counted toward the NSCLC METEx14Del Cohort ; patients with both will be counted as MET -
Amplified.  
 NSCLC MET -Amplified Cohort : approximately 20 patients with advanced NSCLC with 
documented MET -amplification will be enrolled and  treated. Patients may have received 
prior therapy with MET -targeting agents and/or EGF R-targeting agents . 
 NSCLC METEx14Del Cohort : approximately 6-12 patients with advanced NSCLC with 
documented METEx14Del will be enrolled and treated. Tumors need not be MET -amplified , 
and patients  may have received prior therapy with MET -targeting and/or EGF R-targeting 
agents .   
Note:  NSCLC patients with tumors identified as  both MET -Amplified and METEx14Del will be 
enrolled to the MET -Amplified cohort.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 49 of 164 For details regar ding the s ample size considerations,  refer to Section 10.1. 
5.6 End of Trial  
The end of trial will be reached at the latest 1 month (30  +7 days) after the last patient has been 
withdrawn from Sym015.   
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 50 of 164 6. PATIENT SELEC TION AND WITHDRAWAL  
Questions regarding patient eligibility must be addressed and resolved by the Investigator in 
consultation with the Sponsor or designee prior to enrollment.  
6.1 Inclusion Criteria  
For inclusion in the trial, all of the following criteria mu st be fulfilled:  
1. Written informed consent given before any trial -specific procedure  is initiated  
2. Male or female, at least 18 years of age at the time of informed consent  
3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1  
4. Life expec tancy > 3 months assessed during Screening  
5. Documented (histologically - or cytologically -proven) solid tumor malignancy that is 
locally advanced or metastatic, and that is refractory to standard therapy or for which no 
standard therapy is available  or access ible (i.e., patients must have recurrent and/or 
progressive disease and be without available  therapeutic options)  
6. Part 1 ONLY : Tumor documented to be KRAS  WT by local assessment according to 
institutional standards . If KRAS  WT is not previously documented and if archival tissue is 
not available for pretrial assessment, patient must be willing to undergo  a tumor biopsy to 
confirm eligibility  
7. Part 2  ONLY : 
a. Measurable disease according to  the RECIST v1.1 that has been confirmed by 
computed tomography ( CT) or ma gnetic resonance imaging ( MRI ) within 4 weeks 
prior to C1/D1  
Note : Measurable disease is defined as 1 or more target lesions assessed by CT or MRI. A 
tumor lesion situated in a previously irradiated area is considered measurable only if 
subsequent PD has b een documented in the lesion  
b. Basket Cohort ONLY : 
 Tumor documented to be KRAS  WT by local assessment according to 
institutional standards. If KRAS  WT is not previously documented and if 
archival tissue is not available for pretrial assessment, patient must be willing to 
undergo a tumor biopsy to confirm eligibility.   
Note:  Peripheral blood collection for KRAS -mutation assessment in ctDNA will be 
allowed as a local pre -screening methodology by Guardant360* analysis.  Other liquid 
biopsy methodologies,  if used to detect METEx14Del, are acceptable alternatives . 
*<http://guardanthealth.com>  
 Confirmed MET -amplification  by local assessment ; i.e., MET  gene copy 
number  to control probe ratio [G:CN] > 2.2 scored in 50 tumor nuclei by FISH, 
chromogenic in situ  hybridi zation ( CISH ), silver in situ  hybridization (SISH)  or 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 51 of 164 similar  (5), or a copy number  >5 by next-generation sequencing  (NGS)  or 
quantitative polymerase chain reaction  (qPCR)  
Note:  Peripheral blood collection for MET -amplification assessment in ctDNA will be 
allowed as a local pre -screening metho dology provided results are 3+ by Guardant360* 
analysis  (or equivalent to 3+ by Guardant360 if an alternative Sponsor -approved 
methodology is used ), and provided subsequent  required confirmatory tumor tissue 
evaluation results meet the above inclusion criterion.   
*<http://guardanthealth.com>  
 No prior therapy with MET -targeting agents  
Note:  An exception will be a subset of approximately 6 patients entered to the Basket 
Coho rt after having received prior therapy with a MET -targeting TKI.  
 Willingness to undergo a pre - and post -dosing biopsy (maximum of 2 biopsies) 
from primary or metastatic tumor site(s) considered safely accessible for biopsy  
 
c. NSCLC MET -Amplified Cohort ONLY : 
 Documented NSCLC  meeting disease criteria as defined above   
 Documented MET -amplification  by either : 
o Local assessment in a recent * tumor biopsy ; i.e.,  G:CN ≥3.0 scored in 50 
tumor nuclei by FISH , CISH, SISH or similar assay, or a copy number >5 
by NGS or  qPCR (subsequent central confirmation required, however 
patient may be enrolled and treated based on local assessment, before 
central confirmation results have been obtained)  
*Tissue for local assessment may be from a recent tumor biopsy, defined as one 
performed since last documented disease progression as part of the site’s usual 
practice, and  where no intervening antineoplastic  therapy has been 
administered; otherwise tissue from a newly performed biopsy must be obtained 
and submitted.       
o Central con firmation ** in a newly performed  pre-dosing tumor biopsy ; 
i.e.,  G:CN ≥3.0 scored in 50 tumor nuclei by FISH  
**If central confirmation of MET -amplification status cannot be assessed in 
tumor due to assay failure/technical error, the Sponsor ma y decide to e nroll 
based on MET -amplification detected by Guardant360 on a case per case basis 
(see Note below regarding Guardant360 analysis).  
 May have received prior therapy with MET -targeting and/or EGFR -targeting 
agents  (antibodies or TKIs)  
 Willingness to undergo a  pre-dosing biopsy (mandatory  unless a recent* tumor 
biopsy as defined above is available ), and potentially a biopsy at the E nd of 
Cycle 2 (EOC2) (optional), from a primary or metastatic tumor site considered 
safely accessible for biopsy  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 52 of 164 Note: Peripheral blood for ctDNA analysis by Guardant 360 will be obtained for 
assessment of MET -amplification status . As data are acquired on concordance between 
findings in tumor tissue versus ctDNA, the Sponsor may decide to transition to screening 
for MET -amplification  using Guardant360 analysis only (e.g., 2+ or 3+ amplification 
score) without requiring confirmation in  a recent o r newly performed  tumor  biopsy.  
d. NSCLC METEx14Del Cohort ONLY :  
 Documented NSCLC meeting disease criteria as defined above   
 Documented METEx14 Del (tumors need not be MET -amplified)  
Note: METEx14Del status to be documented according to local institutional standards.  
Assessment in ctDNA by Guardant360 technology or equivalent is allowed. Tissue 
from a recent* or newly performed pre -dosing tumor biopsy must be submitted for 
central assessment .  
*Recent tumor biopsy, defined as one performed since last documented disease 
progression as part of the site’s usual practice, a nd where no intervening antineoplastic 
therapy has been administered; otherwise  tissue from a newly performed biopsy must 
be obtained and submitted.  
 May have received prior therapy with MET -targeting and/or EGFR -targeting 
agents  (antibodies or TKIs)  
 Willingness to undergo a pre -dosing biopsy (mandatory  unless a recent* tumor 
biopsy a s defined above is available ), and potentially a biopsy at the EOC2 
(optional), from a primary or metastatic tumor site considered safely accessible 
for biopsy  
Note: Peripheral blood for ctDNA analysis by Guardant 360 will be obtained for 
assessment of METEX14Del status.   
8. If female and of childbearing potential, a negative pregnancy test  
9. Male or female, either n ot of childbearing potential or agreeing  to use a medically 
effective method of contraception as per institutional standards during the trial and f or 4 
months after the last dose of trial drug  
6.2 Exclusion Criteria  
Patients meeting any of the following criteria will not be permitted to enter the trial:  
1. Any antineoplastic agent for the primary malignancy (standard or investigational) without 
delayed toxi city within 4 weeks or 5 plasma half -lives, whichever is shortest, prior to 
C1/D1 except:  
 Nitrosoureas and mitomycin C within 6 weeks  prior to C1/D1  
2. Part 2  ONLY :  
a. Basket Cohort :  
 Prior therapy with MET -inhibiting agents   
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 53 of 164 Note:  Exception s will be a subset  of approximately 6 patients entered to the Basket Cohort 
after having received prior therapy with a MET -targeting  TKI  
 Prior therapy with antibody to HGF  
b. Basket Cohort and NSCLC MET -Amplified Cohort : Tumor status demonstrating 
MET -polysomy  in the absence of MET -amplification, as specified  
Note: Patients in the NSCLC METEx14Del Cohort with polysomy are eligible .   
c. Radiotherapy against target lesions within 4 weeks prior to C1/D1 , unless there is 
documented progression of the lesion  following the radiotherap y 
Note : Radiotherapy for pain control against non -target lesions is allowed, as long as it does 
not influence bone marrow function  
3. Immunosuppressive or systemic hormonal therapy (> 10 mg daily prednisone equivalent) 
within 2 weeks prior to C1/D1 (for excep tions, see Section 7.5.2 )  
4. Use of hematopoietic growth factors within 2 week s prior to C1/D1  
5. Active second malignancy or history of another malignancy within the last 3 years, with 
the exception of:  
a. Treated, non -melanoma skin cancers  
b. Treated carcinoma in situ  of the breast or cervix  
c. Controlled, superficial carcinoma of the urinary bladder  
d. T1a or b carcinoma of the prostate treated according to local standard of care, with 
prostate -specific antigen (PSA) within no rmal limits for the institution  
6. Central nervous system (CNS) malignancy including : 
a. Primary malignancies of the CNS  
b. Known , untreated  CNS or leptomeningeal metastases , or spinal cord compression; 
patients with any of these  not controlled by prior surgery or radiotherapy, or 
symptoms suggesting CNS metastatic involvement for which treatment is required  
Note: Patients with treated CNS metastases will be eligible if they are asymptomatic, do not 
require corticosteroids or anticonvulsants, and have confirmation o f at least stable brain 
disease status as assessed by 2 imaging studies performed  > 4 weeks apart with the most 
recent performed within  4 weeks prior to first trial drug administration  
Patients with newly identified CNS metastases  during study treatment wi ll be considered to 
have PD and will be discontinued from treatment  
7. Inadequate recovery from an acute toxicity associated with any prior antineoplastic 
therapy  
Note : With the exception of persistent Grade 2 alopecia  and/or peripheral neuropathy , patients 
must have recovered  (to Grade ≤ 1)  from acute toxicity by C1/D1   
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 54 of 164 8. Major surgical procedure within 4 weeks prior to C1/D1 or inadequate recovery from any 
prior surgical procedure  
9. Non-healing wounds on any part of the body  
10. Active thrombosis, or a history of de ep vein thrombosis or pulmonary embolism, within 1 
month prior to C1/D1 , unless adequately treated and stable  
11. Active uncontrolled bleeding or a known bleeding diathesis  
12. Significant cardiovascular disease or condition, including:  
a. Congestive heart failure currently requiring therapy  
b. Class III or IV cardiovascular disease according to the New York Heart 
Association's (NYHA) functional criteria ( 30) 
c. Need for antiarrhythmic medical therapy for a ventricular arrhythmia  
d. Severe conduction disturbance (e.g. , 3rd degree heart block)  
e. Unstable angina pectoris (last episode at least 6 months prior to C1/D1)  
f. Uncontrolled hypertension (per the Investigator's discretion)  
g. Myocardial infarction within 6 months prior to C1/D1  
13. Abnor mal hematologic, renal or hepatic function as defined by the following criteria:  
a. Absolute neutrophil count (ANC) < 1.5 ×109/L (1500/mm3) 
b. Hemoglobin ≤ 9 g/dL  
c. Platelet count < 75 ×109/L (75 ,000/mm3)  
d. Serum creatinine > 1.5 × upper limit of normal (ULN) for the institution  
e. Aspartate aminotransfera se (AST) > 3.5 × ULN for the institution  or AST >5 × 
ULN for the institution in case of known liver met astases  
f. Alanine aminotransferase (ALT) >3.5 × ULN for the institution or ALT >5 × ULN 
for the institution in  case of known liver metastases  
g. Total bilirubin > 1.5 × ULN for the institution  
h. Prothrombin time as assessed by Interna tional Normalized Ratio (INR) >1.5 × ULN 
for the institution *  
i. Partial thromboplastin time (PTT) > 1.5 × ULN for the institution * 
* unless the patient is on a stable dose of anticoagulant therapy for a prior 
thrombotic event  
14. Any of the following within 2 weeks prior to C1/D1:  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 55 of 164 a. Any seriou s or uncontrolled infection  
b. Any infection requiring parenteral antibiotics  
c. Unexplained fever > 38.0 °C  
15. Known or suspected hypersensitivity to any of the excipients of the Sym015 drug product  
16. Any other life -threatening illness, significant organ system dysfu nction, or clinically 
significant laboratory abnormality, which in the opinion of the Investigator, would either 
compromise the patient’s safety or interfere with the evaluation of the safety of the trial 
drug 
17. Any kind of disorder that compromises the abil ity of the patient to give written informed 
consent and/or to comply with trial procedures or is unwilling or unable to comply with 
trial requirements at the discretion of the Investigator  
18. Breast feeding, or plans by the patient (or the patient’s partner)  to become pregnant 
during treatment or within 4 months after the end of treatment  
6.3 Withdrawal  
The visit schedule for the treatment period will apply until Sym015 has been discontinued. Once 
this has occurred, an EOT Visit will be performed within 10 days following the decision to 
discontinue Sym015.  
After EOT, the patient will continue to be followed for safety until 1 month ( 30 +7 days) after 
the last dose of Sym015, when the 1M FUP Visit must be completed.  
6.3.1 Withdrawal from Treatment with Sym015  
The patien t must be withdrawn from treatment with Sym015 in the event of any of the following:  
 A DLT considered by the Investigator to require treatment discontinuation . Refer to  
Section 9.5 for DLT definition  (dose -escal ation cohorts only)  
 Occurrence of an AE considered by the Investigator to require treatment discontinuation  
 Basket Cohort ONLY : Results from a rchival tumor tissue or a tumor biopsy  submitted to 
confirm MET -amplification status  that do not meet  study eligib ility criteria .   
Note:  Such p atients may remain on study if there is evidence of an OR, SD, or other clinical 
benefit, but will not be included in the Evaluable for Response Population.  
 PD, verified by CT/MRI according to RECIST v1.1  
 Treatment failure no t meeting the criteria for PD, but considered by the Investigator to 
require treatment discontinuation  
 Requirement for a significant surgical procedure  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 56 of 164 Note : Patients requiring a minor surgical proced ure (e.g. , port placement, skin abscess drainage) 
may c ontinue at the Investigator's discretion following discussion with the Sponsor or designee.  
A brief interruption in therapy may be considered  
 An intercurrent illness which, in the opinion of the Investigator, would prevent 
completion of trial -related eval uations  
 Use of prohibited concomitant medication, as defined in Section 7.5.2  
 Pregnancy  
 Significant deviation from the eligibility criteria may require discontinuation  after 
discussion with the Sponsor  
 Noncompli ance with trial procedures may require discontinuation after discussion with 
the Sponsor  
 Patient withdrawal of consent and election to discontinue treatment. (Patients may leave 
the trial at any time for any reason if they wish to do so, without any conseq uences)  
 Termination of the trial by the Sponsor  
 Patients who meet Hy’s Law criteria that cannot be explained by factors not related to 
Sym015 . 
Note: Patients meeting all three  of the following are considered to have met Hy’s Law criteria:  
o The drug causes hepatocellular injury, generally shown by a higher incidence of 3 -fold or 
greater elevations above ULN of ALT or AST  
o Among trial subjects showing such aminotransferase elevations, often much greater than 
3xULN, one or more show elevation of serum total bil irubin to ≥2xULN, without initial 
findings of cholestasis (elevated serum alkaline phosphatase [ ALP]). 
o No other reason can be found to explain the combination of increased aminotransferase and 
serum total bilirubin , such as viral hepatitis A, B, or C; pree xisting or acute liver disease; or 
another drug capable of causing the observed injury.  
6.3.2 Withdrawal from Trial  
The patient must be withdrawn from trial in the event of any of the following:  
 The patient withdraws consent to participate  
 The Investigator judge s it necessary due to medical reasons  
The EOT and the 1M FUP visits should be performed to the extent possible and the Investigator 
should ensure any SAE is followed as described in Section 9.3. 
After the 1M FUP  Visit, the Investigator will make every effort to obtain follow -up information 
on response assessment and/or OS every 2 months. Response assessment follow -up is required in 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 57 of 164 the event of an ongoing SD, PR or CR, as per RECIST v1.1 at the 1M FUP Visit, unti l PD or 
another therapeutic intervention is initiated. Survival follow -up is required until death, 
withdrawal of consent, or termination of the trial.  This continued follow -up does not require an 
in-person visit at the trial site, but may  be obtained by co llection of data/documentation.  
6.4 Replacement of Patients  
6.4.1 Part 1, Dose -Escalation  
Patients who do not complete Cycle 1 as defined in Section 9.5.2 , for reasons other than drug 
toxicity, will be replaced.  
Data fro m these patients will be included in the safety analysis, but will not contribute to the 
determination of the Q2W RP2D.  
6.4.2 Part 2  
Basket Cohort ONLY : Patients enrolled to the study based on local MET -amplification 
assessment s conducted in ctDNA , but with subs equent confirmatory tumor tissue evaluation 
results not meeting the protocol -specified inclusion criteria, will be replaced  (patients may 
remain on study if there is evidence of an OR, SD, or other clinical benefit, but will not be 
included in the Evaluabl e for Response Population ).
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 59 of 164 7.1.3 Administration of Sym015  
7.1.3.1  Treatment Schedule  
All patients will be administered IV infusions of Sym015, dosed according to body weight, 
through a peripheral line or indwelling catheter, and with the use of an infusion pump and an 
inline filter. Sym015 will be administered Q2W (Day 1 and Day 15 of each 28 -day cycle [±2 
days]).   
For all Sym015 infusions, a complete dosing history will be rec orded, i.e. ,: 
 Total dose and volume administered  
 Start and stop time of infusion  
 Infusion interruption or termination and reason for such actions  
7.1.3.2  Part 1, Dose -Escalation  
During the dose -escalation part  of the trial, the following dose levels of Sym015  admi nistered 
Q2W  will potentially be evaluated in a standard 3+3 dose -escalation design:  
 Dose Level 1: 6 mg/kg  
 Dose Level 2: 12 mg/kg  
 Dose Level 3: 18 mg/kg  
 Dose Level 4: 24 mg/kg  
A substitute or additional dose level, within the dose levels listed above, could potentially be 
evaluated. Any decision to add or replace a dose to be tested will be guided by PK data and/or 
data on target occupancy in skin biopsy samples. This substitute or additional dose level would 
be chosen between the currently listed dose levels, and a dose higher than 24 mg/kg will not be 
evaluated without a formal amendment to this protocol.  
Cohorts will be filled sequentially until establishment of the highest safe dose . Patients will be 
allocated to the next available treatment slot wit hin the current or next cohort, as appropriate and 
depending on the ongoing observation of DLTs and other safety parameters.  
Enrollment will be staggered between the first and second patient in each new higher dose level 
tested. The first patient must have  completed and tolerated the first dose of Sym015 , including 
follow -up until Day 8 of Cycle 1  (C1/D8) , in order to allow for review of clinical and laboratory 
assessments. Thereafter patients within a cohort may be added concurrently.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 60 of 164 There is potential fo r entry of additional patients in the dose -escalation portion of the trial to 
assure a sufficient number of evaluable patients per cohort by entering an additional patient to a 
cohort (e.g. , increase a 3 patient cohort to 4 patients, or a 6 patient cohort to 7 patients).   
Note: Should this action be taken, cohort tolerability assessment and subsequent dose -escalation will 
occur when the minimum number of patients required to evaluate tolerability have completed Cycle 1. 
However, if any additional patient ex periences an event that would, per protocol, result in either cohort 
expansion or the halting of dose -escalation, protocol rules as outlined herein will be followed.  
Progression from a current dose level to the next will only proceed following evaluation o f 
tolerability of the current dose level. Thus, dosing of the first patient at Dose Level 2 will 
commence only once all patients to be treated at Dose Level 1 have completed Cycle 1, and Dose 
Level 1 has been found to be tolerable. Similarly, dosing in Dos e Level 3 will only commence 
once all patients to be treated at Dose Level 2 have completed Cycle 1, and Dose Level 2 has 
been found to be tolerable. The dose -escalation decision points are listed below:  
 If no DLTs are encountered in any of the first 3 pat ients completing Cycle 1 within a 
dose level, dose -escalation may continue to the next level  
 If 1 of 3 patients within a dose level experiences a DLT, 3 more patients will be enrolled 
at the same dose level. If no DLTs are encountered in the 3 additional p atients, dose -
escalation may continue to the next level  
 If  ≥ 2 patients within a dose level (of up to 6 patients) experience a DLT, then that dose 
will be considered to have exceeded the MTD and the dose level just below this dose 
level will be considere d to be the MTD  
 If no DLTs are encountered in any of the first 3 patients at Dose Level 4, 24 mg/kg will 
be considered the highest safe dose tested  
The SMC  will review safety data throughout  the trial. During Part 1, the SMC will  make 
decisions regarding t he advisability of : continuing accru al to a particular dose cohort; dose-
escalation and accrual of patients to a higher dose cohort ; and the dose(s) to be used in Part 2  
(i.e., Q2W RP2D to be evaluated).  
Each patient enrolled will receive Sym015 at the all ocated dose  until treatment withdrawal , 
unless dose -reduction is necessary as specified in Section  7.1.4 . There will be no intra -patient 
dose-escalation.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 61 of 164 7.1.3.3  Part 2  
During Part 2 of this trial, patients will receive  the RP2D of Sym015 on a Q2W  dosing schedule.  
The SMC will continue to review safety data and assess the tolerability of Sym015 during Part 2 
of the trial.  
7.1.3.4  Duration of Infusion for Administration of Sym015  
Sym015 will be administered over a 1 .5-hour (+10 m inutes) period  for doses ≥18 mg/kg, and 
over a 1 hour (+10 minutes) period for doses <18 mg/kg,  follo wing delivery of premedication as 
specified in section 7.2.1 .  
Note:  Effective with protocol  version 5.0  (Nov ember 2016) , the duration of infusion has been extended 
to 1.5 hours for all patients receiving doses ≥18 mg/kg due to the occurrence of Grade 2 IRRs in 2 of 3 
patients treated in the 18 mg/kg cohort  during Part 1  (This action was i mplemented 13Sep2016).  
Administration should be at a constant rate using a programmable volumetric infusion pump in 
order to assure accuracy of delivery. The times of infusion initiation and completion must be 
recorded.  
The duration of Sym015 -infusion will be prolonged for all s ubsequent patients entered to the trial 
in the following situations:  
 In the event of a Grade 2 IRR in ≥ two thirds of the patients entered to a cohort, the 
duration of infusion for subsequent patients entered at that dose and higher doses  will be 
extended  from 1 hour (+10 minutes)  to 1.5 hours  (+10 minutes)  (or longer, if in dicated)  
Note: This action was i mplemented 13Sep2016  and applies to doses ≥18 mg/kg .  
 In the event of a Grade 3 or greater IRR in any patient within a cohort, the duration of 
infusion for subsequent patients entered at that dose and higher doses  will be ex tended  
from 1 hour (+10 minutes) to 1.5 hours  (+10 minutes)  (or longer, if indicated). Such a 
case will also be considered to have met the protocol criteria for a DLT, thus requiring 
expansion of the cohort  
These same criteria will be applied in the event IRRs occur on the extended 1.5 hours infusion 
schedule. In such a case, the duration of infusion for subsequent patients entered at that dose and 
higher doses  will be extended to 2 hours (or longer, if indicated).  
Recommendations for management of an IRR in individual patients can be found in Section 
7.1.3.7 . 
7.1.3.5  Patient Monitoring During and After Infusion of Sym015  
Patients will be treated on an outpatient basis.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 62 of 164 Sym015 infusions must be administered under the clo se supervision of an experienced physician 
in an environment where full resuscitation facilities are immediately available.  
Patients will be carefully observed for a minimum of 2 hours following completion of the first 
administration of Sym015 and a minim um of 1 hour following completion of subsequent 
administrations. At the end of each infusion, the IV line must remain in place for at least 1 hour 
to allow administration of IV drugs, if necessary.  
7.1.3.6  Infusion -Related Reactions to Sym015  
An IRR is defined as an AE occurring during the Sym015 infusion and up to 2 hours after the 
end of infusion ( EOI), which is assessed by the Investigator to be related to the infusion of 
Sym015.  Signs of IRRs may include  but are not limited to facial flushing and swelling, shor tness 
of breath, headache, diaphoresis, tachycardia, hypotension, chills, rigors, chest and throat 
tightness, as well as chest, back and/or abdominal discomfort.  
7.1.3.7  Handling of Infusion -Related Reactions to Sym015  
The risk of an IRR is highest for the first a dministration of a mAb and diminishes with 
subsequent infusions.  
If an IRR occurs, it should be classified according to the Common Terminology Criteria for 
Adverse Events ( Version 4.03 ) (CTCAE v4.03) . Recommended management guidelines are 
shown in  Table 6. In all cases, the Investigator should use best clinical judgment in managing 
such reactions.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 63 of 164 Table 6 Infusion -Related Reactions Management Guidelines  
CTCAE Grade  Management/Treatment  
Grad e 1 
Mild transient reaction;  
infusion interruption not indicated;  
intervention not indicated   Continue infusion; consider slowing to 50% of the prior rate  
 Monitor closely  
 If infusion is extended, administer subsequent infusions during 
Cycle 1 at the prolong ed rate  
 Thereafter, if vital signs remain stable and symptoms do not 
recur, at the discretion of the Investigator an attempt may be 
made to slowly increase the rate of infusion. Final infusion 
duration should not be briefer than the initial rate attempted in 
the patient  
Grade 2  
Therapy or infusion interruption indicated but 
responds promptly to symptomatic treatment 
(e.g., antihistamines, NSAIDs, narcotics, IV 
fluids); prophylactic medications indicated for 
≤ 24 h   Interrupt infusion for a minimum of 30 minutes  
 Administer symptomatic treatment (e.g. , antihistamines, 
NSAIDs, etc.) and appropriate supportive care (e.g. , 
bronch odilator, oxygen, etc.), as indicated  
 When symptoms have resolved or decreased to Grade 1, restart 
infusion at 50% of the prior rate  
 Monitor closely  
 If symptoms recur, stop the infusion, institute remedial therapy, 
monitor closely and evaluate whether the  patient can continue 
the trial  
 Administer subsequent infusions during Cycle 1 at the 
prolonged rate  
 Thereafter, if vital signs remain stable and symptoms do not 
recur, at the discretion of the Investigator an attempt may be 
made to slowly increase the rat e of infusion. Final infusion 
duration should not be briefer than the initial rate attempted in 
the patient  
Grade 3  
Prolonged (e.g. , not rapidly responsive to 
symptomatic medication and/or brief 
interruption of infusion); recurrence of 
symptoms following initial improvement; 
hospitalization indicated for clinical sequelae   Discontinue the infusion  
 Administer symptomatic treatment (e.g. , antihistamines, 
NSAIDs, glucocorticoid etc.) and appropriate supportive care 
(e.g., bronchodilator, oxygen, IV fluid etc.) , as indicated  
 Do not resume infusion  
 Patient will either be discontinued from further treatment or 
receive subsequent treatments at a reduced dose; if treatment is 
continued administer subsequent infusions during Cycle 1 at 
50% of the prior rate  
 Thereafte r, if vital signs remain stable and symptoms do not 
recur, at the discretion of the Investigator an attempt may be 
made to slowly increase the rate of infusion. Final infusion 
duration should not be briefer than the initial rate attempted in 
the patient.  
Grade 4  
Life-threatening consequences; urgent 
intervention indicated   Discontinue infusion  
 Administer necessary life -support measures, as indicated  
 Discontinue from further treatment  
Abbreviations (in alphabetical order): CTCAE, Common Terminology Criteria  for Adverse Events  v4.03; h, hours; IRR, infusion -related 
reaction; IV, intravenous; NSAID, nonsteroidal anti -inflammatory drug  
 
7.1.4 Dose -Adjustment and Delays of Sym015  
The dose of Sym015 in mg/kg assigned to the individual patient will be confirmed by the 
Sponsor or designee prior to C1/D1  on the Screening and Allocation Form . 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 64 of 164 Based on the body weight of the patient, the site will calculate the nominal dose of Sym015 to be 
administered in mg.  
Weight changes (> ± 10%) for a patient during trial will re quire r ecalculation of the dose. Refer 
to Section 7.1.4.1 . 
Furthermore, dose -delays of Sym015 and intra -patient dose -reduction(s) may also be required 
upon occurrence of specific toxicities . Refer to Section 7.1.4.2 . 
7.1.4.1  Dose -Adjustment for Body Weight  
Sym015 is dosed in mg/kg and the dose to be administered will be calculated based on the actual 
body weight of the patient. The dose calculated may be used for subsequent infusions , unless 
body weight changes of ≥ ± 10%, in which case the dose should be adjusted according to the 
change in body weight.  Recalculation for lower weight changes is allowed.  
7.1.4.2  Dose -Delays for Sym015 -Related or Disease -Related Toxicities  
Clinical judgment wil l be used when determining whether it is advisable to continue a patient on 
to the next dosing.  In order to dose a patient, the following criteria must be met:  
 ANC >1.0 ×109/L (1000/mm3) 
 Platelet count > 60 ×109/L (60 ,000/mm3) 
 Any ongoing AEs should NOT me et the criteria for DLT, during the DLT observation 
period  
 Any ongoing AEs, assessed as possibly, probably, or related to Sym015, should have 
either ameliorated to ≤ Grade 1 severity, returned to baseline status, or resolved with the 
exception of  Grade 2 clinical events that are being adequately controlled with bes t 
supportive care (e.g. , nausea, vomiting, diarrhea, fatigue) and asymptomatic laboratory 
abnormalities that are considered clinically insignificant  or that are resolving with 
medical therapy  
Should any one of the criteria above not be met, dosing of Sym01 5 must be delayed until the 
patient meets the above criteria. All per protocol assessments must be done.  
7.1.4.3  Dose -Reduction for Sym015 -Related Toxicities  
Patients experiencing any of the following toxicities, assessed as possibly, probably, or related to 
Sym01 5, will have their dose reduced in accordance with the reduction schedule outlined in 
Table 7. 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 65 of 164 1. Grade 3 non -hematologic toxicity regardless of duration, with the exceptions of:   
a. Grade 3 nausea, vomiting, diarrhea, o r fatigue lasting ≤ 2 days with best supportive 
care  
b. Grade 3 asymptomatic electrolyte abnormalities lasting ≤ 3 days that are not 
considered clinically relevant by the Investigator and that resolve with medical 
therapy without requiring hospitalization  
2. Any Grade 4 non -hematologic toxicity , with the exception of:  
a. Grade 4 asymptomatic electrolyte abnormalities lasting ≤ 3 days that are not 
considered clinically relevant by the Investigator and that resolve with medical 
therapy  
3. Neutropenia that is:  
a. Grade 3 -4 febrile neutropenia  
b. Grade 4 and sustained (i.e. , ANC < 500 per mm3, duration > 5 days)  
4. Thrombocytopen ia that is : 
a. Grade 3 with clinically significant hemorrhage  
b. Grade 4 (platelets < 25,000 per mm3) 
5. AST/ALT elevation > 3×ULN with bilirubin elevation >2×ULN that cannot be explained 
by factors not related to study drug  
 
Table 7 Sym015 Dose -Reduction Schedule  
Allocated Dose  First Reduction  Second Reduction  Subsequent Reductions  
6 mg/kg  3 mg/kg  1.5 mg/kg  Reduce by 50%  
12 mg/kg  6 mg/kg  3 mg/k g Reduce by 50%  
18 mg/kg  12 mg/kg  6 mg/kg  Reduce by 50%  
24 mg/kg  18 mg/kg  12 mg/kg  Reduce to 6 mg/kg , then 
by 50%  
Note : In the event that an intermediate dose is explored in this study, dose -reductions in such cases will be to the next lower established  
tolerated dose level(s).  If further dose -reductions are indicated, proceed as outlined above.  
 
7.2 Other Drugs to be Used in the Trial  
7.2.1 Premedication for Sym015 Infusions  
There is an inherent risk for IRRs with the administration of mAbs. A premedication sched ule 
will therefore be implemented for all patients treated.  
For Part 1 of the trial, premedication is mandatory prior to each dose of Sym015.  
 
For Part 2 of the trial, premedication is mandatory  prior to each dose of Sym015  during Cycle 1 . 
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 66 of 164 All patients mu st be premedicated as described with standard therapies that include a 
glucocorticoid and an H1 antagonist.  Where indicated, consideration may be given to including 
an H2 antagonist and/or acetaminophen.  The recommended premedication doses are as follows :  
 Glucocorticoid therapy equivalent to 80 -100 mg IV methylprednisolone, approx. 0.5 to 2 
hours prior to the start of Sym015 infusion  
 Antihistamine (H1 antagonist) equivalent to 25 -50 mg IV diphenhydramine, approx. 0.5 
hours prior to the start of Sym015 in fusion  
 Antihistamine (H2) antagonist (optional) such as 50 mg IV ranitidine or 30 mg 
famotidine, approx. 0.5 hours prior to the start of Sym015 infusion  
 Acetaminophen (optional) such as 1000 mg IV or PO  (orally) , approx. 0.5 hours prior to 
the start of Sym 015 infusion  
In Part 2, i f a patient is without evidence of IRRs after Cycle 1 , the Investigator may opt to 
withdraw premedication on a patient -by-patient basis with subsequent dosing in order to 
determine whether such continued therapy is necessary in tha t patient. Where practical, it is 
recommended that withdrawal of premedication be done in a gradual fashion.  
For those patients who experienced  symptoms suggestive of  an IRR  after Cycle 1 , consideration 
should be given to continuing premedication for at mi nimum 1 to 2 additional doses  before any 
future attempt to withdraw . 
7.2.2 Prophylactic and Therapeutic Treatment  
7.2.2.1  Mandatory Prophylactic Treatment  
Mandatory prophylactic treatment will be implemented for all patients treated in this trial should 
an increased in cidence begin to occur of mild-to-moderate Sym015 -related reactions that are 
amenable to prophylaxis with standard agents. Such actions will occur following discussions 
within the SMC.  
7.3 Blinding  
Not applicable as this is an open -label trial.  
7.4 Drug Accountabil ity and Compliance Check  
The Investigator is responsible for ensuring accountability for the IMP, including maintenance of 
IMP accountability records.  
IMP accountability records will include a full inventory of the IMP including:  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 67 of 164  Confirmation of IMP delive ry to the trial site  
 Record of each dose dispensed  
 The return of unused IMP to the Sponsor or designee  
 Record of any on -site destruction of unused IMP, as agreed with the Sponsor or designee  
Records will specify dates, quantities, batch numbers, use -by da tes and patient numbers, as 
applicable.  
The Investigator, or designee, should maintain records that adequately document:  
 That the patients were provided the doses specified by the protocol , and  
 That all IMP provided by the Sponsor was fully reconciled  
7.5 Conc omitant Medication/Therapy  
7.5.1 Allowed Medication/Therapy and Procedures During the Trial  
Patients may receive their current concomitant medication and any medication considered 
necessary for the welfare of the patient during trial, except if listed in Section  7.5.2 .  
Furthermore, the following are permitted during the trial:  
 Premedication with standard therapies prior to Sym015 administration to reduce the risk 
of IRRs  
 Prophylaxis and treatment of Sym015 -related tox icities  
 Radiotherapy for pain control against non -target lesions, as long as it does not influence 
bone marrow function  
 Bisphosphonates and denosumab :  Bisphosphonates and denosumab for bone metastases 
and other skeletal conditions provided the patient is on a stable dose for at least 2 months 
prior to study start and remains on the stable dose while receiving study treatment  
7.5.2 Prohibited Medication/Therapy and Procedures During the Trial  
The following medications and procedures are not allowed from C1/D1, or  as specified in the 
inclusion/exclusion criteria, until the EOT Visit:  
 Anti-cancer treatment, including cytotoxic or cytostatic agents, hormonal therapy (except 
as physiologic hormone replacement)  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 68 of 164  Basket Cohort ONLY : MET -targeting therapies , except in su bset of approximately 6 
patients  
 Radiotherapy against target lesion(s)  (Part 2 only)  
 Systemic immunosuppressive or systemic hormonal therapy with the exception  of the 
following allowed therapies:  
o Hormonal therapy (e.g. , Megace) for appetite stimulation  
o Nasal, ophthalmic, inhaled, and topical glucocorticoid preparations  
o Oral replacement glucocorticoid therapy for adrenal insufficiency  
o Low-dose maintenance steroid therapy for other conditions (excluding steroid tapers 
for brain edema/metastases/radiation)  
o Steroid therapy as prophylaxis for contrast reactions  
o Stable hormonal therapy for ovarian suppression for non -malignant conditions, 
hormonal contraceptive therapy , or post -menopausal HRT*   
o GnRH analogs in patients with prostate cancer  
o Intra -articular steroid injections  
o Higher dose steroid therapy for treatment of an acute intercurrent illness in patients 
with stable disease or an ongoing response. In such situations, protocol therapy 
treatment should be interrupted.  
*Prior or concomitant therapies are permitte d; however, patients must have been on a stable dose for at 
least 6 months prior to study start, and if continuing must remain on the stable dose while receiving study 
treatment (i.e. , such treatment will not be considered as systemic hormonal therapy for the purpose of study 
eligibility).  
 Prophylactic use of hematopoietic growth factors during Cycle 1 
 Major surgery that would preclude the patient from complying with the requirements of 
the protocol  
If any one of the above listed medications/procedures beco mes necessary during the trial, the 
patient must be withdrawn from Sym015 and the EOT Visit should be performed. The 1M FUP 
Visit should then be performed , no less than 1 month ( 30 +7 days) after the last dose of Sym015.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 69 of 164 7.6 Medical Car e of Patients after End of Trial Participation  
After completing treatment in this trial, patients will be offered standard of care treatment in 
accordance with generally accepted medical practice and depending on the patient’s individual 
medical need.  Patients will continue to be  followed for survival.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 70 of 164 8. TRIAL ASSESSMENTS  
All trial assessments are considered mandatory for all patients included in the trial, unless 
otherwise stated.  All assessments are to be performed on or about the indicated visit day, i.e. , ±2 
days, unless otherw ise stated. A slightly longer allowance for routine assessments is permissible 
in the event of scheduling difficulties associated with weekends, holidays, etc.  
8.1 Baseline Characteristics / Eligibility Assessments  
8.1.1 Signing of Informed Consent  
Prior to any prot ocol-related procedure, unless such testing was performed previously as part of 
the routine clinical management of the patient.  
 Screening  
Note: Informed consent may be obtained outside the 14 -day screening period prior to C1/D1  
8.1.2 Demographics  
To include date  of birth, sex, race and ethnicity  (as allowed by country)  
 Screening  
8.1.3 Medical History  
To include prior and ongoing medical illnesses and conditions and prior surgical procedures not 
related to the primary diagnosis.  
 Screening  
 C1/D1 (prior to dosing)  
8.1.4 Tumor C haracteristics and Extent of Disease  
To include diagnosis and date of initial diagnosis, staging at time of initial diagnosis and at 
screening, tumor histology, current location of metastases, and date of most recent disease 
progression , and mutation statu s. 
 Screening  
8.1.5 Prior Cancer Treatments  
To include prior surgical procedures for the primary diagnosis, as well as prior radiotherapy, 
chemotherapy and/or biological targeted therapy, investigational treatment,  and/or procedures.  
Include dates of treatments,  numbers of cycles, and best response to such treatments.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 71 of 164  Screening  
 C1/D1 (prior to dosing)  
8.2 Safety Assessments  
To be performed within 14 days of C1/D1, unless otherwise specified.  
8.2.1 Medication /Procedure  Survey  
To include all medications taken other than Sym 015 and all procedures performed during trial .  
For medications : Include generic name or brand name, indication for use, dose and frequency, 
route of administration, start and stop dates or if ongoing at 1M FUP Visit . For procedures: 
Include date and reaso n for procedure.  
 Starting from the date of Screening  
 Until the date of the 1M FUP  
8.2.2 Adverse Events Survey  
For details about (S)AEs and (S)AE reporting, refer to  Section 9. 
 Starting from signing of informed consen t for participation in the trial  
 Until the date of the 1M FUP  
Note: Patients who sign informed consent and are subsequently deemed to be screening failures 
will be followed for the occurrence of SAEs/AEs until it is determined that they will not be 
partici pating in the trial 
8.2.3 Dose -Limiting Toxicities Evaluation ( Part 1  Only)  
For details about AEs meeting DL T criteria, refer to Section 9.5. 
 Starting from the first dose of trial drug (C1/D1)  
 Reported during Cycle 1 with a final assessment 14 (±2) days after the last dose of Cycle 
1 or prior to dosing on C2/D1  
8.2.4 Vital Signs and Body Weight  
To include temperature, heart rate, blood pressure, and body weight   
 Screening  
 Prior to each dosing  
 EOT  
 1M FUP  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 72 of 164  As clinically indic ated 
8.2.5 Performance Status  
To be assessed by ECOG PS score.  
 Screening  
 Day 1 of each cycle (prior to dosing)   
o Does not n eed to be assessed prior to C1/D1  if assessed  during screening ≤  7 days 
from C1/D1  
 EOT  
 1M FUP  
 As clinically indicated  
8.2.6 Physical Examination  
To include evaluation of  the following  at Screening : General appearance, skin, head, ears, eyes, 
nose, throat, neck/thyroid, chest, cardiovascular system, abdomen, musculoskeletal system, 
lymph nodes, neurologic status , and mental status ; include height (wi thout shoes, rounded to 
nearest centimeter).  Thereafter, a targeted physical examination may be performed as indicated . 
 Screening  
 Day 1 of each cycle (prior to dosing)  
o Does not n eed to be performed  prior to C1/D1  if performed during screening ≤ 7 days 
from C1/D1  
 EOT  
 1M FUP  
 As clinically indicated  
8.2.7 Electrocardiogram  
To include standard 12 -lead electrocardiogram ( ECG ). The Investigator, or qualified designee, 
should document the evaluation of the ECG, including speci fication of any abnormality as 
clinically significant or not clinically significant.  
 Screening  
 EOT  
 As clinically indicated  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 73 of 164 8.2.8 Echocardiogram or Multi -Gated Acquisition Scan  
Patients will be scheduled for a  transthoracic echocardiogram (ECHO) at baseline to ex clude 
enrollment of patients with insufficient heart function; alternatively, a radionuclide angiography 
(Multi -Gated Acquisition [MUGA] scan) of the heart may be performed.  
 Screening  
 In the event of cardiac symptoms ( e.g., shortness of breath, edema ) an ECHO or MUGA 
is to be scheduled as soon as possible  
 As otherwise clinically indicated  
8.2.9 Laboratory Assessments and Pregnancy Test  
All routine laboratory analyses will be performed at a laboratory facility local to the trial site. 
Results must be available  and assessed  prior to each dosing of Sym015.  
Sponsor or designee must be provided with a list of trial site laboratory normal ranges for all 
required parameters prior to screening of the first patient at the site. Likewise, any change in 
laboratory normal r anges during the trial should be forwarded to the Sponsor or designee 
promptly during the trial.  
Blood samples will be taken at all scheduled visits and  will be  analyzed for the following 
parameters as per Table 8 and as clinically indicated:  
Table 8 Schedule of Safety Blood and Urine Samples  
Sample Analysis  Screening  Cycle 1  Cycles 
Thereafter  EOT  IM 
FUP  
Day within Cycle   D1 D3 
D8 D15 D22 D1 D15   
Hematology Panel  X X1 X X X X X X X 
Bioche mistry Panel  X X1 X X X X X X X 
Coagulation Panel  X X1 X X X X X X X 
Urinalysis  X X1  X  X  X X 
Pregnancy Test  X       X  
Abbreviations (in alphabetical order): D, day; EOT, End of Treatment Visit; 1M FUP, 1-Month Follow -up Visit  
1) Does not n eed to be performed  prior to C1/D1 if performed during screening ≤7 days from C1/D1  
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 74 of 164 8.2.9.1  Hematology Panel  
To include complete blood count with differential, ANC,  and platelet count.  
 Screening  
 Cycle 1  
o Weekly (prior to Sym015 administration on days of dosing)  
 Does not n eed to be performed  prior to C1/D1 if performed during screening ≤7 
days from C1/D1  
o Day 3  
 Each cycle thereafter  
o Prior to each dosing  
 EOT  
 1M FUP  
 As clinically indicated  
In the event of hematologic toxicity, the evaluation frequency should be increased to include 
additional evaluations between scheduled assessments, as clinically indicated.  
8.2.9.2  Biochemistry Panel  
To include sodium, potassium, chloride, bicarbonate or carbon dioxide, blood urea nitrogen 
(BUN), creatinine, glucose, bilirubin [total and direct], AST, ALT, A LP, calcium, magnesium, 
phosphorus, albumin, total protein, uric acid, amylase, lipase, and creatine kinase  (fasting not 
required) . Clinically significant electrolyte abnormalities should be corrected prior to dosing.  
 Screening  
 Cycle 1  
o Weekly (prior to Sym 015 administration on days of dosing)  
 Does not n eed to be performed prior to C1/D1 if performed during screening 
≤7 days from C1/D1  
o Day 3  
 Each cycle thereafter  
o Prior to each dosing  
 EOT  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 75 of 164  1M FUP  
 As clinically indicated  
In the event of significant biochemistr y abnormalities, the evaluation frequency should be 
increased to include additional evaluations between the scheduled assessments, as clinically 
indicated.  In the event of creatine kinase abnormalities, isoenzyme analysis should be 
performed.  
8.2.9.3  Coagulation Panel  
To include prothrombin time , PTT and INR.  
 Screening  
 Cycle 1  
o Weekly (prior to Sym015 administration on days of dosing)  
 Does not n eed to be performed  prior to C1/D1 if performed during screening 
≤7 days from C1/D1  
o Day 3  
 Each cycle thereafter  
o Prior to each dosing  
 EOT  
 1M FUP  
 As clinically indicated  
8.2.9.4  Urinalysis  
Multi -parameter chemical test strips are acceptable and  should include assessment of: s pecific 
gravity, pH, protein, glucose, ketones, occult blood, leukocyte esterase, nitrite, bilirubin, and 
urobilinogen.  
 Screening  
 Cycle 1  
o Prior to each dosing  
 Does not n eed to be performed  prior to C1/D1 if performed during screening 
≤7 days from C1/D1  
o Day 1 of eac h cycle thereafter (prior to dosing)  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 76 of 164  EOT  
 1M FUP  
 As clinically indicated  
8.2.9.5  Pregnancy Test  
Serum human Chorionic Gonadotropin (β -hCG) at screening, urine β -hCG thereafter, in women 
of childbearing potential.  
 Screening  
 EOT  
 As clinically indicated  
Women are cons idered of childbearing potential unless they have been hysterectomized, have 
undergone tubal ligation or have been postmenopausal for at least one year.  
8.3 Disease Assessments  
8.3.1 Disease Status Evaluation by CT or MRI  
The anti -tumor activity of Sym015 will be as sessed by the Investigator, or qualified des ignee, 
according to RECIST v1.1 ( 29). Refer to  Appendix 1. 
Patients will undergo imaging by CT or MRI of neck, chest, abdomen  and pelvis as indicated 
based on tumor type and clinical judgment in order to follow the underlying malignancy. The use 
of CT or MRI must be consistent per patient throughout the trial.  Use of contrast is preferred but 
is at the discretion of the Investi gator, as medically indicated.  
 Screening  
Note : A CT/MRI performed within 28 days prior to Day 1 may be used for evaluation of 
eligibility and as baseline scan, provided that the CT/MRI has been performed according to the 
protocol requirements  
 EOC 2 and end  of every second cycle thereafter, i.e. , EOC 4, EOC 6, EOC 8, etc. 
Note : May be performed  at any time during the week prior to Day 1 of the next cycle , including 
Day 1 of the next cycle, prior to dosing (provided results are available prior to study drug 
admi nistration)  
 Suspected PD (as soon as possible)  
 At least 28 days following an OR (PR, CR)  
 EOT (if > 3 weeks since previous CT/MRI)  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 77 of 164  At 1M FUP (if PD was not documented before or at EOT)  
If PD is documented at any time, no further disease assessments will be required. Patients with 
documented PD will be discontinued from Sym015 so that alternative management of their 
malignancy may be considered.  
To be assigned a status of PR or CR, changes in disease status must be confirmed by repeat 
imaging studies performe d no less than 28 days (4 weeks) after the criteria for response are first 
met.  In the case of  SD, follow -up measurements must have met the SD criteria at least once after 
trial entry at a minimal interval in general no less than 6 -8 weeks from first dose  of Sym015.  
Imaging data (imaging studies and derived assessments) will be stored by the sites and will be 
available upon request for potential review by the Sponsor or an independent radiology reviewer.  
For Part 2 only : In addition, imaging studies will b e sent to an imaging facility for storage  in 
order to ensure central availability and readiness for read at a future time upon Sponsor or Health 
Authority request.  
For all imaging time points, the following will be recorded as per RECIST v1.1: Target lesio ns 
including size, location, and type (nodal/non -nodal); sum of diameters of target lesions; any new 
lesions noted during trial, including size, location, and type (nodal/non -nodal); final response 
assessment at each visit (PD, SD, PR, CR or Not Evaluable [NE]).  
8.3.2 Tumor Marker Evaluation ( Part 1  and Part 2 Basket Cohort)  
To include tumor markers that are part of the  trial site standard practices  as indicated by tumor 
type, if applicable.  
It is recommended that tumor markers are evaluated at timepoints coinci ding with the CT/MRI 
imaging studies as listed in Section 8.3.1 . 
8.3.3 Archival Tumor Tissue for MET  and KRAS  Assessment  (Part 1  and Part 2 Basket 
Cohort)  
To be assessed locally. Does not need to be repeated if MET -amplification and KRAS  mutational 
status have been assessed previously and the pathology report is available to document findings.  
May be performed as part of prescreening outside the 14 -day screening period, provided separate 
informed consent has been obtai ned. 
 Screening  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 78 of 164 o Part 1: Eligibility assessment for KRAS  mutational status will be done  using archival 
tumor tissue, whenever  possible . If archival tissue is not available, tissue from a 
tumor biopsy performed during screening will be used.  
Assessment of MET-amplification status is not required, but tissue should be assessed 
if feasible . 
o Part 2:  
Eligibility assessment for KRAS  mutational status may be done using archival tumor 
tissue. If archival tissue is not available, tissue from the tumor biopsy perform ed 
during screening will be used . Refer to Section 8.3.4 . 
It is preferred that the eligibility assessment for MET -amplification be done using 
tissue from a tumor biopsy performed during screening, however archiv al tumor 
tissue may be used at the investigator’s discretion.  
Note: If a new biopsy is performed for MET -amplification testing, tissue from this biopsy 
may be used for KRAS  mutation testing as well .  
During Part 2 ONLY, p eripheral blood collection for KRAS -mutation assessment and for 
MET -amplification assessment in ctDNA  is allowed as a local pre -screening methodology by 
Guardant360  analysis . Other liquid biopsy methodologies , except if used to detect METEx14Del, 
will only be allowed  if previously approved by the Sponsor.  Subsequent required tumor tissue 
evaluation to confirm MET -amplification must meet the protocol -specified inclusion criteria .   
NSCLC METEx14Del Cohort  (pre-protocol  v8.0) : Eligibility assessment for METEx14Del 
status will be done  according  to local institutional standards.  Assessment in ctDNA 
by Guardant360 technology or equivalent is allowed.  Subsequent confirmation in 
tumor tissue is preferred but not required , however, a rchival tissue to be submitted, if 
available  (applies only to pati ents with METEx14Del tumors entered prior to suspension 
of the Basket Cohort and establishment of NSCLC METEx14Del Cohort) . 
8.3.4 Tumor Biopsy  for Eligibility  Assessment  and Biomarker Analysis  (Part 1  and Part 2 
Basket Cohort)  
To be assessed locally  for eligibil ity:  
 Screening ; Part 1 and Part 2 , if applicable as per Section 8.3.3  (i.e., Basket Cohort)  
Note: It will be permissible to perform this procedure outside the 14 -day screening period, 
provided informed consent  for the trial  has been obtained  
To be assessed centrally  for biomarker analysis :  
 Screening  
o Part 1:  Optional ; only applicable for patients with known  MET -amplification who 
consent to this optional procedure; t o be performed after confirmation of eligibilit y 
o Part 2:  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 79 of 164 Basket Cohort : Required , if archival tissue is unavailable or insufficient for central 
analysis; t o be performed after confirmation of eligibility    
Note: Tissue from a tumor biopsy performed during screening is preferred, however a rchival 
tissue may be submitted for central analysis  at the Investigator’s discretion, provided the 
archival tissue is  suitable as specified in the laboratory manual. It must be ensured that the 
archival tissue can be made available to the central laboratory prior to d eciding to omit the 
tumor biopsy procedure at time of screening  
NSCLC METEx14Del Cohort :  Optional  
 Post-dosing  
If feasible , it is preferred that the second biopsy is taken from the same tumor site from 
which the first biopsy was taken.  
o Part 1: Optional; only applicable for patients with known  MET -amplification who 
consent specifically to this optional procedure ; to be performed as specified below for 
Part 2 patients  
o Part 2:  
Basket Cohort : Required ; EOC 2 (i.e. , coinciding with time of first response 
assessm ent) or upon PD, whichever occurs first  
Note : EOC  assessments may be performed  at any time during the week prior to Day 1 of the 
next cycle , including Day 1 of the next cycle, prior to dosing    
NSCLC METEx14Del Cohort : Optional, at the timepoint specified above  
 
8.3.5 Tumor Biopsy for MET  Status  and Biomarker Analysis (Part 2 NSCLC MET -
Amplified Cohort and NSCLC  METEx14Del Cohort)  
To be assessed centrally:  
 Screening  (Mandatory)  
Note: It will be permissible to perform this procedure outside the 14 -day screening p eriod, 
provided informed consent for the trial has been obtained  
o NSCLC MET -Amplified Cohort : Required; t issue from a newly performed pre -dosing 
tumor biopsy must be submitted for central confirmation of MET -amplification   
(Patient s may be entered and treat ed based on local assessment of a recent tumor 
biopsy  [if available  and performed outside of the screening process as part of the 
site’s usual practice ] provided no intervening antineoplastic  therapy has been 
administered; otherwise tissue from a newly per formed biopsy must be obtained and 
submitted)  
o NSCLC METEx14Del Cohort :  Required; t issue from a recent or newly performed pre -
dosing tumor biopsy must be submitted for central assessment of METEx14Del  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 80 of 164 (Patient s may be entered and treated based on local in stitutional standards; 
alternatively, assessment in ctDNA by Guardant360 technology or equivalent is 
allowed ; a recent [as defined above] or newly performed pre -dosing biopsy must still 
be submitted ) 
 Post-dosing  (Optional)  
EOC 2 (i.e. , coinciding with time of first response assessment) or upon PD, whichever 
occurs first  
Note: EOC  assessments may be performed at any time during the week prior to Day 1 of the 
next cycle, including Day 1 of the next cycle, prior to dosing   
To include a tumor biopsy performed b y a core biopsy of a locally recurrent or metastatic lesion. 
This procedure will take place prior to the first Sym015 administration. The tumor biopsy must 
be performed with minimal morbidity to the patient by a percutaneous core needle biopsy either 
with or without the aid of an imaging modality chosen at the discretion of the physician 
performing the biopsy.  
Biopsy specimens will be obtained using standard sterile surgical techniques and formalin -fixed, 
paraffin -embedded according to standard laboratory techniques. All tumor tissue samples should 
be reviewed by a pathologist to confirm the presence of tumor cells before the tissue sample 
(blocks or slides) is sent to the central laboratory for analysis. A detailed laboratory manual 
specifying sample colle ction, handling, storage , and shipment will be provided to the trial sites.  
Analysis of tumor biopsies may include genes and/or proteins that are unknown or have not been 
included in the scientifi c hypotheses of this trial, but that, during the collection  of data from this 
trial, may evolve as new candidate genes and markers related to Sym015 safety, efficacy, or 
mechanism of action.  
All analyses will be related to and used only in connection with the data collected in the present 
trial and future develop ment of Sym015 , and the identity of the patient will remain confidential. 
The analyses will not have any medical consequences for the patient or their relatives.  
Tumor biopsy samples will be stored for up to 15 years afte r completion of the trial , where  after 
all samples will be destroyed.  
8.4 Pharmacokinetic Assessments  
PK samples will be taken according to the schedules shown in Table 9.  
Analysis of PK will be performed at a central laboratory. A detailed laboratory  manual 
specifying sample collection, handling, storage , and shipment will be provided to the trial sites.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 81 of 164 In the event that a collected serum sample is inadequate or insufficient for PK analysis, the 
analysis of PK can be done using an anti-drug antibody (ADA ) serum sample from the same time 
point, if available.  
Note:  Comprehensive collection of clinical samples is critical to the conduct of this study.  In situations 
where collection of EOI + 8h samples is logistically difficult due to clinic staff avail ability, the 
observation period may be shortened and an "end of day" sample may be obtained at the latest practical 
time.  Such an option (if to be routinely employed) is available only after previous discussion with and 
approval by the Sponsor.  
Table 9 Schedule of Pharmacokinetic Assessments  
 Cycle 1  Cycles Thereafter  EOT  IM FUP  
Sampling Time  Window  D1-D3 D8 D15 D1 D15   
Part 1 / Part 2 Basket Cohort  
Prior to SOI  - 4 h X  X1 X1 X1   
EOI + 10 min  X  X1 X1 X1   
EOI + 1 h  ±15 min  X       
EOI + 2 h  ±30 min  X       
EOI + 4 h  ±30 min  X       
EOI + 8 h  ±90 min  X       
EOI + 24 h  ±6 h X       
EOI + 48 h  ±12 h  X       
During Visit  NA  X    X X 
Part 2 NSCLC Cohorts (effective with protocol  v8.0; December  2018)  
Prior to SOI  - 4 h X  X1 X1 X1   
EOI + 10 min  X  X1 X1 X1   
EOI + 4 h  ±30 min  X       
EOI + 48 h  ±12 h  X       
During Visit  NA  X    X X 
Abbreviations (in alphabetical order): D, day; EOI, End of Infusion, EOT, End of Treatment Visit; NA, Not Applicable; h, hour ; min, mi nutes; 
1M FUP, 1-Month Follow -up Visit; SOI, Start of Infusion  
1) If Sym015 is paused, only one PK sample should be taken during the visit  
 
 
8.5 Anti -Drug Antibody Testing  
To assess formation of ADA. All samples must be taken prior to the Sym015 infusion of that 
visit. Analysis of ADA and residual serum levels of Sym015 will be performed at a central 
laboratory. A detailed laboratory manual specifying sample collection, handling, storage , and 
shipment will be provided to the trial sites. In the event that a collec ted serum sample is 
inadequate or insufficient for ADA analysis, the analysis of ADA can be done using a PK serum 
sample from the same time point, if available.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 82 of 164  C1/D1  
 C2/D1 (Part 2 only)  
 Day 1 of  to every second cycle thereafter, i.e. , Cycle 3, 5, 7 etc.  (prior to dosing)   
 EOT  
 1M FUP  
8.6 Skin Biopsy  (Part 1 only)  
To be performed only after eligibility has been confirmed  
Analysis of skin biopsy samples will be performed at a central laboratory. Biopsy specimens will 
be obtained using standard techniques and for malin -fixed, paraffin -embedded according to 
standard laboratory techniques. A detailed laboratory manual specifying sample collection, 
handling, storage , and shipment will be provided to trial sites.  
Skin biopsies are requested from a rash -free area.  
 Screening, after confirmation of eligibility  
 EOC 2 (i.e., coinciding with time of first response assessment) or upon PD, whichever 
occurs first  
Note : EOC  assessments may be performed  at any time during the week prior to Day 1 of the next 
cycle , including Day 1  of the next cycle, prior to dosing  
8.7 Blood Sample  for Genomic and Biomarker Analys es 
To include assessment of  MET -amplification and METEx14Del status; a nalysis of all samples taken 
will be performed at a central laboratory. A detailed laboratory manual spe cifying sample 
collection, handling, storage,  and shipment will be provided to the trial sites.  
 Screening  (it will be permissible to perform this procedure outside the 14 -day screening 
period, provided informed consent for the trial has been obtained)  
 EOC 2 (coinciding with time of first response assessment or upon PD, whichever occurs 
first)  
Note : EOC  assessments may be performed  at any time during the week prior to Day 1 of the next 
cycle , including Day 1 of the next cycle, prior to dosing  
 EOT  (if after  EOC2; need not repeat if patient is discontinuing at the EOC2 or if a sample 
was obtained upon PD)  
Note:  If a tumor biopsy is collected at the same time point as the biomarker blood sample, 
the biomarker blood sample should be collected prior to collecti ng the tumor biopsy.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 83 of 164 The purpose of the pharmacodynamic biomarker assessments is to develop an approach for the 
identification and validation of genes or proteins that may predict which patients are likely to 
respond to Sym015, and that may change with the  possible development of acquired resistance to 
Sym015. Potential  biomarkers of interest include  genes, gene transcripts and proteins of the 
RTKs  and molecules of the MET signaling pathway , including MET , HGF, EGFR, HER2, 
HER3, IGF1R,  ROS1, RET, PIK3CA, PTEN, cMYC, KRAS, NRAS, BRAF, AKT1, FGFR, and 
RON . 
Analysis of biomarker blood samples may include genes  and/or proteins  that are unknown or 
have not been included in the scientific hypotheses of this trial, but that, during the collection of 
data from thi s trial, may evolve as new candidate genes and markers related to Sym015 safety, 
efficacy, or mechanism of action.  
All analyses will be related to and used only in connection with the data collected in the present 
trial and future development of Sym015 , and the identity of the patient will remain confidential. 
The analyses will not have any medical consequences for the patient or their relatives.  
Biomarker samples will be stored for up to 15 years after completion of the trial , where after all 
samples will  be destroyed.  
8.8 Handling of Biological Samples  
All biological samples to be analyzed locally will be collected and handled according to 
institutional practices.  
All biological samples to be analyzed centrally will be collected and handled according to a 
detailed laboratory manual.  
Retention time for biologic specimens will be specified in the laboratory manual.  
8.9 Follow -up Assessments  
Assessments at the 1M FUP Visit include disease status and subsequent cancer therapy.  
After the 1M FUP Visit, the Investigator  will make every effort to obtain follow -up information 
on response assessment and/or OS every 2 months. Response assessment follow -up is required in 
the event of an ongoing SD, PR or CR, as per RECIST v1.1 at the 1M FUP Visit, until PD or 
another therapeu tic intervention is initiated. Survival follow -up is required until death, 
withdrawal of consent, or termination of the trial.  This continued follow -up does not require an 
in-person visit at the trial site, but may  be obtained by collection of data/documen tation.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 84 of 164 8.10 Appropriateness of Measurements  
Standardized methods for assessments of efficacy and safety variables will be used.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 85 of 164 9. ADVERSE EVENTS  
9.1 Definitions of Adverse Events  
9.1.1 Adverse Event  
An AE is any untoward medical occurrence in a patient or a clinical inve stigation subject 
administered a pharmaceutical product,  and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disea se temporally associated with the 
use of an IMP, whether or not considered related to the IMP.  
Causality for the above -mentioned AE will be assessed appropriately as : Related to IMP, 
Possibly Related to IMP, Probably Related to IMP, Unlikely Related to IM P, or Not Related to 
IMP. In addition, any AE, regardless of causality, that also meets the seriousness criteria, will be 
reported on an SAE form.  
9.1.2 Events Not to be Considered as Adverse Events  
A pre -existing condition (i.e. , a disorder that is present befo re the AE recording period starts and 
is noted on the medical history/physical examination form) should not be recorded as an AE 
unless the condition worsens , or episodes increase in frequency during the AE recording period.  
PD will not be captured as an A E unless the nature of the PD is different than expected (i.e. , 
other diagnosis and/or signs/symptoms that are not typical of PD).   
Note:  PD may be reported as an AE in the case of patient death, with death being the outcome of the event.  
An abnormal labo ratory value or an abnormality in physiological testing (such as ECGs) need 
not be reported as an AE unless one of the following applies:  
 The Investigator considers  the abnormality clinically significant  
 The event meets the definition of an SAE  
 The event requires an intervention  
 The event results in an action taken with Sym015 (dose -reduction and/or withdrawal)  
Diagnostic and therapeutic non -invasive and invasive procedures, such as surgery, should not be 
recorded as AEs. A medical condition for which an u nscheduled procedure was performed, 
should however be recorded if it meets the definition of an AE. For example, an acute 
appendicitis should be recorded as the AE and not the appendectomy.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 86 of 164 Procedures to support the treatment regimens, such as insertion of  central venous catheters , etc. 
should not be recorded as AEs, unless the procedures result in complications.  
9.1.3 Adverse Events of Medical Interest  
Not applicable.  
9.1.4 Serious Adverse Events  
An SAE is an AE that meets one or more of the following outcome criteria : 
 Results in death  
Note : In the case of deaths, the event(s) leading to the death should be recorded and reported as 
SAE(s) with the outcome “Fatal”. The death itself will not be reported as an event (SAE), unless 
the cause of the death is unknown (e.g. , in case of unexplained or sudden death)  
 Is life -threatening  
Note : The term "life -threatening" in this definition refers to an event in which the patient is at 
immediate risk of death at the time of the event; it does not refer to an event which hypothetica lly 
might cause death if it was more severe  
 Requires inpatient hospitalization or prolongation of existing hospitalization  
 Results in persistent or significant disability/incapacity  
 Is a congenital anomaly/birth defect  
 Is medically important  
Note : Medical  and scientific judgment must be exercised in deciding whether an AE is believed 
to be “medically important”. Medically important events may not be immediately life -threatening 
or result in death or hospitalization but may jeopardize the patient or may req uire intervention to 
prevent one of the other outcomes listed in the definition above  
 
9.1.5 Events that Do Not Meet the Definition of Serious Adverse Events  
PD will not be captured as an SAE unless the nature of the PD is different than expected (i.e. , 
other di agnosis and/or signs/symptoms that are not typical of PD).  
Note:  PD may be reported as an SAE in the case of patient death, with death being the outcome of the event.  
Elective surgery or other scheduled hospitalization periods that were planned before th e patient 
was included in this trial are not to be recorded as SAEs, unless an outcome is considered 
serious.  
Hospitalization for observation or convenience following the Sym015 infusions without an SAE 
occurring should not be recorded as an SAE, e.g. , if a patient is hospitalized merely for 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 87 of 164 observation, or if a patient finalizes the infusion at a time of day requiring a convenience 
overnight stay in the hospital.  
If procedures to support the treatment regimens require hospitalization , they should not be 
recorded as SAEs. However, in cases where a procedure results in complications 
requiring/prolonging hospitalization , this must be recorded and reported as an SAE.  
9.2 Adverse Event Recording and Reporting Instructions  
9.2.1 Adverse Event Recording Period  
All AEs wil l be recorded from signing of informed consent  for participation in the trial . The 
recording period ends at the time of the 1M FUP Visit.   
Note: Patients who sign informed consent and are subsequently deemed to be screening failures will be 
followed for th e occurrence of SAEs/AEs until it is determined that they will not be participating in the 
trial. 
The Investigator must record all directly observed AEs and all AEs spontaneously reported by 
the patient. A general, open -ended type of question should be use d to elicit a response from the 
patient, such as, “How have you been feeling?” or “Have you had any health p roblems since 
your last visit?”.  
All AEs that occur in patients during the AE recording period must be recorded/entered on the 
AE section of the Cas e Report Form (CRF), whether or not the event is assessed as related to 
Sym015. If the AE is serious, the SAE report forms must a lso be completed and submitted. Refer 
to Section 9.3. 
9.2.2 Diagnosis  
A diagnosis should  be recorded if possible. If no diagnosis is available, signs and symptoms 
should be recorded instead.  
9.2.3 Severity  
The Investigator will use the CTCAE v4.03 to describe the severity of an AE. If the severity of 
an AE is not specifically graded by the CTCAE gu idance document, the Investigator should use 
the general definitions of Grades 1 to 5 as per the following, and use his/her best medical 
judgment to describe the severity of the AE:  
 Grade 1: Mild  
 Grade 2: Moderate  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 88 of 164  Grade 3: Severe  
 Grade 4: Life -threatening or disabling  
 Grade 5: Death caused by the event  
Changes in severity of AEs will be recorded.  
Generally, an AE of CTCAE Grade 4 or 5 qualifies for SAE reporting to the Sponsor or 
designee. However, a laboratory abnormality of CTCAE Grade 4 does not need to be reported as 
an SAE, unless it meets one of the seriousness criteria in Section  9.1.4 . 
9.2.4 Relationship to Investigational Medicinal Product/Sym015  
The Investigator must assess causal relationship to the IMP, Sym0 15. Relatedness has to be 
assessed and recorded within the initial report (CRF and SAE report form).  
The causal relationship is an assessment of whether or not the event is related to the use of the 
IMP. It is not an evaluation of whether or not the event could hypothetically occur in the 
investigational patient population.  
The causal relationship of an AE to the IMP, Sym015, will be rated as follows:  
Not Related:  The AE is not related to the IMP, which means the event:  
 Does not follow a reasonable temporal  sequence from drug administration  
 Is readily explained by the patient’s clinical state or by other modes of therapy 
administered to the patient  
 The AE is clearly NOT related to the IMP  
Unlikely Related:  The AE is considered not related to the IMP based o n the following:  
 Does not follow a reasonable temporal sequence from administration of drug  
 Could readily be a result of the patient’s clinical state, environmental, or toxic factors, 
or other modes of therapy  
 Does not follow a known response pattern to th e suspected drug  
 Does not reappear or worsen when the drug is re -administered  
Possibly Related:  The AE might not be related, but possibility cannot be ruled out with 
certainty and therefore would be considered related based on:  
 Follows a reasonable tempora l sequence from administration of drug  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 89 of 164  Could readily have been a result of the patient’s clinical state, environmental or toxic 
factors, or other modes of therapy  
 Follows a known response pattern to the suspected drug  
Probably Related:  It has been determin ed with a high degree of certainty that the AE is 
associated with administration of IMP based on:  
 Follows a reasonable, temporal sequence  
 Cannot be reasonably explained by known characteristics of the patient’s clinical 
state, environmental, or toxic facto rs, or other modes of administered therapy  
 The AE disappears or decreases in severity upon cessation of drug, or reduction in 
dose.  
 Follows a known response pattern to the suspected drug  
Related:  The AE is related to the IMP, which means the event:  
 Follows  a reasonable temporal sequence from drug administration  
 Abates upon discontinuation of the IMP (de -challenge)  
 Is confirmed by reappearance of the reaction on repeat exposure (re -challenge)  
 Cannot be reasonably explained by the known characteristics of the patient’s clinical 
state  
 Is not likely to have been produced by the patient’s clinical state or by other modes of 
therapy administered to the patient  
9.2.5 Outcome  
Outcome of the AE must be assessed by the Investigator utilizing one of the following terms:  
 Recovered  
 Recovered with sequelae (if recovered with sequelae, specify sequelae)  
 Not recovered  
 Fatal  
 Unknown  
Instructions for reporting changes in an ongoing AE during a patient's participation in the trial 
are provided in the instructions that accompany t he AE CRF pages.  
9.2.6 Follow -up of Adverse Events  
All AEs should be followed until they are resolved or until the 1M FUP Visit, whichever comes 
first. 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 90 of 164 Note: Patients who sign informed consent and are subsequently deemed to be screening failures will be 
followed  for the occurrence of SAEs/AEs until it is determined that they will not be participating in the 
trial. 
9.3 Serious Adverse Event Recording and Reporting  
All SAEs occurring at any time from signing of informed consent  for participation in the trial  
and until the 1M FUP Visit must be recorded on the SAE Report Form and recorded as an SAE 
in the CRF.  
Note: Patients who sign informed consent and are subsequently deemed to be screening failures will be followed for 
the occurrence of SAEs/AEs until it is determined  that they will not be participating in the trial. 
In case of an SAE, the Investigator must, within 24 hours of first awareness of the event , report 
the SAE to the Sponsor (or designee ) by fax or e -mail. Fax number(s) and e -mail address (es) will 
be stated on the SAE Report Form and the SAE Report Form Completion I nstruction s. SAE 
follow -up information must also be reported to the Sponsor (or designee) within 24 hours of 
awareness . 
SAEs still ongoing after  the 1M FUP Visit should be followed on a regular bas is according to the 
Investigator’s clinical judgment, until the event resolve s or until the Investigator assesses it as 
chronic or stable. The Sponsor (or designee ) will pursue sufficient information and will return to 
the trial sites for such information as deemed required.  
If the Investigator becomes aware of an SAE that occurred after the 1M FUP Visit and finds it to 
be related to the IMP (possibly -, probably -, or related to the IMP ) or trial conduct, it must be 
recorded and reported to the Sponsor (or designee ) as an SAE. These SAEs considered related to 
the IMP and occurring after the 1M FUP Visit will not be reported in the CRF  but only on an 
SAE Report Form for recording in the Safety Database.  
The Investigator should be aware of local reporting regul ations to the Institutional Review Board 
(IRB)/Ethics Committee (EC). The Sponsor (or designee ) will either supply the Investigator with 
the reports, which should be forwarded to the IRB/EC, or report directly to the IRB/EC 
depending on local regulations.  
9.4 Safety Reporting to Health Authorities, Institutional Review Boards/ Ethics 
Committees , and Investigators  
Reportability of an SAE as a  “suspected unexpected serious adverse reaction”  (SUSAR ) will be 
determined solely by the Sponsor, based on seriousness, ca usality and expectedness.  In addition 
to SUSARs, the Sponsor or designee is responsible for reporting all relevant safety information 
regarding SUSARs, or other safety developments, to appropriate Health Authoritie s and c entral  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 91 of 164 IRBs/ECs, as well as partic ipating In vestigators. Requirements for reporting SUSARs to local  
IRBs /ECs  will be handled via the Investigator. The timeline for notification of SUSARs is within 
7 calendar days for fatal/life -threatening events and within 15 calendar days for all other 
SUSARs.  
Additionally, the annual Development  Safety Update Report (DSUR) will be submitted by the 
Sponsor or designee to all appropriate Health Authoritie s and central IRBs/ECs as per ICH 
Guidelines. Submission of the DSUR to local IRBs/ECs will handled  as per local regulations  
and/or requests .  
9.5 Dose -Limiting Toxicities  (Part 1 Only) 
9.5.1 Definition of Dose -Limiting Toxicities  
A DLT is defined as any of the following toxicities that occur during the DLT observa tion 
period, if considered related (causality rating  of possibly, probably, or related) to Sym015:   
1. Grade 3 non -hematologic toxicity regardless of duration, with the exceptions of:  
a. Grade 3 nausea, vomiting, diarrhea, or fatigue lasting ≤ 2 days with best supportive 
care  
b. Grade 3 asymptomatic electrolyte abnormalities lasting ≤ 3 days that are not 
considered clinically relevant by the Investigator and that resolve with medical 
therapy  
2. Any Grade 4 non -hematologic toxicity , with the exception of:  
a. Grade 4 asymptomatic electrolyte abnormalities lasting < 3 days that are not 
considered clinically relevant by the Investigator and that resolve with medical 
therapy.  
3. Neutropenia that is:  
a. Grade  3-4 febrile neutropenia  
b. Grade 4 and sustained (i.e. , ANC <500 per mm3, duration > 5 days)  
4. Thrombocytopenia that is : 
a. Grade 3 with clinically significant hemorrhage  
b. Grade 4 (platel ets <  25,000 per mm3) 
5. AST/ALT elevation > 3xULN with bilirubin elevation > 2xU LN that cannot be explained 
by factors not related to study drug  
6. Inability to complete Cycle 1 at the assigned dose due to ≥ Grade 3 toxicity  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 92 of 164 7. Treatment delays > 2 weeks from the scheduled “next dose” due to ≥ Grade 3 toxicity  
9.5.2 Observation Period for Dose -Limiting Toxicities  
The observation period for DLTs is defined as Cycle 1  with a  final assessment 14 (±2) days after 
the last dose of Cycle 1 or prior to dosing on C2/D1 . 
Cycle 1 must have been completed at the assigned dose of Sym015 for a patient to complet e the 
DLT observation period.  
9.5.3 Reporting of Dose -Limiting Toxicities  
All presumed DLTs must be reported to the Sponsor or designee  within 24 hours after the 
Investigator or designee have become aware of the event. In addition,  DLTs fulfilling the SAE 
criter ia must be reported in an expedited manner according to the procedure for SAEs, as 
outlined in Section 9.3. 
9.6 Reporting of Infusion -Related Reactions  
The definition of an IRR is included in Section 7.1.3.6 . 
All IRRs must be reported in the CRF as an AE with the term “Infusion -related Reaction” 
followed by a specification of symptoms (e.g. , “Infusion -related Reaction with dyspnea and 
flushing”).  
To facilitate ongoing saf ety review throughout the course of this trial, the occurrence of ≥  Grade 
2 IRRs must  be reported  to the Sponsor or designee  within 24 hours  of occurrence.  
IRRs fulfilling the SAE criteria must be reported in an expedited manner according to the 
procedure for SAEs, as outlined in Section 9.3. 
9.7 Pregnancy  
If any trial patient becomes pregnant during the course of the trial, the patient must be 
discontinued from Sym015 immediately and the pregnancy must be reported t o the Sponsor or 
designee according to the same timelines as an SAE. While pregnancy is not considered an AE, 
all pregnancies are tracked as SAEs within the safety database in order to follow -up on exposure 
to the fetus/infant.  
Pregnancies reported in fem ale partners of male t rial patients must also be included in the 
database ; therefore, a pregnant partner must provide informed consent before information can be 
collected.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 93 of 164 All pregnancies must be followed up every third month to determine outcome (includin g 
premature termination) and status of mother and child. Pregnancy complications and elective 
terminations for medical reasons must be reported as AEs or SAEs as appropriate (trial patients 
only). Elective terminations for non -medical reasons should not be  reported as AEs. Spontaneous 
abortion must be reported as an SAE.  
Any SAE occurring in association with a pregnancy brought to the Investigator’s attention after 
the patient has completed the trial and considered by the Investigator as possibly related to  the 
IMP (possibly, probably, or related to Sym015), must be promptly reported to the Sponsor or 
designee.  
All pregnancy information including follow -up information must be reported in a designated 
pregnancy form provided by the Sponsor or designee.  
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 94 of 164 10. STAT ISTICS  
10.1 Statistical Considerations and Analysis Plan  
No formal hypothesis testing is planned.  Descriptive statistics will be used to summarize the 
safety, tolerability, pharmacokinetics, and clinical activity of Sym015 in all patient cohorts.  
Data will be described and summarized as warranted by sample sizes.  Listings will be used in 
place of tables in the event of small sample sizes.  Dose -escalation assessment will be based on 
the DLT -evaluable population, defined as patients who complete the DLT assessm ent window.  
All other analyses will be based on the safety -evaluable population, defined as all patients who 
receive any amount of the study drug.  
Continuous variables will be summarized with the use of means, standard deviations, medians, 
and ranges; cat egorical variables will be summarized using counts and percentages.  All 
summaries will be presented separately by cohort, in both Part 1 and Part 2 of the study.  
All details of the data analyses will be described in the Statistical Analysis Plan . 
10.2 Sample S ize Determination  
The primary endpoint of  Part 1 of the trial  is the occurrence of DLTs measured during Cycle 1 of 
Sym015 administration . The number of enrolled patients will depend on the extent of observed 
DLTs indep endently in each cohort. R efer to Sect ion 7.1.3.1  for a description of planned dose 
levels and decision points  for dose -escalation. Based on a 3+3 design, it  is planned to enroll 
between 12 and 15 patients during dose -escalation , however the actual number of patients will 
depend on observed DLTs .  
In Part 2 of th e trial , the primary endpoint is documented , confirmed  OR assessed by RECIST 
v1.1, at any time during trial participation by Investigator assessment.  It is planned to include 25 
patients with various advanced solid tumor malignancies , documented and confirmed  as MET -
amplified in the Basket C ohort , 20 patients in the NSCLC MET -Amplified Cohort, and 6 -12 
patients in the NSCLC METEx14Del Cohort , for the total of approximately 51 -57 patients in Pa rt 2.  
No power and type I error considerations were used to determine the sample size in each cohort. 
Proposed sample sizes in Basket and NSCLC C ohorts should allow to obtain preliminary safety, 
PK, response , and pharmacodynamic information of Sym015 in t he respective patient 
populations ( Table 10). 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 95 of 164 The expected (target) range of OR in any of these three  cohorts is in the range of 20%-50%, 
depending on histology, previous therapies , and other prognostic factors def ining the enrolled 
patient population.   
Table 10 90% Confidence Intervals for Observed Response Rates for N=20 and N=25  
 Method  Responses  N Mean  Lower  Upper  
1 exact  1 20 0.05 0.002561379  0.2161062  
2 exact  2 20 0.10 0.018065203  0.2826185  
3 exact  3 20 0.15 0.042169408  0.3436638  
4 exact  4 20 0.20 0.071353884  0.4010281  
5 exact  5 20 0.25 0.104080836  0.4555824  
6 exact  6 20 0.30 0.139553749  0.5078184  
7 exact  7 20 0.35 0.177310918  0.5580345  
8 exact  8 20 0.40 0.217068589  0.6064151  
9 exact  9 20 0.45 0.258650610  0.6530686  
10 exact  10 20 0.50 0.301953911  0.6980461  
11 exact  11 20 0.55 0.346931398  0.7413494  
12 exact  12 20 0.60 0.393584887  0.7829314  
 
1 exact  1 25 0.04 0.002049628  0.1761207  
2 exact  2 25 0.08 0.014403198  0.2310399  
3 exact 3 25 0.12 0.033519595  0.2817225  
4 exact  4 25 0.16 0.056562559  0.3296083  
5 exact  5 25 0.20 0.082290900  0.3754051  
6 exact  6 25 0.24 0.110056200  0.4195200  
7 exact  7 25 0.28 0.139475307  0.4622089  
8 exact  8 25 0.32 0.170303654  0.5036416  
9 exact  9 25 0.36 0.202377780  0.5439332  
10 exact  10 25 0.40 0.235586130  0.5831620  
11 exact  11 25 0.44 0.269853059  0.6213784  
12 exact  12 25 0.48 0.305129680  0.6586113  
13 exact  13 25 0.52 0.341388663  0.6948703  
14 exact  14 25 0.56 0.378621563  0.7301469  
15 exact  15 25 0.60 0.416838037  0.7644139  
16 exact  16 25 0.64 0.456066786  0.7976222  
17 exact  17 25 0.68 0.496358438  0.8296963  
18 exact  18 25 0.72 0.537791078  0.8605247  
19 exact  19 25 0.76 0.580479993  0.8899438  
20 exact  20 25 0.80 0.624594865  0.9177091  
  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 96 of 164 10.3 Analysis P opulation  
Analysis sets will be defined in accordance with the conso lidated ICH E9  GCP guidelines .  
The Full Analysis S et (FAS) will comprise all enrolled patients who have received at least one 
dose of Sym015. The FAS will be used for evaluation of all en dpoints except evaluation of 
DLTs . The patients in the FAS will contribute to the analyses as allocated to treatment. For  the 
evaluation of PK endpoints;  patients, full profiles, or single measurements can be excluded from 
the analyses. The decision of exc luding patients, full profiles , or part of pro files will be described 
in the clinical trial r eport (CTR).  
The DLT A nalysis  Set will comprise all patients in the FAS enrolled in Part 1 , except p atients 
who did not complete Cycle 1 (i.e. , the initial 28 -day period of Q2W dosing) for reasons other 
than drug toxicity. The DLT Analysis Set will be used for evaluation of DLTs . 
10.4 Primary Endpoint and Analysis  
10.4.1  Part 1, Dose -Escalation  
The primary objective of the dose -escalation part is to assess the safety and toler ability of 
Sym015. This will be assessed by the primary endpoint for Part 1, occurrence of DLTs during 
Cycle 1 of Sym015 administration . 
All DLT events will be listed by dose cohort and patient. A summary table of DLTs by System 
Organ Class (SOC) and Prefe rred Term will be presented for each dose cohort, if applicable. The 
summaries will include number of DLTs , and number and per centages of patients experiencing  a 
DLT.  The definition of a DLT is included in Section 9.5.1 .  
The MTD is defined as the highest dose with a maximum of 1 out of 6 patients experiencing a 
DLT. The MTD may or may not be found within the dose levels tested. Based on an overall 
evaluation  of the dose -escalation part, the  Q2W  RP2D  and highest safe dose tested  will be 
selected . The Q2W RP2D might not necessarily be the MTD or the highest administered dose.   
10.4.2  Part 2  
The primary objective of Part 2  is to evaluate the antitumor activity of Sym015 when 
administered at the Q2W RP2D. The primary endpoi nt is documented , confirmed  OR, defined as 
documented PR or CR and assessed by RECIST v1.1  at any time during trial participation by 
Investigator assessment . The assessment will be performed after completion of Part 2 of the trial.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 97 of 164 Number and percentages o f patients with documented OR will be presented including 
corresponding 90% exact Confidence Intervals (CI) , separately for each cohort . 
10.5 Secondary Endpoint and Analysis  
All statistical analyses of the secondary endpoints for both phases will be performed a fter 
completion of Part 2  of the trial.  
10.5.1  Efficacy Endpoints and Analyses  
All statistical analys es of the secondary endpoints will be presented using the FAS.  
The following anti -tumor response endpoints will be measured  in Part 1 : 
 Documented OR, defined as documented PR or CR and assessed by RECIST v1.1 at any 
time during trial participation by Investigator assessment.  
 Additionally, t he following anti -tumor response endpoints will be measured in  both Part 
1 and  2: 
o Duration of response (DR)  
o Best overall respo nse (BOR)  
o SD for > 4 months   
o Time to disease progression (TTP) as determined based on radiological evidence  
o Progression -free survival (PFS)  
o Overall survival  (OS)  
Best overall response ( BOR ) by RECIST v1.1 will be summarized by trial part and dose cohort 
by means of counts and percentages for the categories CR, PR, SD, PD and NE.   In addition, the 
number and percentages of patients with SD for more than 4 months will be presented.  
Number and percentages of patients with documented OR in the dose -escalation part will be 
presented including corresponding 90% exact CI. All documented ORs ( Part 1 and Part 2) will 
be listed including duration  (in days) of OR, measured from time of first PR or CR to PD.  
Time to disease progression ( TTP), PFS, and OS will be summar ized using the product -limit 
method and Kaplan -Meier plot s. The median  TTP, PFS, and OS , including  90% CI, will be 
calculated . 
10.5.2  Other Efficacy Assessments  
Tumor markers will be listed  and summarized descriptively, as appropriate . 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 98 of 164 10.5.3  Safety Endpoints and Analys es 
The safety endpoints are presented below . These endpoints  will all be pres ented for the FAS by 
trial part . Safety data will  be summarized using descriptive statistics and frequency distributions 
as appropriate . 
In Part 1 and Part 2 of the trial, the fol lowing safety endpoints will be assessed:  
 Nature, incidence and severity of AEs measured from baseline to end of trial participation  
 AEs leading to dose -reductions, dose delays and permanent treatment cessation  
 Changes in safety laboratory values from bas eline to end of trial participation  
 Changes in vital signs and physical examinations from baseline to end of trial 
participation  
 Occurrence of ADA s to Sym015 measured in serum at selected timepoints from baseline 
to end of trial participation  
10.5.3.1  Adverse Event s 
The AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA) current 
version . AEs will be regarded as treatment emergent AEs (TEAEs) if they occur after first 
treatment. Non -treatment emergent AEs (non -TEAEs) are defined as AEs colle cted before 
dosing. TEAEs will be  presented by SOC and Preferred Term unless stated otherwise. The 
frequencies of TEAEs will be presented including number and percentages of patients having 
experienced an event and the total number of events.  
AEs includin g SAEs are reported from signing of the informed consent  for participation in the 
trial and until the end of trial participation. SAEs reported outside the required reporting window 
are only entered into the safety database and will be described separately  in the report.  
Note: Patients who sign informed consent and are subsequently deemed to be screening failures will be 
followed for the occurrence of SAEs/AEs until it is determined that they will not be participating in the 
trial. 
All AEs will be listed. The TEAEs will be presented using summary tables by trial phase 
including:  
 AEs, in total and sorted by frequency  
 AEs by relationship  
 AEs by CTCAE Grade and max imum  CTCAE Grade  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 99 of 164  SAEs, in total, and by relationship  
 AEs leading to withdrawal from treatment  
 AEs leading to trial dr ug-interruption or dose -reduction  
 Fatal AEs  
10.5.3.2  Clinical Laboratory Values  
Biochemistry, hematology , and coagulation parameters will be presented using box plots by 
visits and by cohort and trial part. In addition, individual patient bioch emistry, hematology , and 
coagulation parameters during the trial will be presented graphically using longitudinal plots. 
Urinalysis parameters will be summarized using descriptive statistics.  
Laborator y values outside normal range will be  flagged,  and all laboratory values will be listed 
including CTCAE grading of abnormal values.  
10.5.3.3  Other Safety  Assessments  
Change in vital signs from baseline to end of trial participation will be summarized by visit, 
cohort , and trial part. Normal and abnormal findings in phy sical examination and ECG 
measurements will be presented in shift tables by visit, cohort , and trial p art. 
ECOG PS, body weight , and ADA results will be listed.  
10.5.4  Pharmacokinetic Endpoints and Analyses  
The PK endpoints will be derived based on the concentrat ion time curves of Sym015, and the 
first infusion of Sym015 in both parts of the trial.  Refer to Table 11. 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 100 of 164 Table 11 PK Endpoints Definitions and Derivations  
Symbol  Definition and derivatio n 
Ctrough Trough concentration (i.e. , concentration of Sym015 
measured pre -infusion ) 
AUC τ 
 Area under the concentration -time curve in a dosing 
interval (i.e. , from time zero (end of infusion) up to 336 
hours or 504 hours depending on regimes). AUC τ will 
be calculated using the linear trapezoidal method and 
interpolated in case of measurements  after 336/504 
hours, or extrapolated using terminal rate constant and 
the last quantifiable concentration, C z 
Cz Last quantifiable concentration . Cz is not an endpoint, 
but is used for derivation of endpoints  
AUC norm,  τ 
 Dose normalized area under the c oncentration -time 
curve in a dosing interval, calculated as AUC  τ divided 
by the dose infused  
Cmax Maximum concentration  
Tmax Time to reach maximum concentration  
λz Terminal rate constant (negative of the slope of an ln -
linear regression of the un -weigh ted data considering 
the terminal phase of the concentration -time curve ≥ 
limit of quantification . λz is not an endpoint, but is used 
for derivation of endpoints  
T½ Terminal elimination half-life, calculated as ln(2)/ λ z 
CL Clearance (Dose/AUC τ)  
Vz Volume of distribution during the terminal phase 
(CL/  λz) 
 
Cmax, Ctrough and T max will be derived from observed data while  AUC τ, AUC norm, τ , CL, V z, and 
T½ will be estimated using non -compartmental methods and actual time points . 
Individual curves of serum concentration versus time after the first dosing of Sym015 will be 
presented on log - and linear scale for all patients in the FAS. Furthermore , trough serum 
concentrations for the period from first dose to end of treatment will be presented on linear scale  
individual plots. In addition , mean concentration time curves will be presented on linear scale 
using nominal time point by cohort and trial p art. All PK endpoints will be listed and 
summarized by cohort and trial part . 
10.5.5  Additional  Endpoints and Analyses  
The following additional endpoints will be assessed in Part 1 and Part 2 of the trial:  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 101 of 164  Part 1 only: MET -receptor down -regulation measured by percentage and nominal change 
in target expression from baseline to EOC 2 or PD (whichever comes first) in skin biops y 
samples  
 Biomarkers relevant to Sym015 activity  
 Tumor genetics, drug target genes, and other biomarker genes that are known to be 
involved in the development and progression of MET -amplified solid tumor malignancies  
The additional endpoints, outlined abov e may include genes that are unknown or have not been 
included in the scientifi c hypotheses  of this trial, but that, during the collection of data from this 
trial, may evolve as new candidate genes and markers related to Sym015 safety, efficacy, or 
mechani sm of action.  
Percentage and nominal change in target expression from baseline to EOC 2 or PD (whichever 
comes first) in skin biopsy samples will be presented . Descriptive statistics will be used, 
including scatter plots of values at EOC 2 versus baseline.  
Potential biomarkers include  genes, gene transcripts , and proteins of RTKs and molecules of the 
MET  signaling pathway. All biomarkers will be listed  and descriptively summarized . 
Exploratory analys es using the biomarkers might be performed.  
10.6 Interim Analysis  
No interim analysis is planned.  
10.7 Deviations from the Statistical Plan  
Any deviation(s) from the original analysis plan will be described in  a protocol  amendment 
and/or in a statistical analysis plan  and/or in the final CTR, as appropriate.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 102 of 164 11. ETHICS  
11.1 Institut ional Review Board /Ethics Committee  
An IRB /EC will review the protocol  and any amendments and advertisements used for 
recruitment, as well as the informed consent documents, their updates (if any), and any other 
written materials given to the patients. The  CTR will include a list of all IRBs /ECs  to which the 
protocol  has been submitted and the name of the committee chair.  
11.2 Patient Information and Informed Consent  
The Investigator or his/her designee must obtain written informed consent from each patient 
before any trial related procedures are performed. Each patient must receive full patient 
information before giving consent. The patient information must contain full and adequate verbal 
and written information regarding the objective and procedures of the tri al and the possible risks 
involved.  
Before signing the informed consent form the patient must be given sufficient time to consider 
his/her possible participation. Each patient must also be informed about his/her right to withdraw 
from the trial at any time . 
Each patient must sign the informed consent form; the patient receives a copy of the signed form 
and the original is retained in the Investigator Site File (ISF). The informed consent form must 
be signed and dated both by the patient and by the Investiga tor or designee providing the 
information to the patient.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 103 of 164 12. SAFETY SURVEILLANCE SET -UP 
12.1 Safety Review  
An SMC will be established. This committee will include Investigator(s), Medical Monitor(s), 
Drug Safety Physician, and Sponsor’s medical representatives. T he SMC  will review clinical and 
laboratory safety data regularly  throughout the trial and make decisions regarding the 
advisability of continuing accrual to a particular dose cohort, and/or escalating the dose and 
allowing accrual to a higher dose cohort.  In order to do so,  the Investigator must ensure  to report 
safety data to the Sponsor or designee in a timely manner.  This includes, but is not limited to : 
 SAEs must be reported within 24 hours of awareness  (SAE report form)  
 DLTs must be reported within 24  hours of occurrence  
 IRRs of ≥ Grade 2 must be reported within 24 hours of occurrence  
 All AEs will be reported in the CRF in a timely manner  
 Dose -modifications (i.e. , dose-reduction, temporary interruptions regardless of cause)  
will be reported in the CRF in a timely manner  
 Local  laboratory data will be reported in the CRF in a timely manner  
Availability of these data will enable the Sponsor to act promptly in response to safety signals 
and to ensure Health Authoritie s, as well as Investigators , who may be  participating in other 
Sym015 clinical trials, are informed of events occurring during this trial.   
Safety  teleconferences will be held between the Investigational Site(s) and the Sponsor and/or 
designee. Patients will be carefully evaluated for evidence of all AEs, including potential 
cumulative and/or delayed toxicities throughout the duration of their time in the trial.  
 Part 1: It is intended that safety teleconferences will be held biweekly; however,  
frequency may fluctuate based on accrual and trial a ctivity, as indicated  
 Part 2: It is intended that safety teleconferences will be conducted after enrollment of 
approximately 15 and 30 patients. If safety concerns emerge, more frequent meetings will 
be held on an ad hoc basis.  
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 104 of 164 12.2 Other Safety Surveillance A ctivities  
A Medical Monitor is assigned to review and evaluate relevant clinical/safety information 
concerning the clinical trial. The responsibilities of the Medical Monitor include, but are not 
limited to:  
 Evaluation of coding and trending of AEs in conj unction with the Drug Safety physician  
 Performing surveillance on potential safety signals in conjunction with the Drug Safety 
physician  
 Evaluating abnormal laboratory values  
 Providing medical support to the Sponsor in answering questions related to the tr ial 
protocol  
 Updating the SMC  on trial status at scheduled meetings  
A Drug Safety physician is assigned to review, assess,  and approve all SAE cases and associated 
reports. This physician will also perform the following:  
 Assess for safety signals and trend s in conjunction with the Medical Monitor  
 Assist with questions regarding medical coding of SAEs  
 Discussing with the Sponsor Chief Medical Officer, any cases which may present a 
concern with regard to a signal or safety issue.  
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 105 of 164 13. MONITORING AND QUALI TY ASSU RANCE  
13.1 Compliance with Good Clinical Practice  
The responsibilities of the Sponsor, the Monitor , and the Investigator are defined in ICH GCP 
E6(R2) , and applicable regulatory requirements in the country where the trial takes place. The 
Investigator is respon sible for adhering to the ICH  GCP responsibilities of the Investigators, and 
for dispensing IMP only in accordance with this protocol  or a signed amendment, and for its 
storage and safe handling throughout the trial.  
13.2 Source Documents  
Each trial site will p ermit authorized representatives of the Sponsor and relevant authorities 
direct access to  (and when required by applicable law, to copy) clinical records for the purposes 
of quality assurance reviews, audits , and evaluation of the trial safety and progress . 
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but  are not limited to: Hospital records, 
clinical and office charts, laboratory notes, memoranda, patients’ written diaries or evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, copies or 
transcriptions certified af ter verification as being accurate and complete, microfiches, 
photographic negatives, microfilm or magnetic media, x -rays, and patient files and records kept 
at the pharmacy, at the laboratories, and medico -technical departments involved in the clinical 
trial. 
The Investigator must maintain source documentations for each patient in the trial and all 
information in the CRF must be traceable to these source documents in the patient’s file. Data 
not requiring a separate written record , i.e., data, which may be  recorded directly in the CRF,  
will be defined before trial start.  
13.3 Monitoring  
Monitoring visits to the trial sites will be made periodically during the trial to ensure that all 
aspects of the protocol  are followed. The Investigator must give the Sponsor an d/or their 
representatives direct access to all relevant source documents to confirm consistency with the 
CRF entries. Source Data Verification will be conducted according to Sponsor or designee 
Standard Operating Procedures (SOPs) and requirements will be  specified in a trial specific 
monitoring plan.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 106 of 164 It is important that the Investigator and their relevant personnel are available during monitoring 
visits and possible audits and that sufficient time is devoted to the process.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 107 of 164 14. DATA HANDLING AND RE CORD KEE PING  
Study data collection, processing, transfer, and reporting, as well as handling of study personnel 
information, will be done in compliance with ICH E6(R2) GCP and all applicable data protection 
regulations, including Regulation (EU) 2016/679 of the Eu ropean Parliament and of the Council 
of 27 April 2016 on the protection of natural persons with regard to the processing of personal 
data and on the free movement of such data (General Data Protection Regulation ; GDPR ). 
14.1 Data Protection  
The Investigator, Sp onsor , and Sponsor designee(s) will ensure that the confidentiality of the 
patients’ data is preserved. Each participating site will maintain appropriate medical and research 
records for this trial, in compliance with ICH GCP E6(R2)  and regulatory and inst itutional 
requirements for the protection of confidentiality of patients.  
14.2 Data Transactions and Access  
The trial data and any other documents transferred to the Sponsor or designee will not contain 
patient names or other confidential personal data, but pat ients will be identified using the 
assigned trial specific patient numbers.  
When data are transferred to the Sponsor or designee, access will be limited to relevant persons.  
Documents that are not for collection by the Sponsor, e.g. , patient identification  list and the 
signed informed consent forms, will be maintained by the Investigator in confidence.  
14.3 Data Processing  
A Data Management Plan (DMP) will be prepared for this trial. The Sponsor (or designee) will 
be responsible for data processing in accordance  with applicable Data Management SOPs and 
the trial DMP.  
Once recorded within the electronic CRF, study data will pass through a set of preprogrammed 
data validation checks designed to identify inconsistencies and other data errors, and will 
undergo an add itional study -specific data review process.  Data issues will be queried via the 
electronic data capture ( EDC ) system and query resolutions will be documented.  
Entry and processing of data other than those directly recorded on electronic CRFs by trial sit es 
(e.g., imports of laboratory results) will follow vendors ’ SOPs. Transfer of such data from 
vendors to Sponsor (or designee) will be handled according to vendors ’ data transfer SOPs and 
the Sponsor data transfer requirements with full compliance to appl icable regulations.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 108 of 164 Database Lock will occur upon reaching the predefined data cut -off for primary analysis and 
completion of Sponsor’s (or designee’s) quality control and quality assurance procedures.  
Portable Document Format (PDF) files of the electronic  CRFs will be provided to the 
Investigator upon removal of access to the electronic CRFs.  
14.4 Clinical Trial Report  
Following study completion, a final integrated clinical/statistical CTR will be prepared.  
14.5 Compliance with the General Data Protection Regulatio n 
The applicable EU data protection legislation requires that parties enter into a written contract if 
one party (data processor) processes personal data on behalf of the other party (data controller). 
This written contract must regulate the subject -matter  and duration of the processing, the nature 
and purpose of the processing, the types of personal data and categories of data subjects, as well 
as the obligations and rights of the data controller. Accordingly, the parties must enter into a data 
processing agreement. To the extent the processing of personal data involves transfers of 
personal data to third countries (e.g., jurisdictions outside of the European Economic Area 
[EEA]), the parties will enter into the European Commission's standard contractual cl auses 
between the data controller, the data processor, and all sub -processors, if any. The European 
Commission's standard contractual clauses ensure an adequate level of protection in relation to 
transfers of personal data to third countries.  
14.6 Retention of Trial Documents at Site  
The Investigator at each trial site must make arrangements to store the essential trial documents 
(including the ISF) after the end of the trial according to ICH GCP E6(R2)  and local 
requirements.  In addition, the Investigator is re sponsible for archiving all relevant source 
documents so that the trial data can be compared against source data after completion of the trial  
(e.g., in case of inspection from  relevant  authorities ). The Investigator is required to ensure the 
continued sto rage of the documents, even if the Investigator should leave the clinic/practice or 
retire before the end of the required storage period.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 109 of 164 15. REGISTRATION AND COM MUNICATION OF RESULT S 
15.1 Use of Information  
All unpublished information relating to this trial and t he IMP is considered confidential by the 
Sponsor and shall remain the sole property of the Sponsor. The Investigator must accept that the 
Sponsor may use information from this trial in connection with the development of the IMP, and 
therefore, may disclose  it as required to Investigators,  government licensing authorities, Health 
Authorities  of other government s, stock exchange market , and commercial partners.  
15.2 Registration and Publication  
The trial will be registered in  one or more  public trial registr ies (e.g., ClinicalTrials.gov). The 
trial results will be posted in the same clinical trial registr ies as the initial registration in 
accordance with the latest International Committee of Medical Journal Editors (ICMJE) 
recommendations (URL: www.icmje.org ). 
The Sponsor acknowledges the Investigators’ rights to publish the full results of the trial, 
regardless of the outcome, in accordance with the latest ICMJE recommendations.  
The Coordinating Investigator and the  Sponsor will decide on the publication strategy. The 
Coordinating Investigator has the right to publish and present the results and methods as first  or 
last author of multicenter publications. Co -authorship will be decided by the Sponsor and the 
Coordinating Investig ator and will be limited to a number of persons who have contributed 
substantially to the trial. The Sponsor will have representation in the list of authors.  
Publication is subject to the following conditions:  
 No publication before the completion of the tr ial at all participating trial sites without 
preceding written approval from the Sponsor  
 Publications shall not disclose any Sponsor confidential information and property (not 
including the trial results)  
 The Sponsor reserves the right to review results co mmunications prior to public release 
and can embargo communications regarding trial results for a period that is less than or 
equal to 60 days. The Sponsor cannot require changes to the communication and cannot 
extend the embargo . 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 110 of 164 16. INSURANCE AND LIABIL ITY 
The Sponsor will obtain  Human Clinical Trials Insurance for its legal liability in accordance with 
laws and regulations, and with limits customary or required by law in the territory in question.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 111 of 164 17. CHANGES TO THE FINAL  CLINICAL TRIAL PROT OCOL  
Changes to the  protocol  will not be implemented without agreement from the Sponsor and prior 
review and written approval from the appropriate Health Authority (as indicated) and the 
IRB/EC, except where necessary to eliminate an immediate hazard to the patient s. No prot ocol 
waivers will be allowed .  
Protocol changes to eliminate an apparent hazard to trial patient s may be implemented by the 
Investigator immediately. The Investigator must then, without delay, inform the local IRB/EC, 
and the Sponsor (or designee) will imm ediately notify local governing Health Authorities.  
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 112 of 164 18. PREMATURE TERMINATIO N OF THE TRIAL OR A TRIAL SITE  
18.1 Premature Termination of the Trial  
If the Sponsor, the Coordinating Investigator , or the SMC  discovers conditions arising during the 
trial, which indic ates that the trial should be halted, the trial can be terminated after appropriate 
consultation between the Sponsor, the SMC , and the Coordinating Investigator. The Health 
Authority  and IRB /EC will be notified in writing. The reason will be stated.  
Condit ions that may warrant termination of the trial include, but are not limited to the following:  
 The discovery of an unexpected and significant or unacceptable risk to the patients 
enrolled in the trial  
 The discovery of lack of efficacy  
 Failure of the Investi gators to enter patients at an acceptable rate in the trial as a whole  
 A decision on the part of the Sponsor to suspend or discontinue development of the IMP  
18.2 Premature Termination of a Trial Site  
The Sponso r can also decide to terminate single trial sites  prematurely . Conditions that may 
warrant termination include, but are not limited to the following:  
 Insufficient adherence to protocol  requirements  
 Failure to enter patients at an acceptable rate  
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 113 of 164 19. REFERENCE S 
1. WHO World Cancer Report 2014 . Edited by Bernard  W. Stewart and Christopher P. 
Wild . 
2. Petrini I: Biology of MET: a double life between normal tissue repair and tumor 
progression. Ann Transl Med. 2015 Apr;3(6):82 . 
3. Kawakami H, Okamoto I, Okamoto W, et al: Targeting MET  Amplification as a New 
Oncogenic Driv er. Cancers (Basel). 2014 Jul 22;6(3):1540 -52. 
4. Sacco JJ, Clague MJ: Dysregulation of the Met pathway in non -small cell lung cancer: 
implications for drug targeting and resistance. Transl Lung Cancer Res. 2015 
Jun;4(3):242 -52. 
5. Wolff AC, Hammond ME, Hicks DG : Recommendations for Human Epidermal Growth 
Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical 
Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin 
Oncol. 2013 Nov 1;31(31):3997 -4013 . 
6. Jardim DL, Tang C , Gagliato D de M, et al: Analysis of 1,115 patients tested for MET 
amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res 
2014 Dec 15;20(24):6336 -45. 
7. Cappuzzo F, Marchetti A, Skokan M , et al: Increased MET  Gene Copy Number 
Negatively Affects Survival of Surgically Resected Non -Small -Cell Lung Cancer 
Patients. J Clin Oncol. 2009 Apr 1;27(10):1667 -74. 
8. Go H, Jeon YK, Park HJ , et al: High MET  Gene Copy Number Leads to S horter Survival 
in Patients with Non -small Cell L ung Cancer . J Thorac Oncol. 2010 Mar;5(3):305 -13. 
9. Okamoto  I, Sakai K, Morita S , et al: Multiplex genomic profiling of non –small cell lung 
cancers from the LETS phase III trial of first -line S -1/carboplatin versus 
paclitaxel/carboplatin: results of a West Japan Oncology  Group study. Oncotarget. 2014 
Apr 30;5(8):2293 -304. 
10. Schildhaus HU, Schultheis AM, Rüschoff J , et al: MET Amplification Status in Therapy -
Naïve Adeno - and Squamous Cell Carcinomas of the Lung. Clin Cancer Res. 2015 Feb 
15;21(4):907 -15. 
11. Gavine  PR, Ren Y, Ha n L, et al: Volitinib, a potent and highly selective c -Met inhibitor, 
effectively blocks c -Met signaling and growth in c-MET  amplified gastric cancer patient -
derived tumor xenograft models. Mol Oncol. 2015 Jan;9(1):323 -33. 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 114 of 164 12. Catenacci  DVT, Tang R, Oliner KS , et al: MET as a prognostic biomarker of survival in 
a large cohort of patients with gastroesophageal cancer (GEC). J Clin Oncol 33, 2015 
(suppl; abstr 4034) . 
13. Kong -Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic 
deletion of MET  in lung cancer. Cancer Res. 2006 Jan 1;66(1):283 -9. 
14. Awad MM, Oxnard GR, Jackman DM, et al. MET  Exon 14 Mutations in non-small-cell 
lung cancer are associated with advanced age and stage-dependent MET genomic 
amplification and c -Met overexpression. J Clin Oncol. 2016 Mar 1;34(7):721 -30. 
15. Frampton, GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 
splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET 
inhibitors . Cancer Discov. 2015 Aug;5(8):850 -9. 
16. Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV 
lung adenocarcinomas harboring MET  mutations causing exon 14 skipping.  Cancer 
Discov. 2015 Aug;5(8):842 -9. 
17. Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and m utational profile of 
lung adenocarcinoma . Genome Res. 2012 Nov;22(11):2109 -19. 
18. Xu R, Qiu M, Zhou Y , et al: Evaluation of tumor MET protein expression, MET  gene 
amplification, and HER2 expression in Chinese patients with advanced gastric or 
gastroesophageal  junction (G/GEJ) cancer. J Clin Oncol 33, 2015 (suppl; abstr 4048) . 
19. Leiser D, Medová M, Mikami K , et al: KRAS and HRAS mutations confer resistance to 
MET targeting in preclinical models of MET -expressing tumor cells. Mol Oncol. 2015 
Aug;9(7):1434 -46. 
20. Kwak  EL, Ahronian LG, Sirabegna G , et al: Molecular Heterogeneity and Receptor 
Coamplification Drive Resistance to Targeted Therapy in MET -Amplified 
Esophagogastric Cancer. Cancer Discov. 2015 Oct 2 . 
21. Camidge DR, Ou SH, Shapiro G , et al: Efficacy and safety of crizotinib in patients with 
advanced c-MET -amplified non -small cell lung cancer (NSCLC). J Clin Oncol 32:5s, 
2014 (suppl; abstr 8001) . 
22. Kwak EL, LoRusso P, Hamid O , et al: Clinical activity of AMG 337, an oral MET kinase 
inhibitor, in adult patients (pts) w ith MET -amplified gastroesophageal junction (GEJ), 
gastric (G), or esophageal (E) cancer. J Clin Oncol 33, 2015 (suppl 3; abstr 1) . 
23. Goldman JW, Rosen LS, Algazi AP , et al: First -in-human dose escalation study of 
LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with 
erlotinib (E) in patients with advanced cancer. J Clin Oncol 31, 2013 (suppl; abstr 8093) . 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 115 of 164 24. Strickler JH, LoRusso P, Yen C , et al: Phase 1, open -label, dose -escalation, and 
expansion study of ABT -700, an anti -C-met antibo dy, in patients (pts) with advanced 
solid tumors. J Clin Oncol 32:5s, 2014 (suppl; abstr 2507) . 
25. Mol Cancer Ther. 2017 Aug 11. pii: molcanther.0374.2017. doi: 10.1158/1535 -
7163.MCT -17-0374. [Epub ahead of print]  
<https://www.ncbi.nlm.nih.gov/pubmed/28802255 > 
26. Poulsen TT, Grandal MM, Skartved NJØ, et al : Sym015: A highly efficacious antibody 
mixture against MET -amplified tumors. Clin Cancer Res. 2017 Oct 1;23(19):5923 -5935.  
27. Aftimos PG, Barthelemy P,  Rolfo CD , et al: A phase I, first -in-human study of argx -111, 
a monoclonal antibody targeting c -met in patients with solid tumors. J Clin Oncol 33, 
2015 (suppl; abstr 2580) . 
28. Camid ge DR, Moran T, Demedts I , et al: A randomized, open -label, phase 2 study of  
emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients 
with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic 
NSCLC.  J Clin Oncol 34, 2016 (suppl; abstr 9070) . 
29. Eisenhauer EA, Therasse P, Bogaerts J , et al: New response evaluation criteria in solid 
tumors: Revised RECIST guideline (version 1.1) . Eur J Cancer 2009; 45:228 –247.  
30. American Heart Association. Classification of Functional Capacity and Objective 
Assessment.  Available at: 
http://my.americanheart.org/professional/StatementsGuidelines/ByPublicationDate /Previ
ousYears/Classification -of-Functional -Capacity -and-Objective -
Assessment_UCM_423811_Article.jsp  
31. Dela Cruz CS, Tanoue LT, and Matthay RA. Lung cancer: Epidemiology, etiology, and 
prevention. Clin Chest Med  2011; 32(4) :doi:10.1016/j.ccm.2011.09.001 . 
32. Tong JH, Yeung SF, Chan AWH , et al. MET  amplification and exon 14 splice site 
mutation define unique molecular subgroups of non-small cell lung carcinoma with poor 
prognosis. Clin ical Cancer Res earch 2016 ; 22(12):3048 -3056 . 
33. Ye S, Li, J, Hao K, et al.  The eff icacy and risk profile of c -Met inhibitors in non -small 
cell lung cancer: a meta -analysis. Scientific Repo rts 2016 ; 6:35770 : 
doi:10.1038/srep35770 . 
34. Felip E, Horn L, Patel JD , et al. Tepotinib in patients with advanced non -small cell lung 
cancer (NSCLC) harboring MET  exon  14-skipping mutations: Phase II trial. J Clin Oncol  
2018;  36 (suppl; abstr 9016 ). 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 116 of 164 35. Wolf J, Seto T, Han J -Y, et al. Results of the GEOMETRYmono -1 phase II study for 
evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with ME Tex14 
mutated advanced non-small cell lung cancer ( NSCLC ). Annals of Oncology  2018 , 29(8), 
https://doi.org/10.1093/annonc/mdy424.090 . 
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 117 of 164 20. APPENDICES  
Appendix 1: Summary of Response Evaluation Criteria in Solid Tumors (RECIST v1.1) 
For details, see Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation 
criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228 -247 (29) 
Definitions  
At baseli ne, tumor lesions/lymph nodes will be categorized as measurable or non -measurable as 
follows:  
Measurable:  
Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum s ize of:  
 10 mm by CT scan (CT scan slice thickness no greater than 5 mm)  
 10 mm caliper measurement by clinical exam (lesions which cannot be accurately 
measured with calipers should be recorded as non -measurable)  
 20 mm by chest X -ray 
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be ≥ 15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and in follow -up, only the short axis will 
be measure d and followed. See also notes below on “Baseline documentation of target and non -
target lesions” for information on lymph node measurement.  
Non-measurable:  
All other lesions, including sm all lesions (longest diameter < 10 mm or pathol ogical lymph nodes 
with 10 to < 15 mm short axis) as well as truly non -measurable lesions. Lesions considered truly 
non-measurable include: leptomeningeal disease, ascites, pleural or pericardial effusion, 
inflammatory breast disease, lymphangitic involvement of skin or lung, ab dominal 
masses/abdominal organomegaly identified by physical exam that is not measurable by 
reproducible imaging techniques.  
Special considerations regarding lesion measurability:  
Bone lesions, cystic lesions, and lesions previously treated with local ther apy require particular 
comment:  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 118 of 164 Bone lesions  
 Bone scan, PET scan , or plain films are not considered adequate imaging techniques to 
measure bone lesions. However, these techniques can be used to confirm the presence or 
disappearance of bone lesions  
 Lytic bo ne lesions or mixed lytic -blastic lesions, with identifiable soft tissue components, 
that can be evaluated by cross sectional imaging techniques such as CT or MRI can be 
considered as measurable lesions if the soft tissue component meets the definition of 
measurability described above  
 Blastic bone lesions are non -measurable  
Cystic lesions  
 Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non -measurable) since they a re, 
by definition, simple cysts  
 “Cystic lesions” thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above. However, if non -
cystic lesions are present in the same patient, t hese are preferred for selection as target 
lesions  
Lesions with prior local treatment  
 Tumor lesions situated in a previously irradiated area, or other loco -regional therapy area, 
are usually not considered measurable unless there has been demonstrated prog ression in 
the lesion. Study protocols should detail the conditions under which such lesions would 
be considered measurable  
Methods of measurement  
Measurement of lesions  
All measurements should be recorded in metric notation, using calipers if clinically a ssessed. All 
baseline evaluations should be performed as close as possible to the treatment start and never 
more than 4 weeks before the beginning of the treatment.  
Method of assessment  
The same method of assessment and the same technique should be used to  characterize each 
identified and reported lesion at baseline and during follow -up. Imaging based evaluation should 
always be done rather than clinical examination unless the lesion(s) being followed cannot be 
imaged but are assessable by clinical exam.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 119 of 164  Clinical lesions: Clinical lesions will only be considered measurab le when they are 
superficial and ≥10 mm diameter as assessed using calipers (e.g. , skin nodules). For the 
case of skin lesions, documentation by color photography including a ruler to estimate the 
size of the lesion is suggested. As noted above, when lesio ns can be evaluated by both 
clinical exam and imaging, imaging evaluation should be undertaken since it is more 
objective and may also be reviewed at the end of the study  
 Chest X -ray: Chest CT is preferred over chest X -ray, particularly when progression is  an 
important endpoint, since CT is more sensitive than X -ray, particularly in identifying new 
lesions. However, lesions on chest X -ray may be considered measurable if they are 
clearly defined and surrounded by aerated lung  
 CT, MRI: CT is the best currentl y available and reproducible method to measure lesions 
selected for response assessment. This guideline has defined measurability of lesions on 
CT scan based on the assumption that CT slice thickness is 5 mm or less. When CT scans 
have slice thickness grea ter than 5 mm, the minimum size for a measurable lesion should 
be twice the slice thickness. MRI is also acceptable in certain situations (e.g. , for body 
scans)  
 Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used 
as a m ethod of measurement  
 Endoscopy, laparoscopy: The utilization of these techniques for objective tumor 
evaluation is not advised. However, they can be useful to confirm complete pathological 
response when biopsies are obtained or to determine relapse in tria ls where recurrence 
following CR or surgical resection is an endpoint  
 Tumor markers: Tumor markers alone cannot be used to assess objective tumor response  
 Cytology, histology: These techniques can be used to differentiate between PR and CR in 
rare cases if  required by protocol (for example, residual lesions in tumor types such as 
germ cell tumors, where known residual benign tumors can remain). When effusions are 
known to be a potential adverse effect of treatment (e.g. , with certain taxane compounds 
or ang iogenesis inhibitors), the cytological confirmation of the neoplastic origin of any 
effusion that appears or worsens during treatment can be considered if the measurable 
tumor has met criteria for response or SD in order to differentiate between response ( or 
SD) and progressive disease  
Tumor response evaluation  
To assess objective response or future progression, it is necessary to estimate the overall tumor 
burden at baseline and use this as a comparator for subsequent measurements. Only patients with 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 120 of 164 measu rable disease at baseline should be included in protocols where objective tumor response is 
the primary endpoint. Measurable disease is defined by the presence of at least one measurable 
lesion. Response criteria are listed in Table 12 and Table 13. 
 
Table 12 Response Criteria for Evaluation of Target Lesions  
 Evaluation of Target Lesions  
Complete Response 
(CR)  Disappearance of all target lesions. An y pathological lymph nodes 
(whether target or non -target) must ha ve reduction in short axis to < 10 
mm 
Partial Response 
(PR)  At least a 30% decrease in the sum of diameters of target lesions, taking 
as reference the baseline sum diameters  
Progressive Dise ase 
(PD)  At least a 20% increase in the sum of diameters of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that 
is the smallest on study). In addition to the relative increase of 20%, the 
sum must also demo nstrate an absolute increase of at least 5 mm.   
(Note: the appearance of one or more new lesions is also considered progression)  
Stable Disease  
(SD)  Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as refe rence the smallest sum diameters while on 
study  
 
Table 13 Response Criteria for Evaluation  of Non -Target Lesions  
 Evaluation of Target Lesions  
Complete Response (CR)  Disappearance of all non -target lesions and normalization of tum or 
marker level. All lymph nodes must be non -pathological in size 
(<10 mm short axis)  
Progressive Disease (PD)  Unequivocal progression of existing non -target lesions.  
(Note: the appearance of one or more new lesions is also considered 
progression)  
Non-CR/Non -PD Persistence of one or more non -target lesion(s) and/or maintenance 
of tumor marker level above the normal limits  
 
 
Evaluation of Best Overall Response  
It is assumed that at each protocol specified time point, a response assessment occurs.  Table 14 
provides a summary of the overall response status calculation at each time point for patients who 
have measurable disease at baseline.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 121 of 164 Table 14 Overall Response Status for Patients with Baseline Measurable Disease  
Target Lesions  Non-target Lesions  New 
Lesions  Overall 
Response  
CR CR No CR 
CR Non-CR/Non -PD No PR 
CR Not evaluated  No PR 
PR Non-PD or not all evaluated  No PR 
SD Non-PD or not all evaluated  No SD 
Not all evaluated  Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
Abbreviation: CR, complete response; NE, non -evaluable; PD, progressive disease; PR, partial response; SD, stable disease  
 
The best overall response is determined once all the data for the pati ent is known.  
 
Best response determination in trials where confirmation of CR or PR is NOT required:  
Best response in these trials is defined as the best response across all time points (for example, a 
patient who has SD at first assessment, PR at second assessment, and PD on last assessment has 
a best overall response of PR). When SD is believed to be best response, it must also meet the 
protocol specified minimum time from baseline. If the minimum time is not met when SD is 
otherwise the best time point response, the patient’s best response depends on the subsequent 
assessments. For example, a patient who has SD at first assessment, PD at second and does not 
meet minimum duration for SD, will have a best response of PD. The same patient lost to follow -
up after the first SD assessment would be considered NE. 
 
Best response determination in trials where confirmation of CR or PR is required:  
Complete or partial responses may be claimed only if the criteria for each are met at a 
subsequent time point as speci fied in the protocol (generally 4 weeks later). In this circumstance, 
the best overall response can be interpreted as shown in  Table 15. 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 122 of 164 Table 15 Best Overall Response when Confirmation of CR and PR Required  
Overall Response  
First Time Point  Overall Response  
Subsequent Time Point  Best Overall Response  
CR CR CR 
CR PR SD, PD or PR1 
CR SD SD provided minimum criteria for SD 
duration met, otherwise PD  
CR PD SD provided minimum criteria fo r SD 
duration met, otherwise PD  
CR NE SD provided minimum criteria for SD 
duration met, otherwise NE  
PR CR PR 
PR PR PR 
PR SD SD 
PR PD SD provided minimum criteria for SD 
duration met, otherwise PD  
PR NE SD provided minimum criteria for SD 
duration me t, otherwise NE  
NE NE NE 
Abbreviation: CR, complete response; NE, non -evaluable; PD, progressive disease; PR, partial response; SD, stable disease  
1) If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease me eting PR criteria relative to 
baseline, makes the disease PD at that point (since disease must have reappeared after CR). Best response would depend on whe ther 
minimum duration for SD was met. However, sometimes ‘CR’ may be claimed when subsequent scans su ggest small lesions were 
likely still present and in fact the patient had PR, not CR at the first time point. Under these circumstances, the original CR should be 
changed to PR and the best response is PR.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 123 of 164 21. SUMMARY OF CHANGES  
21.1 Protocol Amendment 1  dated 17 -Feb-2016  
1. Modified Part 1 of the trial to make premedication mandatory prior to each dose of 
Sym015. Modified Part 2 of the trial to make premedication mandatory prior to each dose 
of Sym015 during Cycle 1   
2. Modified the definition of dose -limiting toxicit ies 
3. Modified protocol to discontinue therapy for all patients who meet Hy’s Law criteria that 
cannot be explained by factors not related to Sym015  
4. Includ ed additional criteria for dose reduction due to toxicity  
5. Allow ed GnRH analogs in patients with prostate  cancer  
 
Refer to Table 16 for the changes in Protocol Amendment 1 .  
 
Table 16 Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
1. Synopsis: 
Investigational 
Medicinal 
Product, 
Dose(s) and 
Treatment 
Schedule  Sym015 will be administered over a 1 -hour (+10 
minutes) period following delivery of premedication 
prior to the first infusion. If the patient is without 
evidence of infusion related reactions (IRRs) after 
the first dose of Sym015, the I nvestigator may opt to 
withdraw premedications with subsequent dosing.  
 For Part 1 of the trial, Sym015 will be administered over a 
1-hour (+10 minutes) period, following delivery of 
premedication prior to each infusion. For Part 2 of the trial, 
Sym015 wil l be administered over a 1 -hour (+10 minutes) 
period, following delivery of premedication prior to each 
infusion during Cycle 1. In Part 2, if the patient is without 
evidence of infusion related reactions (IRRs) after Cycle 1, 
the Investigator may opt to w ithdraw premedication on a 
patient -by-patient basis with subsequent dosing.  
6.2 Exclusion 
Criteria  Not applicable  f. GnRH analogs in patients with prostate cancer  
6.3.1 Withdrawal 
from Treatment 
with Sym015  Not applicable  Patients who meet Hy’s Law crite ria that cannot be 
explained by factors not related to Sym015 … 
7.1.4.3 Dose -
Reduction for 
Sym015 -Related 
Toxicities  1. Grade 3 non -hematologic toxic ity regardless of 
duration, with the exceptions of:   
b.     Grade 3 asymptomatic electrolyte 
abnormalities … 
 
3. Neutropenia that is:  
a. Grade 3 or 4, associated with fever (ANC 
<1000 per mm3; temperature >38.5ºC), 
and requiring antibiotic therapy  
b. Grade 4 and sustained (i.e. ANC <500 per 
mm3, duration >5 days)  
 
4. Thrombocytopenia that is Grade 4 (platelets 
<25,00 0 per mm3) 1. Grade 3 non -hematologic toxicity regardless of duration, 
with the exceptions of:   
b.     Grade 3 asymptomatic electrolyte 
abnormalities … without requiring 
hospitalization  
 
3. Neutropenia that is:  
a. Grade 3 -4 febrile neutropenia  
b. Grade 4 and sust ained (i.e. ANC <500 per mm3, 
duration >5 days)  
 
4. Thrombocytopenia that is:  
a. Grade 3 with clinically significant hemorrhage  
b. Grade 4 (platelets <25,000 per mm3) 
7.2.1 Pre -
Medication for 
Sym015 
Infusions  Prior to the first infusion of Sym015, all patients will 
receive …  
 
If a patient is without evidence of IRRs after the first 
dose of Sym015, the Investigator may opt to 
withdraw premedications with subsequent dosing in 
order to determine whether such continued therapy 
is necessary in that patient. Where pra ctical, it is 
recommended that withdrawal of premedication be For Part  1 of the trial, premedication is mandatory prior to 
each dose of Sym015.  
 
For Part 2 of the trial, premedication is mandatory prior to 
each dose of Sym015 during Cycle 1.  
 
All patients will receive the following premedication … 
 
In Part 2, if a patient is without evidence of IRRs after 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 124 of 164 Table 16 Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
done in a gradual fashion.  
For those patients who have previously experienced 
an IRR, consideration should be given to continuing 
premedications for at minimum 1 to 2 additional 
doses.  
 Cycle 1, the Investigator may opt to withdraw 
premedication on a patient -by-patient basis with 
subsequent dosing in order to determine whether such 
continued therapy is necessary in that patient. Where 
practical, it is recomm ended that withdrawal of 
premedication be done in a gradual fashion.  
 
For those patients who experienced symptoms suggestive 
of an IRR after Cycle 1, consideration should be given to 
continuing premedication for at minimum 1 to 2 additional 
doses before an y future attempt to withdraw.  
7.5.2 Prohibited 
Medication/  
Therapy and 
Procedures 
During the Trial  Not applicable  o GnRH analogs in patients with prostate cancer  
9.5.1 Definition 
of Dose -Limiting 
Toxicities  A DLT is defined as any of the following … 
 
3. Neutropenia that is:  
a. Grade 3 or 4, associated with fever (ANC 
<1000 per mm3; temperature >38.5ºC), 
and requiring antibiotic therapy  
b. Grade 4 and sustained (i.e. ANC <500 per 
mm3, duration >5 days)  
4. Thrombocytopenia that is Grade 4 (platelets 
<25,000 per mm3) A DLT is defined as any of the following ... 
 
3. Neutropenia that is:  
a. Grade 3 -4 febrile neutropenia  
b. Grade 4 and sustained (i.e. ANC <500 per mm3, 
duration >5 days)  
 
4. Thrombocytopenia that is:  
a. Grade 3 with clinically significant hemorrhage  
b. Grade 4 (plate lets <25,000 per mm3) 
 
5. AST/ALT elevation > 3xULN with bilirubin elevation  > 
2xULN that cannot be explained by factors not related 
to study drug  
 
21.2 Protocol Amendment 2  dated 22 -Feb-2016  
1. Modified Part 1 of the trial to make KRAS  mutation testing mandatory  to include only 
patients  with KRAS  WT solid tumor malignancies  
 
Refer to Table 17 for the changes in Protocol Amendment 2 .  
 
Table 17 Protocol Amendment 2  
SECTION  ORIGINAL TEXT  NEW TEXT  
1. Synopsis: 
Phase and 
Overall Trial 
Design  Part 1 is a Phase 1a dose -escalation in patients with 
advanced solid tumor malignancies … Part 1 is a Phase 1a dose -escalation in patients with Kirsten 
Rat Sarcoma ( KRAS ) wild -type (WT) advanced solid 
tumor malignanci es… 
1. Synopsis: 
Objectives  Primary objective of Part 1, Dose -Escalation: To 
assess … with advanced solid tumor malignancies … Primary objective of Part 1, Dose -Escalation: To assess … 
with KRAS  WT advanced solid tumor malignancies … 
1. Synopsis: 
Overall Trial 
Design During Part 1 of the trial, patients with advanced 
solid tumor malignancies …  During Part 1 of the trial, patients with KRAS  WT 
advanced solid tumor malignancies … 
1. Synopsis: Main 
Inclusion and 
Exclusion 
Criteria  Not applicable  
 
 
 Main inclusion criteria all patients, Part 1 and Part 
2:… 
 Tumor documented to be KRAS  WT by local 
assessment (i.e. the tumor must express the 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 125 of 164 Table 17 Protocol Amendment 2  
SECTION  ORIGINAL TEXT  NEW TEXT  
 
 
Additional main incl usion criteria applicable to 
Part 2, Basket Cohort patients ONLY :… 
 Tumor documented to be without KRAS  
gene mutation by local assessment (i.e. the 
tumor must express the KRAS  WT, exon 2, 
3 and 4)  
 
Additional main exclusion criteria applicable to 
Part 1, Do se-escalation cohort patients ONLY : 
 Patients with known KRAS  gene mutation  KRAS  WT, exon 2, 3 and 4)  
 
Additional m ain inclusion criteria applicable to Part 2, 
Basket Cohort patients ONLY :… 
Removed indicated text  under this heading  
 
 
 
 
Removed  heading and text  
 
1. Synopsis: Trial 
Assessments  Disease Assessments  
 Archival tumor tissue for MET  and KRAS  
assessment: Not re quired for patients in 
Part 1, but tissue should be assessed if 
available. .. 
 Disease Assessments  
 Archival tumor tissue for MET  and KRAS  
assessment: For patients in Part 1, local 
eligibility assessment for KRAS  mutational status 
will be done. Assessment of  MET -amplification 
status is not required for patients in Part 1, but 
tissue should be assessed if available. .. 
4.1.1 Primary 
Objective  To assess … with advanced solid tumor 
malignancies …  To assess … with KRAS  wild-type (WT) advanced solid 
tumor malignanci es…  
5.1 Overall 
Design and Plan  Part 1 is a Phase 1a dose -escalation in patients with 
advanced solid tumor malignancies … 
 
During Part 1, dose -escalation, cohorts of patients 
with advanced solid tumor malignancies …  Part 1 is a Phase 1a dose -escalation in  patients with KRAS  
WT advanced solid tumor malignancies … 
 
During Part 1, dose -escalation, cohorts of patients with 
KRAS  WT advanced solid tumor malignancies … 
5.2.2 Rationale 
for Trial 
Population  In Part 1, patients with advanced solid tumor 
malignancies … In Part 1, patients with KRAS  WT advanced solid tumor 
malignancies … 
6.1 Inclusion 
Criteria  6.     Part 2, Basket Cohort ONLY :… 
c. Tumor documented to be without KRAS  
gene mutation by local assessment (i.e. the 
tumor must express the KRAS  WT, exon 2, 
3 and 4 ) 6.     Tumor documented to be KRAS  WT by local 
assessment (i.e. the tumor must express the KRAS WT, 
exon 2, 3 and 4)  
7.     Part 2, Basket Cohort ONLY :… 
Removed indicated text under this heading  
6.2 Exclusion 
Criteria  2.     Part 1, dose -escalation coho rts ONLY : Patients 
with known KRAS  gene mutation  Removed  
 
8.3.3 Archival 
Tumor Tissue for 
MET  and KRAS  
Assessment   Screening  
o Part 1: Not required; to be assessed if 
available   Screening  
o Part 1: Local eligibility assessment for KRAS  
mutational status will b e done. Assessment of 
MET -amplification status is not required for 
patients in Part 1, but tissue should be assessed if 
available.  
 
21.3 Protocol Amendment 3  dated 02 -May -2016  
1. Modified inclusion criteri a No. 6 to require KRAS  mutation testing according to 
institutional standards  in order to utilize the various testing platforms that are available at 
the participating trial sites  
2. Modified Part 1 of the trial to include a tumor biopsy during screening for assessment of 
KRAS  mutational status , if necessary  for eli gibility assessment  
3. Modified Part 2 of the trial to include an ADA sample timepoint at C2/D1  
4. Clarified that AEs/SAEs are reported from signing of informed consent for participation 
in the trial . Furthermore, clarified that patients who sign informed consen t and are 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 126 of 164 subsequently deemed to be screening failures will be followed for AEs/SAEs until it is 
determined that they will not be participating in the trial  
5. Clarified reporting requirements for safety data to Sponsor or designee  
6. Clarified that the sample s ize considerations are based on a 2 -stage design, not a 2 -stage 
Minmax design  
 
Refer to Table 18 for the changes in Protocol Amendment 3.      
 
Table 18 Protocol Amendment 3  
SECTION  ORIGINAL  TEXT  NEW TEXT  
1. Synopsis: Main 
Inclusion and  
Exclusion 
Criteria  
 
6.1 Inclusion 
Criteria N o. 6 Tumor documented to be KRAS  WT by local 
assessment (i.e. the tumor must express the KRAS  
WT, exon 2, 3 and 4)  Tumor documented to be KRAS  WT by local assessme nt 
according to institutional standards. If KRAS  WT is not 
previously documented and if archival tissue is not 
available for pretrial assessment, patient must be willing to 
undergo a tumor biopsy to confirm eligibility  
1. Synopsis: Trial 
Assessments  
 Safety Assessments  
DLT evaluation (Part 1, dose -escalation only) during 
Cycle 1 with a final assessment on scheduled first 
day of Cycle 2, prior to dosing  
 
 
Disease Assessments  
For patients in Part 1, local eligibility assessment for 
KRAS  mutational status wi ll be done.  
 
 
 
Tumor biopsy (optional for patients in Part 1 with 
known MET -amplification; required for patients in 
Part 2):  
 
 
 
Additional Assessments  
Skin biopsy  Safety Assessments  
DLT evaluation (Part 1, dose -escalation only) during Cycle 
1 with a final assessment 14 (±2) days (Q2W dosing) or 21 
(±2) days (Q3W dosing) after the last dose of Cycle 1 or 
prior to dosing on Cycle 2/Day 1 (C2/D1)   
 
Disease Assessments  
For patients in Part 1, local eligibility assessment for KRAS  
mutational status will be done using archival tissue 
whenever possible. If archival tissue is not available, a 
tumor biopsy will be performed for eligibility assessment.    
 
Tumor biopsy to be assessed locally as part of eligibility 
assessment for Part 1 and Part 2 patients, if applicab le. In 
addition, to be assessed centrally for biomarker analysis 
(optional for patients in Part 1 with known MET -
amplification; required for patients in Part 2):  
 
Additional Assessments  
Skin biopsy for biomarker analysis  
1. Synopsis: 
Statistical 
Methods and 
Sample Size 
Calculation  
 
10.1 Sample Size 
Determination  Sample size considerations are based on a 2 -stage 
MinMax design, testing a null hypothesis…  Sample size considerations are based on a 2 -stage design, 
testing a null hypothesis…  
5.3.1 Screening  Furthermore, once eligibility is confirmed:  
 All patients in Part 1 and 2 will have a 
blood sample taken for exploratory 
biomarker analysis  
 All patients in Part 1 and 2 will have a skin 
biopsy performed  
 Patients in Part 1 with known MET -
amplification who cons ent to optional 
biopsies will have a biopsy performed, 
unless it is confirmed that suitable archival 
tissue is available for central analysis  Furthermore, once eligibility is confirmed:  
 Patients in Part 1 with known MET -amplification 
who consent to optional biopsies will have a 
biopsy performed for biomarker analysis 
(archival tissue or tissue from a biopsy 
performed during screeni ng as part of eligibility 
assessment may be submitted)  
 All patients in Part 2 will have a tumor biopsy 
performed for biomarker analysis  (archival 
tissue or tissue from a biopsy performed during 
screening as part of eligibility assessment may 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 127 of 164 Table 18 Protocol Amendment 3  
SECTION  ORIGINAL  TEXT  NEW TEXT  
 All patients in Part 2 will have a tumor 
biopsy performed, unless it is confirmed 
that suitable archival tissue i s available for 
central analysis  
Note: The tumor biopsy at screening may 
be assessed locally as part of eligibility 
assessment in Part 2 patients for whom 
MET -amplification and KRAS  mutational 
status have not previously been assessed 
and no archival tissue  is available  be submitted)  
 All patients in Part 1 and 2 will have a skin 
biopsy performed for biomarker analysis  
 All patients in Part 1 and 2 will have a blood 
sample taken for biomarker analysis  
8.1.1 Signing of 
Informed Consent  Not applicable  Note: Informed consent may be obtain ed outside the 14 -
day screening period prior to C1/D1  
8.2.2 Adverse 
Events Survey  Starting from signing of informed consent  Starting from signing of informed consent for participation 
in the trial  
8.2.2 Adverse 
Events Survey  
 
9.2.1 Adverse 
Event Recordin g 
Period  
 
9.2.6 Follow -up 
of Adverse 
Events  
 
9.3 Serious 
Adverse Event 
Recording and 
Reporting  
 
10.4.3.1 Adverse 
Events  Not applicable  Note: Patients who sign informed consent and are 
subsequently deemed to be screening failures will be 
followed for the oc currence of SAEs/AEs until it is 
determined that they will not be participating in the trial.  
8.2.3 Dose -
Limiting 
Toxicities 
Evaluation (Part 1 
Only)  Reported during Cycle 1 with final assessment on 
scheduled Day 1 of Cycle 2 (C2/D1)  Reported during Cycle  1 with a final assessment 14 (±2) 
days (Q2W dosing) or 21 (±2) days (Q3W dosing) after the 
last dose of Cycle 1 or prior to dosing on C2/D1  
8.3.3 Archival 
Tumor Tissue for 
MET  and KRAS  
Assessment  To be assessed locally, if tissue is available … 
 Screening  
o     Part 1: Local eligibility assessment for 
KRAS  mutational status will be done.  
Assessment of MET -amplification status 
is not required for patients in Part 1 … 
o     Part 2: Local eligibility assessment … To be assessed locally … 
 Screening  
o Part 1: Eligibilit y assessment for KRAS  
mutational status will be done using archival 
tumor tissue, whenever possible. If archival 
tissue is not available, tissue from a tumor 
biopsy performed during screening will be 
used.  
Assessment of MET -amplification status is 
not req uired … 
o Part 2: Eligibility assessment … 
8.3.4 Tumor 
Biopsy for 
Eligibility 
Assessment and 
Biomarker 
Analysis  To be assessed centrally. In addition; to be assessed 
locally as part of eligibility assessment for Part 2 
patients, if applicable as per Section 8 .3.3. Archival 
tissue may be accepted for central analysis if suitable 
as specified in the laboratory manual. It must be 
ensured that the archival tissue can be made 
available to the central laboratory prior to deciding 
to omit the tumor biopsy procedure a t time of 
screening.  To be assessed locally for eligibility:  
 Screening; Part 1 and Part 2, if applicable as per 
Section 8.3.3  
Note: It will be permissible to perform this 
procedure outside the 14 -day screening period, 
provid ed informed consent has been obtained  
To be assessed centrally for biomarker analysis:  
 Screening  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 128 of 164 Table 18 Protocol Amendment 3  
SECTION  ORIGINAL  TEXT  NEW TEXT  
 Screening  
o Part 1: … 
o Part 2: …   o Part 1: … 
o Part 2: …   
Note: Archival tissue may be accepted for 
central analysis if suitable as specified in the 
laboratory manual … 
8.5 Anti -Drug 
Antibody Test ing Not applicable  Added additional timepoint:  
 C2/D1 (Part 2 only)  
9.2.1 Adverse 
Event Recording 
Period  All AEs will be recorded from signing of informed 
consent.  All AEs will be recorded from signing of informed consent 
for participation in the trial.  
9.3 Serious 
Adverse Event 
Recording and 
Reporting  All SAEs occurring at any time from signing of 
informed consent and until the 1M FUP Visit, must 
be recorded…  All SAEs occurring at any time from signing of informed 
consent for participation in the trial a nd until the 1M FUP 
Visit must be recorded…  
9.5.2 Observation 
Period for Dose -
Limiting 
Toxicities  The observation period for DLTs is defined as Cycle 
1, i.e. the initial 28 -day (± 2 days) period of Q2W 
dosing or 42 -day (± 2 days) period of Q3W dosing, 
starting from C1/D1.  The observation period for DLTs is defined as Cycle 1 
with a final assessment 14 (±2) days (Q2W dosing) or 21 
(±2) days (Q3W dosing) after the last dose of Cycle 1 or 
prior to dosing on C2/D1.  
9.5.3 Reporting 
of Dose -Limiting 
Toxicities  All presumed DLTs must be reported in the eCRF 
within 24 hours…  All presumed DLTs must be reported to the Sponsor or 
designee within 24 hours…  
9.6 Reporting of 
Infusion -Related 
Reactions  To facilitate ongoing safety review … in the eCRF 
within 24 hours of occurrence.  To facilitate ongoing safety review … to the Sponsor or 
designee within 24 hours of occurrence.  
10.4.3.1 Adverse 
Events  AEs including SAEs are reported from signing of the 
informed consent and until the end of trial 
participation  AEs including SAEs are reported from signing of the 
informed consent for participation in the trial and until the 
end of trial participation.  
12.1 Safety 
Review  In order to do so, the Investigator must ensure the 
data in the eCRF is up to date at all times. This 
includ es, but is not limited to:  
 SAEs must be reported within 24 hours of 
awareness (SAE report form and eCRF)  
 DLTs must be reported in the eCRF within 
24 hours of occurrence  
 Grade 2 IRRs must be reported in the 
eCRF within 24 hours of occurrence … 
…Such Safety T eam teleconferences may fluctuate 
in frequency based on accrual and trial activity, as 
indicated…  In order to do so, the Investigator must ensure to report 
safety data to the Sponsor or designee in a timely manner. 
This includes, but is not limited to:  
 SAE s must be reported within 24 hours of 
awareness (SAE report form)  
 DLTs must be reported within 24 hours of 
occurrence  
 IRRs of ≥ Grade 2 must be reported within 24 
hours of occurrence … 
…Such safety teleconferences may fluctuate in frequency 
based on accrual  and trial activity, as indicated…  
 
21.4 Protocol Amendment 4  dated 04 -Nov-2016  
1. Modified the overall trial design by moving the Q3W cohort from Part 1 to Part 2 to 
ensure patients with MET -amplification are treated in this cohort  and thereby introducing 
a Q2W Basket Cohort as well as a Q3W Basket Cohort in Part 2  
2. Updated t rial objectives, trial endpoints and patient numbers according to th e change in 
overall trial design  
3. Allow ed 6-12 patients to be included in the Q3W Basket Cohort  
4. Confirm ed the selection of th e Q2W RP2D as 18 mg/kg loading dose infused over 1.5 
hours on C1/D1 followed by Q2W maintenance doses of 12 mg/kg infused over 1 hour 
beginning on C1/D15  
5. Modified select inclusion criteria   
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 129 of 164 6. Modified and/or deleted select exclusion cr iteria  
7. Clarif ied that a  trial site may choose to prescreen patients utilizing archival tumor tissue 
to confirm MET -amplification status and/or KRAS  mutational status before entering 
patients into screening for the treatment portion of the trial  
8. Modified the Sym015 infusion time to 1.5 hour (+10 minutes) for doses ≥18 mg/kg  
9. Clarif ied preference for the eligibility assessment for MET -amplification be done using 
tissue from a tumor biopsy performed during screening and that this biopsy be submitted 
to the central laboratory  
10. Removed  skin biopsies from Part 2 of the trial  
11. Updated dose -delay criteria #4  
12. Clarified one of the dose -limiting toxicities (#2)  
13. Updated dose -reduction criteria #2 and #5 to be in accordance with dose -limiting toxicity 
criteria  
14. Includ ed overall survival status in the continued follow -up after the 1M FUP Visit and 
adjust ed the follow -up schedule to be every 2 months  
15. Updated events not to be considered as AEs to include PD, unless the nature of the PD is 
different than expected  
16. Updated timelines for reporting of SAE Follow -up information  
17. Updated sample size determination to be based on a Simon’s Optimal 2 -stage design. 
Futility will be performed when 20 patients evaluable for OR have been included in the 
Q2W Basket Cohort  
18. Made updates and clarifications to the seconda ry endpoints  and PK endpoints  
 
Refer to Table 19 for the changes in Protocol Amendment 4.     
 
Table 19 Protocol Amendment 4  
SECTION  ORIGINAL TEXT  NEW TEXT  
1. Synopsis: 
Phase and 
Overall T rial 
Design  Part 2 is a Phase 2a dose -expansion, in which the 
recommended phase 2 dose (RP2D) and regimen will 
be explored in a Basket Cohort of patients with MET -
amplified, KRAS  WT solid tumor malignancies 
without available therapeutic options…  Part 2 is a Phase 2a dose -expansion in patients with MET -
amplified, KRAS  WT solid tumor malignancies without 
therapeutic options. Two cohorts will be included:  
o Q2W Basket Cohort: A cohort of approximately 
45 patients …  
o Q3W Basket Cohort: A cohort of 6 -12 patients … 
1. Synopsis: 
Trial Site and 
Countries  Part 2, Basket Cohort: 15 to 20 investigational trial 
sites…  Part 2: 15 to 20 investigational trial sites … Enrollment to 
the Q3W Basket Cohort is expected to take place at select 
sites only.  
1. Synopsis: 
Planned Trial  
Period  Patients will be enrolled in dose -escalation cohorts 
until establishment of a RP2D and regimen, expected 
by Q2 2017.  
 
Enrollment to the Basket Cohort in Part 2 of the trial 
will commence once the RP2D and regimen has been 
established. Enrollment is  expected completed by Q3 
2018.  
 
The end of trial will be reached... Patients with stable 
disease (SD) or an ongoing objective response …at 
that time will continue to be followed to assess 
duration of disease stabilization or response.  Patients will be enr olled in dose -escalation cohorts until 
establishment of a maximum tolerated dose (MTD) or until 
24 mg/kg has been evaluated, whichever comes first, 
expected by Q1 2017.  
 
Enrollment to Part 2 of the trial will commence upon 
establishment of the Q2W RP2D. En rollment is expected 
to complete by Q3 2018.  
 
The end of trial will be reached … Patients will continue to 
be followed to assess duration of disease stabilization, 
response, and overall survival (OS).  
1. Synopsis: 
Objectives  Primary objective of Part 1, Dose -Escalation: To 
assess the safety and tolerability… to patients…  Prim ary objective of Part 1, Dose -Escalation: To assess the 
safety and tolerability … on a Q2W schedule to patients … 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 130 of 164 Table 19 Protocol Amendment 4  
SECTION  ORIGINAL TEXT  NEW TEXT  
 
4.1.1 Primary 
Objective  
 
4.2.1 Primary 
Objective   
Primary objective of Part 2, Basket Cohort: To 
evaluate the antitumor activity of Sym015 when 
administered at the RP2D and regimen….   
Primary objective of Part 2: To evaluate the antitumor 
activity of Sym015 when administered at the Q2W 
RP2D … 
1. Synopsis: 
Endpoints  Primary En dpoint of Part 1, Dose -Escalation: The 
occurrence of dose -limiting toxicities (DLT) 
measured during Cycle 1 of Sym015 administration 
on an every second week (Q2W, 28 days equals 1 
cycle) or every third week (Q3W, 42 days equals 1 
cycle) dosing schedule.  
 
Primary Endpoint of Part 2, Basket Cohort: 
Documented OR (defined as PR or CR)…  Primary Endpoint of Part 1, Dose -Escalation: The 
occurrence of dose -limiting toxicities (DLT) measured 
during Cycle 1 of Sym015 administration on a Q2W (28 
days equals 1 cycle) dosing schedule.  
 
Primary Endpoint of Part 2: Documented objective 
response (OR) (defined as partial response [PR] or 
complete response [CR]) in the Q2W Basket Cohort … 
1. Synopsis: 
Overall Trial 
Design  
 During Part 1 of the trial, patients… will receive 
increasing doses of Sym015 until establishment of a 
RP2D and regimen to be used in Part 2… Patients 
will be assigned to the next available open treatment 
cohort until establishment of the RP2D and 
regimen…The highest dose level tested and evaluated 
to be sa fe will be explored … The second -highest dose 
level tested will be expanded … During Part 1 of the trial, patients… will receive increasing 
doses of Sym015 on a Q2W schedule until establishment 
of the MTD or until 24 mg/kg has been evaluated…  
 
 
The SMC wil l review clinical and laboratory safety 
data regularly throughout the trial and will select the 
RP2D and regimen to be used in Part 2 … The SMC will review clinical and laboratory safety data 
regularly throughout the trial. The SMC will select the 
Q2W RP2D and the highest safe dose for the Q3W 
regimen to be used in Part 2 … 
During Part 2, the RP2D and regimen will be 
evaluated in a Basket Cohort of patients with MET -
amplified, KRAS  WT advanced solid tumor 
malignancies.  During Part 2, basket cohorts of patie nts with MET -
amplified, KRAS  WT advanced solid tumor malignancies 
will be evaluated: Q2W Basket Cohort administering the 
Q2W RP2D on a Q2W dosing schedule and Q3W Basket 
Cohort administering the highest safe dose tested in Part 1 
on a Q3W dosing schedule.  
1. Synopsis: 
Trial Periods  
 
6.3.2 
Withdrawal 
from Trial  
 
8.9 Follow -up 
Assessments  In the event of an ongoing SD or OR as per RECIST 
v1.1 at the 1M FUP Visit, the Investigator will make 
every effort to obtain follow -up information on 
response assessments every 3 months during the first 
year and every 6 months thereafter, until disease 
progression or another therapeutic intervention is 
initiated.  After the 1M FUP Visit, the Investigator will make every 
effort to obtain follow -up information on response 
assessment and/or OS, every 2 months. Response 
assessment follow -up is required in the event of an 
ongoing stable disease (SD), PR, or CR at the 1M FUP 
Visit, until PD or another therapeutic intervention is 
initiated. Survival follow -up is required until deat h, 
withdrawal of consent, or termination of the trial.  
1. Synopsis: 
Number of 
Patients  It is planned to enroll approximately 70 patients…  
Approximately 21 -25 patients… during Part 1.  
Approximately 45 patients… during Part 2.  It is planned to enroll approx imately 63 -72 patients…  
Approximately 12 -15 patients… during Part 1.  
Approximately 51 -57 patients… during Part 2.  
1. Synopsis: 
Main Inclusion 
and Exclusion 
Criteria  
 
6.1 Inclusion 
Criteria  Additional main inclusion criteria applicable to 
Part 2, Basket Co hort patients ONLY : 
 Confirmed MET -amplification by local 
assessment; i.e…  
 Willingness to undergo… (total of 2 
biopsies)…  Additional main inclusion criteria applicable to Part 2 
patients ONLY : 
 Confirmed MET -amplification by local 
assessment; i.e… silver in situ hybridization 
(SISH)…  
 Willingness to undergo … (maximum of 2 
biopsies)…  
1. Synopsis: 
Main Inclusion 
and Exclusion 
Criteria  
 Main exclusion criteria all patients, Part 1 and 
Part 2:  
 Known central nervous system (CNS) or 
leptome ningeal metastases not controlled by 
prior surgery or radiotherapy, or symptoms Main exclusion criteria all patients, Part 1 and Part 2:  
 Central nervous system (CNS) malignancy 
including primary malignancies of the CNS 
and/or known CNS or leptomeningeal…  
 Abnormal hematologic , renal or hepatic function 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 131 of 164 Table 19 Protocol Amendment 4  
SECTION  ORIGINAL TEXT  NEW TEXT  
6.2 Exclusion 
Criteria  suggesting CNS involvement for which 
treatment is required  
 Abnormal hematologic , renal or hepatic 
function as defined by the following 
criteria:  
o Prothrombin time… institution  
o Partial thromboplastin time (PTT)… 
institution  
 Known history of human immunodeficiency 
virus (HIV) infection  
 Known active hepatitis B or C virus 
infection  as defined by  the following criteria:  
o Prothrombin time… institution*  
o Partial thromboplastin time (PTT)… 
institution*  
*Unless on a stab le dose of anticoagulant 
therapy for a prior thrombotic event  
 
 
Removed known history of HIV infection  
 
Removed known active hepatitis B or C virus infection  
Additional main exclusion criteria applicable to 
Part 2, Basket Cohort patients ONLY : 
Radiothera py against target lesions within 4 weeks 
prior to C1/D1  Additional main exclusion criteria applicable to Part 2 
patients ONLY : 
 Prior therapy with antibody to hepatocyte growth 
factor (HGF)  
 Radiotherapy against…unless there is 
documented progression of the lesion following 
the radiotherapy  
1. Synopsis: 
Investigational 
Medicinal 
Product, Dose(s) 
and Treatment 
Schedule  Note: Q3W dosing is implemented after highest…  
 
For Part 1 of the trial, Sym015 will be administered 
over a 1 -hour (+10 minutes) period, follo wing 
delivery of premedication prior to each infusion. For 
Part 2 of the trial, Sym015 will be administered over a 
1-hour (+10 minutes) period, following delivery of 
premedication prior to each infusion during Cycle 1.  
 Note: Q3W dosing is implemented in Part 2 after 
highest…  
 
Sym015 will be administered over a 1.5 -hour (+10 
minutes) period for doses ≥18 mg/kg and over a 1 hour 
(+10 minutes) period for doses <18 mg/kg, following 
delivery of premedication prior to each infusion.  
Part 1/Dose -Escalation  
During the dose -escalatio n part of the trial, the 
following dose levels…  
 
Dosing will be on a Q2W schedule for all cohorts 
until completion of Dose Level 4 or establishment of 
an MTD, whichever comes first. At this point, a Q3W 
schedule will be evaluated…  
 Part 1/Dose -Escalation  
During the dose -escalation part of the trial, the following 
dose levels of Sym015 administered Q2W…  
 
 
Part 2/Basket Cohort  
Once the RP2D and regimen has been established 
during dose -escalation, the enrollment into the Basket 
Cohort will commence.  
 
All p atients enrolled to the Basket Cohort will be 
treated with the established RP2D on the selected 
dosing schedule of Sym015 (Q2W or Q3W).  Part 2  
Once the Q2W RP2D has been established during dose -
escalation, the enrollment into the Q2W Basket Cohort 
will com mence.  
Note:   Effective with clinical trial protocol (CTP) version 
5.0 (November 2016), following review…  
 
Once the highest safe dose tested in Part 1 has been 
determined, all patients in the Q3W Basket Cohort will be 
treated at that dose level on a Q3W d osing schedule.  
1. Synopsis: 
Trial 
Assessments  Safety Assessments  
 Medication survey  
 DLT evaluation (Part 1, dose -escalation 
only) during Cycle 1 with a final 
assessment 14 (±2) days (Q2W dosing) or 
21 (±2) days (Q3W dosing)…  Safety Assessments  
 Medication/ Procedure survey  
 DLT evaluation (Part 1, dose -escalation only) 
during Cycle 1 with a final assessment 14 (±2) 
days… 
1. Synopsis: 
Trial 
Assessments  Disease Assessments  
Archival tumor tis sue for MET  and KRAS  assessment:  Disease Assessments  
Archiv al tumor tissue for MET  and KRAS  assessment:  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 132 of 164 Table 19 Protocol Amendment 4  
SECTION  ORIGINAL TEXT  NEW TEXT  
 
8.3.4 Tumor 
Biopsy for 
Eligibility 
Assessment and 
Biomarker 
Analysis  o For patients in Part 2, local eligibility 
assessment for MET -amplification and KRAS  
mutational status will be done using archival 
tumor tissue whenever possible…  
Tumor biopsy to be assessed locally as part of 
eligibility a ssessment for Part 1 and Part 2 patients…  
o Q2W dosing… Archival tissue may be 
acceptable at screening, if suitable for central 
analysis  
o Q3W dosing… Archival tissue may be 
acceptable at screening, if suitable for central 
analysis  
 
 o For patients in Part 2, local eligibility assessment 
for KRAS  mutational status may be done using 
archival tumor tissue…  
It is preferred that the eligibility assessment for 
MET -amplification will be done using tissue from 
a tumor biopsy performed during screening … 
Tumor biopsy to be assessed locally as part of eligibility 
assessment for Part 1 and Part 2 patients…  
o Q2W dosing : At screening and at the end … 
o Q3W Basket Cohort : At screening and at the 
end… 
Tissue fro m a tumor biopsy performed during screening is 
preferred, however archival tissue may be submitted  for 
central analysis … 
1. Synopsis: 
Trial 
Assessments  
 
 Additional Assessments  
Skin biopsy for biomarker analysis:  
o Q2W dosing : At screening, at the end … 
o Q3W dosing: At screening and at the end … Additional Assessments  
Part 1 only: Skin biopsy for biomarker analysis at 
screening, at the end of Cycle 2 or upon PD, whichever 
comes first  
1. Synopsis: 
Statistical 
Methods and 
Sample Size 
Calculation  
 
10.1 Sample 
Size 
Determination  
 
10.3.1 Part 1, 
Dose -Escalation  
 
10.3.2 Part 2  
 
10.5 Interim 
Analysis  Based on a 3 + 3 design and inclusion of a Q3W 
cohort, it is planned to enroll between 21 and 25 
patients during dose -escalation.  
 
Based on an overall evaluation of the d ose-escalation 
part, the RP2D and regimen to be used in Part 2 will 
be selected.  
 
In Part 2 of the trial, the primary endpoint is 
documented OR, assessed by RECIST v1.1 at any 
time during trial participation by Investigator 
assessment. It is planned to in clude…  
 
Sample size considerations are based on a 2 -stage 
design, testing a null hypothesis (poor response) of 
10% OR versus an alternative hypothesis (promising 
response) of 25% OR at an approximate 5% 1 -sided 
significance level and 80% power …  Based on a  3+3 design, it is planned to enroll between 12 
and 15 patients during dose -escalation.  
Based on an overall evaluation of the dose -escalation part, 
the Q2W RP2D and highest safe dose tested will be 
selected.  
In Part 2 of the trial, the primary endpoint is  documented 
OR in the Q2W Basket Cohort, assessed by RECIST v1.1 
at any time during trial participation by Investigator 
assessment. It is planned to include…  in this cohort.  
Sample size considerations are based on Simon’s Optimal 
2-stage design, testing a  null hypothesis (poor response) of 
11% OR versus an alternative hypothesis (promising 
response) of 25% OR at an approximate 10% 1 -sided 
significance level and 85% power … 
For the Q3W Basket Cohort, assuming the response rate is 
at least 20%, there is a 74 -93% probability of observing 1 
or more responses in 6 -12 patients.  
3.2.4.1 Protocol 
Sym015 -01 This is the first clinical trial to study Sym015.  Addition of new section heading  
This is the first clinical trial to study Sym015.  As of 19 
October 2016, a tot al of 9 patients have been enrolled in 
this trial…  
3.2.4.2 Other 
Monoclonal 
Antibodies 
Targeting MET  Section heading did not previously exist  
Based on available literature/reports…  Addition of new section heading  only 
Based on available literature/reports … 
3.4.1 Rationale 
for Starting 
Dose  Section heading did not previously exist  
The starting dose of Sym015…  Addition of new section heading  
The starting dose of 6 mg/kg Sym015…  
3.4.2 Rationale 
for 
Recommended 
Phase 2 Dose  Section did not previously exist  
 As of 19 October 2016, following review of available 
safety…  
Addition of new Table 1: Preliminary Sym015 Geometric 
Mean PK Parameters  
3.5 Overall 
Benefits/Risk  If the dose administered in a cohort is safe… to 
establish a recommended phase 2 dose (RP2D) an d 
regimen.  If the dose administered in a cohort is safe… to establish a 
Q2W RP2D and to define an MTD or highest safe dose.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 133 of 164 Table 19 Protocol Amendment 4  
SECTION  ORIGINAL TEXT  NEW TEXT  
4.1.2 Secondary 
Objectives  
 1. To determine a RP2D and regimen of Sym015  1. To determine a Q2 W RP2D of Sym015  
4.2.2 Secondary 
Obje ctives  1. To further evaluate the safety…  
2. To further evaluate the PK…  
3. To further evaluate target -engagement in skin 
biopsy tissue  
4. To further evaluate the immunogenicity…  
5. To further evaluate potential  
pharmacodynamic … 
 1. To further evaluate the safety… when adm inistered at 
the Q2W RP2D  
2. To further evaluate the PK… when administered at 
the Q2W RP2D  
3. To further evaluate the immunogenicity… when 
administered at the Q2W RP2D  
4. To further evaluate potential  pharmacodynamic … 
when administered at the Q2W RP2D  
5. To make a pr eliminary evaluation of the antitumor 
activity of Sym015, and to evaluate…  
5.1 Overall 
Design and Plan  Part 2 is a Phase 2a dose -expansion, in which the 
RP2D and regimen will be explored in a Basket 
Cohort of patients with MET -amplified, KRAS  WT 
solid tum or malignancies without available 
therapeutic options.  
 
 
During Part 1… doses of Sym015 until establishment 
of a RP2D and regimen to be used in Part 2.  Part 2 is a Phase 2a dose -expansion in patients with MET -
amplified, KRAS  WT solid tumor malignancies w ithout 
therapeutic options. Two cohorts will be included:  
o A Basket Cohort of approximately 45 patients…  
o A Basket Cohort of 6 -12 patients…  
 
During Part 1… doses of Sym015 on a Q2W schedule until 
establishment of the MTD or until 24 mg/kg has been 
evaluated.   
Dosing will be on a Q2W schedule for all cohorts 
until completion of Dose Level 4 or establishment of 
an MTD, whichever comes first. At this point, a Q3W 
schedule will be evaluated in 6 patients at the highest 
safe dose tested. Furthermore, the dose le vel below 
the highest safe dose will be expanded to 6 patients on 
a Q2W schedule, if this has not already been done.  Removed  
The SMC will… select the RP2D and regimen to be 
used in Part 2 based on safety data, as well as 
available PK and target engagemen t results in skin 
tissue biopsies.  
 
 The SMC will… select the Q2W RP2D and the highest 
safe dose for the Q3W regimen to be used in Part 2 based 
on safety data and available PK results.  
 
Note:  Effective with CTP version 5.0 (November 2016), 
following revi ew of available safety and PK data, the 
decision has been made to choose the following as the 
Q2W RP2D of Sym015…  
During Part 2, the RP2D and regimen will be 
evaluated in a Basket Cohort of patients with MET -
amplified, KRAS  WT, advanced solid tumor 
malig nancies.  
 During Part 2, basket cohorts of patients with MET -
amplified, KRAS  WT, advanced solid tumor malignancies 
will be evaluated: Q2W Basket Cohort administering the 
Q2W RP2D on a Q2W schedule and Q3W Basket Cohort 
administering the highest safe dose tested in Part 1 on a 
Q3W schedule.  
 
Enrollment to the Q3W Basket Cohort is expected to take 
place at select trial sites only.  
5.2.1 Rationale 
for Trial Design  The trial is designed to select a safe and well -tolerated 
dose of Sym015 on a Q2W basis (3 to 6  patients to be 
treated at the highest safe dose and 6 patients to be 
treated at the next lower dose) and also to explore the 
safety of a Q3W dosing schedule at the highest safe 
dose (6 patients). Part 2 of this trial is designe d…  This part of the trial i s designed to select a safe and well -
tolerated dose of Sym015 on a Q2W schedule. Part 2 of 
this trial is designed …  
5.3.1 
Prescreening for 
MET -Section did not previously exist  The trial site may choose to prescree n patients utilizing 
archival tumor tissue to confirm MET -amplification status 
and/or KRAS  mutational status before entering patients into 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 134 of 164 Table 19 Protocol Amendment 4  
SECTION  ORIGINAL TEXT  NEW TEXT  
amplification 
and KRAS  
Mutational 
Status  
 screening for the treatment portion of the trial. In this case, 
the site will use a separate pre -screening informed c onsent 
form…  
5.3.2 Screening  This number is composed…  
 
 
Furthermore, once eligibility is confirmed:  
 All patients in Part 2 will have a tumor 
biopsy performed for biomarker analysis  
(archival tissue or tissue from a biopsy 
performed during screening as pa rt of 
eligibility assessment may be submitted)  
 All patients in Part 1 and 2 will have a skin 
biopsy performed for biomarker analysis  This number will identify the patient throughout the trial 
and will be composed…  
 
Furthermore, once eligibility is confirme d: 
 All patients in Part 2 will have a tumor biopsy 
performed for biomarker analysis (tissue from a 
biopsy performed during screening as part of 
eligibility assessment is preferred …, however 
archival tissue may be submitted at the 
Investigator’s discretion)  
 All patients in Part 1 will have  a skin biopsy … 
5.3.4 Treatment  Heading previously 5.3.3  
Patients in Part 1 will receive infusions of Sym015 
Q2W at the specified dose level  until… 
 
During Part 2, all patients will receive the RP2D of 
Sym015…   
Removed  
 
 
Removed  
 
5.3.5 End of 
Treatment and 
Follow -up Visits  Heading previously 5.3.4  
In the event of an ongoing stable disease (SD) or 
objective response (OR, defined as partial response 
[PR] or complete response [CR])…  After the 1M FUP Visit, the Investigator wi ll make every 
effort to obtain follow -up information on response 
assessment and/or overall survival (OS) every 2 months. 
Response assessment follow -up is required … Survival 
follow -up is required until…  
5.4 Recruitment 
Period  Patients will be sequentially enrolled to dose -
escalation cohorts until establishment of a RP2D and 
regimen, expected by Q2 2017.  
 
Enrollment to the Basket Cohort in Part 2 of the trial 
will commence once the RP2D and regimen have 
been established. Enrollment is expected completed 
by Q 3 2018.  Patients will be sequentially enrolled to dose -escalation 
cohorts until completion of Dose Level 4 or establishment 
of an MTD, whichever comes first, expected by Q1 2017.  
Enrollment to Part 2 of the trial will commence upon 
establishment of the Q2W  RP2D. Enrollment is expected 
to complete by Q3 2018.  
5.5 Number of 
Patients  In total, approximately 70 patients will be included in 
this trial.  
 
It is estimated that approximately 21 -25 patients… 
Sym015 and occurrence of discontinuation of patients 
durin g the DLT observation period for reasons other 
than toxicity.  
 
It is planned to enroll and treat approximately 45 
patients with documented and confirmed MET -
amplified and KRAS WT advanced solid tumor 
malignancies during Part 2.  In total, approximately 63 -72 patients will be included in 
this trial.  
It is estimated that approximately 12 -15 patients… 
Sym015 and the potential for adding additional patients to 
a cohort to assure a sufficient number of evaluable patients 
per cohort…  
During Part 2, it is planned t o enroll and treat 
approximately 45 patients in the Q2W Basket Cohort and 
6-12 patients in the Q3W Basket Cohort … 
5.6 End of Trial  Patients with SD or an ongoing OR at that time will 
continue to be followed to assess duration of disease 
stabilization or r esponse.  Patients will continue to be followed to assess duration of 
disease stabilization, response and/or overall survival.  
7.1.3.2 Part 1, 
Dose -Escalation  Dosing will be on a Q2W schedule for all cohorts 
until completion of Dose Level 4 or establishmen t of 
an MTD, whichever comes first. At this point, a Q3W 
schedule…  Removed  
Not applicable  There is potential for entry of additional patients in the 
dose-escalation portion of the trial to assure a sufficient 
number of evaluable patients per cohort…  
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 135 of 164 Table 19 Protocol Amendment 4  
SECTION  ORIGINAL TEXT  NEW TEXT  
Note: Should this action be taken, cohort tolerability 
assessment and subsequent dose -escalation…  
If the MTD is declared, 6 patients will be included on 
a Q3W dosing schedule at the MTD…  Removed  
If no DLTs are encountered in any of the first 3 
patients a t Dose Level 4, 6 patients will be included 
on a Q3W dosing schedule…  If no DLTs are encountered in any of the first 3 patients at 
Dose Level 4, 24 mg/kg will be considered the highest safe 
dose tested  
The SMC will review safety data and make decisions 
regarding the advisability of; continuing accrual to a 
particular dose cohort; dose -escalation and accrual of 
patients to a higher dose cohort; and the RP2D and 
regimen to be used in Part 2, the Basket Cohort.  The SMC will review safety data throughout the trial. 
During Part 1, the SMC will make decisions regarding the 
advisability of: continuing accrual to a particular dose 
cohort; dose -escalation and accrual of patients to a higher 
dose cohort; and the doses to be used in Part 2…  
7.1.3.3 Part 2  During Par t 2 of this trial, all patients will receive the 
RP2D of Sym015 on the chosen dosing schedule 
(Q2W or Q3W).  During Part 2 of this trial, patients included in the Q2W 
Basket Cohort will receive the Q2W RP2D of Sym015 on 
a Q2W dosing schedule. Patients inclu ded in the Q3W 
Basket Cohort…  
The SMC will continue to review safety data and assess 
the tolerability of Sym015 during Part 2 of the trial.  
7.1.3.4 Duration 
of Infusion for 
Administration 
of Sym015  Sym015 will be administered over a 1 -hour (+10 
minutes) p eriod following delivery of 
premedication…  
 
 
 
 
In the event of a Grade 2 IRR … entered to the trial 
will be extended to 1.5 hours (+10 minutes) (or 
longer, if indicated)  
 
 
 
 
In the event of a Grade 3 or greater IRR… entered to 
the trial will be extended to 1.5 hours (+10 minutes) 
(or longer, if indicated)…  
  
 
These same criteria will be applied in the event IRRs 
occur on the extended 1.5 hours infusion schedule. In 
such a case, the duration of infusion for subsequent 
patients entered to the trial will be ext ended to 2 hours 
(or longer, if indicated).  Sym015 will be administered over a 1.5 -hour (+10 
minutes) period for doses > 18 mg/kg, and over a 1 hour 
(+10 minutes) period for doses <18 mg/kg, following …  
Note:  Effective with CTP version 5.0 (November 2016) , 
the duration of infusion has been extended to 1.5 hours … 
In the event of a Grade 2 IRR ... entered at that dose and 
higher doses will be extended from 1 hour (+10 minutes) 
to 1.5 hours (+10 minutes) (or longer, if  indicated)  
Note: This action was implemen ted 13Sep2016 and applies 
to doses > 18 mg/kg.  
In the event of a Grade 3 or greater IRR… entered at that 
dose and higher doses will be extended from 1 hour (+10 
minutes) to 1.5 hours (+10 minutes) (or longer, if 
indicated)….  
These same criteria will be ap plied in the event IRRs occur 
on the extended 1.5 hours infusion schedule. In such a 
case, the duration of infusion for subsequent patients 
entered at that dose and higher doses will be extended to 2 
hours (or longer, if indicated).  
7.1.4.2 Dose -
Delays fo r 
Sym015 -Related 
or Disease -
Related 
Toxicities  4. Any ongoing AEs, assessed as possibly, 
probably, or related to Sym015, should have 
either ameliorated to ≤ Grade 1 severity, returned 
to baseline status, or resolved with the exception 
of laboratory abnormalities that are considered 
clinically insignificant  
 4. Any ongoing AEs, assessed as possibly, probably, or 
related to Sym015… with the exception of  Grade 2 
clinical events that are being adequately controlled 
with best supportive care (e.g. nausea, vomiting, 
diarrhea, fatigue) and asymptomatic laboratory 
abnormalities that are considered clinically 
insignificant or that are resolving with medical 
therapy  
7.1.4.3 Dose -
Reduction for 
Sym015 -Related 
Toxicities  
 2. Any Grade 4 non -hematologic toxicity  2. Any Grade 4 non -hematologic toxicity, with the 
exception of:  
b. Grade 4 asymptomatic electrolyte abnormalities 
lasting ≤ 3 days that are not considered clinically 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 136 of 164 Table 19 Protocol Amendment 4  
SECTION  ORIGINAL TEXT  NEW TEXT  
9.5.1 Definition 
of Dose -
Limiting 
Toxicities  relevant by the Investigator and that resolve with 
medical therapy  
5. AST/ALT elevation > 3×ULN with bilirubin 
elevati on >2×ULN that cannot be explained by 
factors not related to study drug  
7.6 Medical 
Care of Patients 
after End of 
Trial 
Participation  After completing participation…  After completing treatment…  
Patients will continue to be followed for survival.  
8.2.1 
Medication/ 
Procedure 
Survey  To include all medications and/or treatments taken…  
 To include all medications taken other than Sym015 and 
all procedures performed during trial.  For medications… 
For procedures: Include date and reason for procedure.  
8.2.6 Ph ysical 
Examination  To include evaluation of: General appearance, skin, 
head…  Removed breasts, lungs, pulses  
 
 
8.3.3 Archival 
Tumor Tissue 
for MET  and 
KRAS  
Assessment  Not applicable  May be performed as part of prescreening outside the 14 -
day screening peri od, provided separate informed consent 
has been obtained.  
Part 2: Eligibility assessment for MET -amplification 
and KRAS  mutational status will be done using 
archival tumor tissue, whenever  possible. If archival 
tissue is not available, tissue from the tu mor biopsy 
performed during screening will be used.  Part 2: Eligibility assessment for KRAS mutational status 
may be done using archival tumor tissue. If archival tissue 
is not available…  
 
It is preferred that the eligibility assessment for MET -
amplificati on will be done using…  
Note: If a new biopsy is performed for MET -amplification 
testing, tissue from this biopsy…  
8.6 Skin Biopsy 
(Part 1 only)  
 Skin biopsies are requested from a rash -free area.  
• Screening, after confirmation of eligibility  
• For Q2W do sing schedule only: End of Cycle 2 (i.e. 
coinciding with time of first response assessment) or 
upon PD, whichever occurs first  
• For Q3W dosing schedule only: At the end of the 
follow -up… 
 Skin biopsies are requested from a rash -free area.  
• Screening, af ter confirmation of eligibility  
• End of Cycle 2 (i.e. coinciding with time of first response 
assessment) or upon PD, whichever occurs first  
9.1.1 Adverse 
Event  PD will be captured as an AE. Events associated with 
the actual PD will also be captured, as determined by 
the Investigator. Additionally, AEs occurring 
simultaneously with PD, but which may not be related 
to the actual PD, will also be captured.  
 Removed  
9.1.2 Events Not 
to be Considered 
as Adverse 
Events  
 
9.1.5 Events that 
Do Not Meet the 
Defin ition of 
Serious Adverse 
Events  Not applicable  PD will not be captured as an AE/SAE unless the nature of 
the PD is different than expected (i.e. other diagnosis 
and/or signs/symptoms that are not typical of PD). PD may 
be reported as an AE/SAE in the case of patient death, with 
death being the outcome of the event.  
An abnormal laboratory value or an abnormality in 
physiological testing (such as ECGs) need not be reported 
as an AE unless one of the following applies:  
 The Investigator considers the abnormalit y 
clinically significant  
 The event meets the definition of an SAE  
 The event requires an intervention  
 The event results in an action taken with Sym015 
(dose -reduction and/or withdrawal)  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 137 of 164 Table 19 Protocol Amendment 4  
SECTION  ORIGINAL TEXT  NEW TEXT  
9.5.1 Definition 
of Dose -
Limiting 
Toxicities  2. Any Grade 4 non -hemat ologic toxicity  
 2. Any Grade 4 non -hematologic toxicity, with the 
exception of:  
a. Grade 4 asymptomatic electrolyte abnormalities lasting  
< 3 days that are not considered clinically relevant by the 
Investigator and that resolve with medical therapy  
10.4. 1 Efficacy 
Endpoints and 
Analyses  The following anti -tumor response endpoints will be 
measured in Part 1, Dose -Escalation…  
 The following anti -tumor response 
endpoints will be measured in Part 2, 
Basket Cohort:  
o Changes in sum of diameters of target 
lesions from baseline to end of trial 
participation  
o SD for >4 months from baseline  
o Time to documented PD, death, patient 
withdrawal or end of trial participation, 
whichever comes first  
 
Number and percentages of patients with documented 
OR in the dose -escalation p art will be presented 
including corresponding 95% exact CI.  
 
All documented ORs (Part 1 and 2) will be listed 
including duration (in days) of OR, measured from 
time of first PR or CR to PD.  
 
Duration of SD is calculated from baseline until first 
measureme nt of PD…  
 
Time to documented PD, death, patient withdrawal or 
end of trial participation, whichever comes first, will 
be presented in a Kaplan -Meier plot. The median 
progression free survival time, including 95% CI, will 
be derived.  The following anti -tumor response endpoints will be 
measured in Part 1 and in the Q3W Basket Cohort…  
 Additionally, the following anti -tumor response 
endpoints will be measured in both Part 1 and 2:  
o Duration of response (DR)  
o Best overall response (BOR)  
o SD for >4 months  
o Time to disease progression (TTP) as 
determined based on radiological evidence  
o Progression -free survival (PFS)  
o Overall survival  (OS)  
 
In addition, the number and percentages of patients with 
SD for more than 4 months will be presented…  
 
TTP, PFS, and OS will be summarized using the product -
limit method and Kaplan -Meier plots. The median TTP, 
PFS, and OS, including 95% CI, will be calculated.  
12.1 Safety 
Review  Biweekly safety teleconferences will be held between 
the Investigational Site(s) and the Sponsor and/or  
designee. Such safety teleconferences may fluctuate 
in frequency based on accrual and trial activity, as 
indicated. Patients will be carefully evaluated…  
 Safety teleconferences will be held between the 
Investigational Site(s) and the Sponsor and/or desig nee. 
Patients will be carefully evaluated…  
 Part 1: It is intended that safety teleconferences 
will be held biweekly; however frequency may 
fluctuate based on accrual and trial activity, as 
indicated  
 Part 2: It is intended that safety teleconferences 
will b e conducted after enrollment of 
approximately 15 and 30 patients. If safety 
concerns emerge, more frequent meetings will be 
held on an ad hoc basis.  
 
21.5 Protocol Amendment 5 dated 11-May -2017  
1. Modified inclusion criterion 5 to clarify that patients must have recurrent and/or 
progressive disease and be without other therapeutic options  
2. Revised inclusion criterion 7 to allow local assessment of KRAS -mutation and MET -
amplification based on a peripheral blood sample (liquid biopsy)  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 138 of 164 3. Modified inclusion and exclusion  criteria  to allow  a subset of patients pretreated with  a 
MET -targeting TKI  
4. Specified that patients included based on MET -amplification from a liquid biopsy will be 
withdrawn if subsequent analysis of a tumor biopsy do es not meet eligibility criteria, and 
the patient s do not have clinical benefit from therapy. Such patients will be replaced  
5. Added the option for investigators to include an H2 antagonist and/or acetaminophen 
premedication, where indicated  
6. Modified prohibited medication section to allow steroi d therapy as prophylaxis for 
contrast reactions  
7. Included other minor updates and clarificati ons 
 
Refer to Table 20 for the changes in Protocol Amendment 5.     
 
Table 20 Protocol Amendment 5  
SECTION  ORIGINAL TEXT  NEW TEXT  
1. Synopsis: Phase 
and Overall Trial 
Design  
 
5.1 Overall Design 
and Plan  Part 2 is a Phase 2a dose -expansion in patients with 
MET -amplified, KRAS  WT solid tumor malignancies 
without therapeutic options. Two cohorts will be  
included:  
 Q2W Basket Cohort: A cohort of 
approximately 45 patients, in which dosing will 
be…  
 Part 2 is a Phase 2a dose -expansion in patients with MET -
amplified, KRAS  WT solid tumor malignancies without 
therapeutic options. With the exception of a subset of 
patients entered to the Q2W Basket Cohort, patients must 
not have received prior therapy with MET -inhibiting 
agents.  Two cohorts will be included:  
 Q2W Basket Cohort: A cohort of approximately 45 
patients, in which dosing will be… Included in this 
group  will be a subset of approximately 6 patients 
who have received prior therapy with a MET -
targeting tyrosine kinase inhibitor (TKI).  
1. Synopsis: Main 
Inclusion and 
Exclusion Criteria  
 
6.1 Inclusion 
Criteria  Documented (histologically - or cytologically -
proven) solid tumor malignancy…  Documented (histologically - or cytologically -proven) 
solid tumor malignancy… (i.e. patients must have 
recurrent and/or progressive disease and be without other 
therapeutic options)  
Not applicable  Additional main inclusion c riteria applicable to Part 2 
patients ONLY : 
 Tumor documented to be KRAS  WT by local 
assessment according to institutional standards.  
Note:  Peripheral blood collection for KRAS -mutation 
assessment in circulating tumor deoxyribonucleic acid 
(ctDNA)…  
Addit ional main inclusion criteria applicable to 
Part 2 patients ONLY : 
 Confirmed MET -amplification by local 
assessment; i.e. gene [G] -to-copy number 
[CN] control probe ratio…  Additional main inclusion criteria applicable to Part 2 
patients ONLY : 
 Confirmed MET -amplification by local 
assessment; i.e. gene [G] -to-copy number [CN] 
control probe ratio…  
Note:  Peripheral blood collection for MET -amplification 
assessment in ctDNA will be allowed…  
Not applicable  Additional main inclusion criteria applicable to Part 2  
patients ONLY : 
 No prior therapy with MET -targeting agents  
Note:  An exception will be a subset of approximately 6 
patients entered to the Q2W Basket Cohort after having 
received prior therapy with a MET -targeting TKI.  
1. Synopsis: Main 
Inclusion and 
Exclusion Criteria  
 Additional main exclusion criteria applicable to 
Part 2 patients ONLY : 
 Prior therapy with MET -inhibiting agents  Additional main exclusion criteria applicable to Part 2 
patients ONLY : 
 Prior therapy with MET -inhibiting  agents  
Note:  An exception will be a subset of approximately 6 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 139 of 164 Table 20 Protocol Amendment 5  
SECTION  ORIGINAL TEXT  NEW TEXT  
6.2 Exclusion 
Criteria  patients entered to the Q2W Basket Cohort after having 
received prior therapy with a MET -targeting TKI.  
 
6. Central nervous system (CNS) malignancy 
including:  
Note: Patients with treated CNS  metastases… 
performed at least 4 weeks prior to first trial drug 
administration  6. Central nervous system (CNS) malignancy including:  
Note: Patients with treated CNS metastases… performed 
> 4 weeks apart with the most recent performed within 4 
weeks prior  to first trial drug administration  
7. Inadequate recovery from an acute toxicity…  
Note: With the exception of alopecia, patients must 
have recovered…  7. Inadequate recovery from an acute toxicity…  
Note: With the exception of persistent Grade 2 alopecia 
and/or peripheral neuropathy, patients must have 
recovered…  
 
1. Synopsis: Trial 
Assessments  Disease Assessments  
 Archival tumor tissue for MET  and KRAS  
assessment:  
o For patients in Part 2… It is preferred 
that the eligibility assessment for 
MET -amplificati on will be done using 
tissue…  
   
 Disease Assessments  
 Archival tumor tissue for MET  and KRAS  
assessment:  
o For patients in Part 2… It is preferred that 
the eligibility assessment for MET -
amplification will be done using tissue…  
Note:  During Part 2 ONLY, pe ripheral blood collection 
for KRAS -mutation assessment and for MET -
amplification assessment in ctDNA is allowed…   
 
3.2.4.1 Protocol 
Sym015 -01 As of 19 October 2016, a total of 9 patients have 
been enrolled in this trial: 3 patients at each of 3 
dose leve ls (6, 12, and 18 mg/kg, dosed every 
second week [Q2W]). All 3 dose levels have been 
considered well tolerated, no DLTs or trial drug -
associated serious adverse events (SAEs) have been 
reported to date…  
 As of Amendment 5, a total of 12 patients were enrol led 
in the completed Part 1 of this trial: 3 patients at each of 4 
dose levels (6, 12, 18, and 24 mg/kg, dosed every second 
week [Q2W]). All 4 dose levels were considered well 
tolerated, no DLTs or trial drug -associated serious 
adverse events (SAEs) were r eported….  
3.4.2 Rationale for 
Recommended 
Phase 2 Dose  As of 19 October 2016…  As of Amendment 4…  
4.2.2 Secondary 
Objectives  Not applicable  5. To make a preliminary evaluation of the antitumor 
activity of Sym015, and to evaluate all of the above 
secondar y objectives, in a subset of approximately 6 
patients administered Sym015 at the Q2W RP2D after 
having received prior therapy with a MET -targeting 
tyrosine kinase inhibitor (TKI)  
5.3.1 Prescreening 
for MET -
amplification and 
KRAS  Mutational 
Status  Not appl icable  *Part 2 ONLY:  Peripheral blood collection for MET -
amplification assessment and for KRAS -mutation 
assessment in circulating tumor deoxyribonucleic acid 
(ctDNA) (also referred to as “liquid biopsy”) will be 
allowed…   
 
5.3.2 Screening  The trial site  staff must complete a Screening and 
Allocation Form , stating the allocated patient 
number…  The trial site staff must complete a Screening and 
Allocation Form , stating the allocated patient number… 
and whether the patient has received prior therapy with 
MET-inhibiting agents.  
6.3.1 Withdrawal 
from Treatment 
with Sym015  Not applicable  Results from archival tumor tissue or a tumor biopsy 
submitted to confirm MET -amplification status that do 
not meet study eligibility criteria.   
Note:  Such patients may rema in on study if there is 
evidence of an OR, SD, or other clinical benefit, but will 
not be included in the Evaluable for Response Population.  
6.4.2 Part 2  It is not planned to replace any patients in Part 2 of 
the trial.  Patients enrolled to the study base d on local MET -
amplification assessments conducted in ctDNA, but with 
subsequent confirmatory tumor tissue evaluation…  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 140 of 164 Table 20 Protocol Amendment 5  
SECTION  ORIGINAL TEXT  NEW TEXT  
7.2.1 
Premedication for 
Sym015 Infusions  All patients will receive the following premedication  All patients must be premedicated as desc ribed with 
standard therapies that include a glucocorticoid and an H1 
antagonist.  Where indicated, consideration may be given 
to including an H2 antagonist and/or acetaminophen...   
 Antihistamine (H2) antagonist (optional) such 
as 50 mg IV ranitidine or 3 0 mg famotidine, 
approx. 0.5 hours prior to the start of Sym015 
infusion  
 Acetaminophen (optional) such as 1000 mg IV 
or PO (orally), approx. 0.5 hours prior to the 
start of Sym015 infusion  
7.5.2 Prohibited 
Medication/ 
Therapy and 
Procedures During 
the Tri al Not applicable  Steroid therapy as prophylaxis for contrast reactions  
 
8.3.3 Archival 
Tumor Tissue for 
MET  and KRAS  
Assessment  Not applicable  During Part 2 ONLY, peripheral blood collection for 
KRAS -mutation assessment and for MET -amplification 
assessme nt in ctDNA is allowed as a local pre -screening 
methodology by Guardant360 analysis…   
 
8.4 
Pharmacokinetic 
Assessments  Not applicable  Note:  Comprehensive collection of clinical samples is 
critical to the conduct of this study.  In situations where 
colle ction of EOI + 8h samples is logistically difficult…  
 
8.7 Biomarker 
Blood Sample  Aliquots of plasma samples will be stored…  Biomarker samples will be stored…  
 
 
21.6 Protocol Amendment 6 dated 20-Nov-2017  
1. Modified the overall trial design by removing Q3W dosin g with Sym015, which will not 
be evaluated, and added a separate cohort of KRAS  WT, advanced NSCLC patients with 
METex 14 mutation .  
2. Updated secondary trial objectives  according to the change in overall trial design . 
3. Updated the summary of clinical findings  based on the 7 MET -amplified patients that 
have been enrolled in the ongoing Part 2 Basket Cohort at the time of the amendment . 
4. Modified inclusion and exclusion criteria to allow enrollment of patients with NSCLC  
and other malignancies  with METex 14 mutati on, and who have been pre -treated with 
MET -targeting TKI . 
5. Modified  exclusion criteria  to specify  time required between prior antineoplastic agent 
and C1 /D1, and prior immunosuppressive or systemic hormonal therapy .   
6. Modified prohibited medication to speci fy when the use of steroid therapy is considered 
not allowed . 
7. Specified the order of collection of tumor biopsy and biomarker blood sample if collected 
at the same timepoint . 
8. Included other minor updates and clarifications.  
 
Refer to Table 21 for the changes in Protocol Amendment 6.     
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 141 of 164  
Table 21 Protocol Amendment 6  
SECTION  ORIGINAL TEXT  NEW TEXT  
1. Synopsis: Trial 
Phases   Part 1 is a Phase 1a dose -escalation in patients with 
Kirsten Rat Sarcoma ( KRAS )… 
 Part 2 is a Phase 2a dose -expansion in patients with 
MET -amplified, KRAS  WT solid tumor malignancies 
without therapeutic options. With the exception of a 
subset of patients entered to the Q2W Basket Cohort, 
patients must not have received prior therapy with  
MET -inhibiting agents.  Two cohorts will be 
included:  
o Q2W Basket Cohort: A cohort of approximately 
45 patients, in which dosing will be at the 
recommended phase 2 dose (RP2D) on an every 
second week (Q2W) schedule, in the following 
referred to as the Q2W RP2D…  
o Q3W Basket Cohort: A cohort of 6 -12 patients, 
in which the highest safe dose tested in Part 1 
will be evaluated on an every third week (Q3W) 
schedule  
A basket trial is designed…   Part 1 is a Phase 1a dose -escalation in patients with 
KRAS  proto -oncoge ne (KRAS )… 
 Part 2 is a Phase 2a dose -expansion in which dosing 
will be at the recommended phase 2 dose (RP2D) on 
an every second week (Q2W) schedule. Two cohorts 
will be included:  
o Basket* Cohort: A cohort of approximately 45 
patients with KRAS  WT advanced solid tumor 
malignancies with MET -amplification, and 
without therapeutic options…  
o NSCLC Cohort: A cohort of 6 -12 patients with 
KRAS  WT non -small cell lung carcinoma 
(NSCLC) with MET  exon 14 skipping mutation 
(METex14 ), and without therapeutic options.  
Patients need not be MET -amplified and may have 
received prior therapy with a MET -targeting TKI.  
Note:  Patients with malignancies other than 
NSCLC may be considered for entry to this cohort 
following discussion with the Sponsor’s Medical 
Monitor(s).  
 
*A bask et cohort is designed…  
 
1. Synopsis: Trial 
Sites and Countries  Part 2: 15 to 20 investigational trial sites, located 
within the USA, Asia Pacific, and Europe. Enrollment 
to the Q3W Basket Cohort is expected to take place at 
select sites only.  
 Part 2: 15 to 25 investigational trial sites, located 
within the USA, Asia Pacific, and Europe.  
1. Synopsis: 
Planned Trial 
Period  Enrollment to Part 2… Enrollment is expected to 
complete by Q3 2018.  Enrollment to Part 2… Enrollment is expected to 
complete by Q2 201 9. 
 
1. Synopsis: 
Overall Trial 
Design  The SMC will select the Q2W RP2D and the highest 
safe dose for the Q3W regimen to be used in Part 2…  
 
During Part 2, basket cohorts of patients with MET -
amplified, KRAS  WT advanced solid tumor 
malignancies will be eva luated: Q2W Basket Cohort 
administering the Q2W RP2D on a Q2W dosing 
schedule and Q3W Basket Cohort administering the 
highest safe dose tested in Part 1 on a Q3W dosing 
schedule.  The SMC will select the Q2W RP2D to be used in Part 
2… 
 
During Part 2, two co horts will receive Sym015 at the 
RP2D on a Q2W dosing schedule:  
• Basket Cohort: A basket cohort of KRAS  WT, 
advanced solid tumor malignancy patients with 
MET -amplification will be evaluated. Patients must 
be MET -targeting TKI -naïve; an exception will be 
a subset of approximately 6 patients entered who 
have received prior therapy with a MET -targeting 
TKI.  
• NSCLC Cohort:  A cohort of KRAS WT, advanced 
NSCLC patients with METex14  mutation will be 
evaluated. Patients need not be MET -amplified and 
may have receive d prior therapy with a MET -
targeting TKI.  
1. Synopsis: Trial 
Periods  Treatment Period: Patients in the trial will receive IV 
infusions of Sym015 on a Q2W or Q3W schedule…  
  Treatment Period: Patients in the trial will receive IV 
infusions of Sym015 on a Q2W schedule…  
  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 142 of 164 Table 21 Protocol Amendment 6  
SECTION  ORIGINAL TEXT  NEW TEXT  
End of Treatment/Follow -up: …This One -Month 
Follow -up (1M FUP) visit will constitu te the end of 
trial participation for the patient.  
 
After the 1M FUP Visit, the Investigator will make 
every effort to obtain follow -up information on 
response assessment and/or OS, every 2 months… 
Survival follow -up is required until death, withdrawal 
of consent, or termination of the trial.  End of Treatment/Follow -up: … Removed   
 
 
After the 1 -Month Follow -up (1M FUP) Visit, the 
Investigator will make every effo rt to obtain follow -up 
information on response assessment and/or OS, about 
once every 2 months… Survival follow -up is required 
until death, withdrawal of consent, trial site closure, or 
termination/end of the trial. Occurrence of one of these 
events consti tutes the end of trial for the patient.  
1. Synopsis: 
Number of Patients  Approximately 51 -57 patients with documented and 
confirmed MET -amplified and KRAS  WT advanced 
solid tumor malignancies will be enrolled and treated 
during Part 2.  Approximately 51 -57 patients will receive Sym015 at 
the RP2D on a Q2W schedule during Part 2.  Two 
cohorts will be included:  
• Approximately 45 patients with KRAS  WT, 
advanced solid tumor malignancies with 
documented and confirmed MET -amplification will 
be enrolled and treated .  A subset of approximately 
6 patients will have received prior therapy with a 
MET -targeting TKI.  
• 6-12 patients with KRAS  WT, advanced NSCLC 
with documented METex14  mutation will be 
enrolled and treated. Patients need not be MET -
amplified and may have rec eived prior therapy with 
a MET -targeting TKI.  
1. Synopsis: Main 
Inclusion and 
Exclusion Criteria  Additional main inclusion criteria applicable to 
Part 2 patients ONLY : 
 Tumor documented to be KRAS  WT…  
Note:  …Other liquid biopsy methodologies will only be 
allowed if previously approved by the Sponsor.    
 
 
 
 Confirmed MET -amplification by local 
assessment…  
 No prior therapy with MET -targeting agents  
Note:  An exception will be a subset of approximately 6 
patients entered to the Q2W Basket Cohort…  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Main exclusion criteria all patients, Part 1 and Part 
2: 
 Any antineoplastic agent (standard or Additional main inclusion criteria applicable to 
Part 2 patients ONLY : 
 Tumor documented to be KRAS  WT…  
Note:  …Other liquid biopsy methodologies, except if 
used to detect METex14  mutation, will only be allowed if 
previously approved by the Sponsor.   
  
 Basket Cohort ONLY:  
o Confirmed MET -amplification by local 
assessment…  
o No prior therapy with MET -targeting agents  
Note:  An exception will be a subset of approximately 
6 patients entered to the Basket Cohort …  
 
 NSCLC Cohort ONLY:  
o Documented METex14  mutations* (patients 
need not be MET -amplified and may have 
received prior therapy with a MET -targeting 
TKI)  
Note:  Patients with malignancies other than NSCLC 
may be considered for entry to this cohort following 
discussion with the Sponsor’s Medical Monitor(s).  
METex14  mutation status to be documented according 
to local institutional standards.  Assessment in ctDNA 
by Guardant360 technology or equivalent is allowed.  
Subsequent confirmation in tumor tissue is pre ferred 
but not required.  
 
Main exclusion criteria all patients, Part 1 and Part 
2: 
 Any antineoplastic agent for the primary 
malignancy (standard or investigational) without 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 143 of 164 Table 21 Protocol Amendment 6  
SECTION  ORIGINAL TEXT  NEW TEXT  
investigational) within 4 weeks prior to C1/D1  
 
 
 
 
 
 Central nervous system (CNS) malignancy 
including primary malignancies of the CNS and/or 
known CNS or lepto meningeal metastases not 
controlled by prior surgery…  
Additional main exclusion criteria applicable to Part 2 
patients ONLY : 
 Prior therapy with MET -inhibiting agents  
Note:  An exception will be a subset of approximately 6 
patients entered to the Q2W Basket  Cohort…  
 
 
 
 Tumor status demonstrating MET -polysomy  
 delayed toxicity within 4 weeks or 5 plasma half -
lives, whichever is shortest, prio r to C1/D1, except:  
o Nitrosoureas and mitomycin C within 6 weeks 
prior to C1/D1  
 
 Central nervous system (CNS) malignancy 
including primary malignancies of the CNS and/or 
known, untreated CNS or leptomeningeal 
metastases, or spinal cord compression; patient s 
with any of these not controlled by prior surgery…  
Additional main exclusion criteria applicable to Part 2 
patients ONLY : 
 Prior therapy with MET -inhibiting agents  
Note:  Exceptions will be a subset of approximately 6 
patients entered to the Basket Cohort …, and patients 
entered to the NSCLC Cohort who may have received 
prior therapy with a MET -targeting TKI.  
 
 Basket Cohort ONLY: Tumor status demonstrating 
MET -polysomy in the absence of MET -
amplification, as specified  
Note: Patients in the NSCLC Cohort with  polysomy are 
eligible  
 
1. Synopsis: 
Investigational 
Medicinal Product, 
Dose(s) and 
Treatment 
Schedule  Sym015 will be administered on a Q2W or Q3W 
schedule by IV infusion.  
 Q2W dosing: Day 1 and Day 15 of each 28 -day 
cycle (± 2 days)  
 Q3W dosing: Day 1 and  Day 22 of each 42 -day 
cycle (± 2 days)  
Note: Q3W dosing is implemented in Part 2 after 
highest safe dose is identified on Q2W schedule  
 
Part 2  
Once the Q2W RP2D has been established during 
dose-escalation, the enrollment into the Q2W Basket 
Cohort will c ommence…  
 
Once the highest safe dose tested in Part 1 has been 
determined, all patients in the Q3W Basket Cohort will 
be treated at that dose level on a Q3W dosing schedule.  
 Sym015 will be administered on a Q2W schedule by 
IV infusion.  
 Q2W dosing: Day 1 and Day 15 of each 28 -day 
cycle (± 2 days)  
 
 
 
 
Part 2  
Once the Q2W RP2D has been established during 
dose-escalation, the enrollment into the Basket Cohort 
and NSCLC Cohort will commence.  
 
 
Removed  
1. Synopsis: Trial 
Assessments  Disease Assessments  
 Q2W dos ing schedule: Disease status evaluation…  
 Q3W Basket Cohort only: Disease status evaluation 
by CT or MRI at screening and at the end of the 
follow -up period following every third dose. 
Further potential timepoints are in the event of 
suspected PD, in the ev ent of CR/PR and at 
EOT/1M FU  
 Archival tumor tissue for MET  and KRAS  
assessment:  
o For patients in Part 2…  
It is preferred…  Disease Assessme nts 
 Disease status evaluation…  
Removed  
 
 
 
 
 
 Archival tumor tissue for MET  and KRAS  
assessment:  
o For patients in Part 2…  
 Basket Cohort: It is preferred…  
Note:  …Other liquid biopsy methodologies, 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 144 of 164 Table 21 Protocol Amendment 6  
SECTION  ORIGINAL TEXT  NEW TEXT  
Note:  …Other liquid biopsy methodologies will only 
be allowed if previously approved by the Sponsor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Tumor biopsy to b e assessed locally as part of 
eligibility assessment for Part 1 and Part 2 patients, 
if applicable. In addition, to be assessed centrally 
for biomarker analysis (optional for patients in Part 
1 with known MET -amplification; required for 
patients in Part 2) : 
o Q2W dosing: At screening and at the end of 
Cycle 2 or upon PD, whichever comes first.  
o Q3W Basket Cohort: At screening and at the 
end of the follow -up period following the third 
dose or upon PD, whichever comes first.  
Tissue from a tumor biopsy performe d during 
screening is preferred, however archival tissue 
may be submitted for central analysis at the 
Investigator’s discretion, provided the archival 
tissue is suitable as specified in the laboratory 
manual.  
 
 
 
 
 
 
Additional Assessments  
 Biomarker blood sa mple:  
o Q2W dosing: At screening, at the end of Cycle 
2 or upon PD, whichever comes first, and at 
EOT  
o Q3W Basket Cohort: At screening, at the end of 
the follow -up period following the third dose or 
upon PD, whichever comes first, and at EOT  
 except if used to detect METex14  mutation, will 
only be allow ed if previously approved by the 
Sponsor.  
 
 NSCLC Cohort: Eligibility assessment for 
METex14  mutation status will be done 
according to local institutional standards.  
Assessment in ctDNA by Guardant360 
technology or equivalent is allowed.  
Subsequent confi rmation in tumor tissue is 
preferred but not required, however, 
archival tissue to be submitted for central 
testing, if available.  
 Tumor biopsy for eligibility assessment and 
biomarker analysis:  
o To be assessed locally for eligibility assessment 
for Part 1  and Part 2 patients if not already 
assessed in archival tumor tissue and if 
applicable (i.e. Basket Cohort only)  
o To be assessed centrally for biomarker analysis  
 Part 1, optional for patients with known 
MET -amplification  
 Part 2:  
 Basket Cohort: Required at screening if 
archival tissue is unavailable or 
insufficient, and at the end of Cycle 2 
or upon PD, whichever comes first.  At 
screening, tissue from a tumor biopsy 
is preferred, however archival tissue 
may be submitted for central analysis 
at the Investiga tor’s discretion, 
provided the archival tissue is suitable 
as specified in the laboratory manual.  
 NSCLC Cohort: Optional, at the 
timepoints specified  
 
 
Additional Assessments  
 Biomarker blood sample: At screening, at the end 
of Cycle 2 or upon PD, whichever  comes first, and 
at EOT  
 
 
Removed  
 
1. Synopsis: 
Statistical Methods 
and Sample Size 
Calculation  In Part 2 of the trial, the primary endpoint is 
documented OR in the Q2W Basket Cohort…  
 
For the Q3W Basket Cohort, assuming the response…  In Part 2 of the tr ial, the primary endpoint is 
documented OR in the Basket Cohort…  
 
For the NSCLC Cohort, assuming the response…  
 
3.1.2 MET -
amplified Solid 
Tumor Not applicable  Mutations leading to skipping of MET  exon 14 
(METex14 ) result in the deletion of th e juxtamembrane 
domain of MET, which stabilizes and accumulates 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 145 of 164 Table 21 Protocol Amendment 6  
SECTION  ORIGINAL TEXT  NEW TEXT  
Malignancies  receptor on the cell surface and leads to enhanced 
signaling through the MET receptor pathway. MET  
alterations that result in exon 14 skipping are found in 
3-4% of lung adenocarcinomas, both i n the presence 
and absence of MET -amplification and studies have 
demonstrated clinical benefit of targeting patients with 
tumors harboring METex14  mutations. Over 100 
mutations in MET -mutated cancers resulting in exon 
14 skipping have been described.  
3.2.3 Summary of 
Non-Clinical 
Findings  Responsive models include MET -amplified, MET -exon 
14 deleted, and autocrine HGF -expressing tumors.  Response to Sym015 was observed in models with 
MET -amplification, METex14  mutations, and autocrine 
HGF -expression.  
 
3.2.4 .1 Protocol 
Sym015 -01 While data in this ongoing clinical trial have not been 
fully monitored…  While data in this ongoing clinical trial have not been 
fully monitored… all AEs were Grade 1 or Grade 2 in 
severity.   
As of Amendment 6, a total of 7 MET -ampli fied 
patients have been enrolled in the ongoing Part 2 
Basket Cohort of this trial … 
 
3.3 Trial Rationale  As outlined in the sections above, recent results 
suggest that MET -amplification identifies a small but 
clinically important subgroup of patients who are 
likely to respond to MET targeted therapies. The 
potent tumor inhibitory activity, observed in preclinical 
studies in MET -amplified models, suggests that 
Sym015 may provide a clinically relevant effect in this 
patient population. Based on the nonclinic al 
pharmacology and toxicity testing, Sym015 is expected 
to be well tolerated and the benefit -risk ratio for 
patients enrolled is considered to be favorable.  As outlined in the sections above, recent results 
suggest that MET -amplification and METex14  
mutat ions identify small but clinically important 
subgroups of patients who are likely to respond to 
MET targeted therapies. The potent tumor inhibitory 
activity, observed in preclinical studies in models with 
MET -amplification and/or METex14  mutations, 
suggest s that Sym015 may provide a clinically relevant 
effect in these patient populations. Based on the 
nonclinical pharmacology and toxicity testing, Sym015 
is expected to continue to be well tolerated and the 
benefit -risk ratio for patients enrolled is conside red to 
be favorable.  
 
3.4.1 Rationale for 
Starting Dose  The dosing schedules to be explored in this clinical 
trial are based on... PK data (long terminal T½ and 
accumulation with weekly dosing) support the 
selection of the dosing schedules, dosing every s econd 
week (Q2W) and dosing every third week (Q3W), to 
be evaluated in this trial.  
 The dosing schedule to be explored in this clinical trial 
is based on... PK data (long terminal T½ and 
accumulation with weekly dosing) support the 
selection of the dosing schedule, dosing every second 
week (Q2W), to be evaluated in this trial.  
4.2.2 Secondary 
Objectives  6. To make a preliminary evaluation of the antitumor 
activity of Sym015, and to evaluate all of the above 
secondary objectives, in a cohort of patients 
administered Sym015 on a Q3W dosing schedule at the 
highest safe dose tested in Part 1  6. To make a preliminary evaluation of the antitumor 
activity of Sym015, and to evaluate all the above 
secondary objectives, in a subset of approximately 6 -
12 KRAS WT NSCLC  patients with METex14 
mutations administered Sym015 at the Q2W RP2D.  
Patients need not be MET -amplified and may have 
received prior therapy with a MET -targeting TKI.  
Note:  Patients with malignancies other than NSCLC may be 
considered for entry to this c ohort following discussion with 
the Sponsor’s Medical Monitor(s).  
 
5.1 Overall Design 
Plan  Part 2 is a Phase 2a dose -expansion in patients with 
MET -amplified, KRAS  WT solid tumor malignancies 
without therapeutic options. With the exception of a 
subset of patients entered to the Q2W Basket Cohort, 
patients must not have received prior therapy with 
MET -inhibiting agents.  Two cohorts will be  Part 2 is a Phase 2a dose -expansion in which dosing 
will be at the recommended phase 2 dose (RP2D) on 
an every second week (Q2W) schedule, in the 
following referred to as the Q2W RP2 D.  Two 
cohorts will be included:  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 146 of 164 Table 21 Protocol Amendment 6  
SECTION  ORIGINAL TEXT  NEW TEXT  
included:  
o A Basket Cohort of approximately 45 patients, 
in which dosing will be at the Q2W RP2D 
(Q2W Basket Cohort).  Included in this group 
will be a subset of approximately 6 patients who 
have received prior therapy with a MET -
targeting TKI.   
o A Basket Cohort of 6 -12 patients, in which the 
highest safe dose tested in Part 1 will be 
evaluated on a Q3W schedule (Q3W Baske t 
Cohort)  
A basket trial is designed…  
 
The SMC will select the Q2W RP2D and the highest 
safe dose for the Q3W regimen to be used in Part 2…  
 
During Part 2, basket cohorts of patients with MET -
amplified, KRAS  WT, advanced solid tumor 
malignancies will be ev aluated: Q2W Basket Cohort 
administering the Q2W RP2D on a Q2W schedule and 
Q3W Basket Cohort administering the highest safe 
dose tested in Part 1 on a Q3W schedule.  
 
 
 
 
 
 
 
 
 
 
 
The number of investigational trial sites…15 to 20 in 
Part 2. Enrollment to the  Q3W Basket Cohort is 
expected to take place at select trial sites only.  
 o Basket* Cohort: A cohort of approximately 45 
patients with KRAS  WT advanced solid tumor 
malignancies with MET -amplification, and 
without therapeutic options. Included in this 
group will be a subset of approximately 6 
patie nts who have received prior therapy with a 
MET -targeting TKI.   
o NSCLC Cohort: A cohort of 6 -12 patients with 
KRAS  WT NSCLC with METex14  mutation, 
and without therapeutic options.  Patients need 
not be MET -amplified and may have received 
prior therapy with a MET -targeting TKI.  
*A basket cohort is designed…  
 
The SMC will select the Q2W RP2D to be used in Part 
2… 
 
During Part 2, two cohorts will receive Sym015 at the 
RP2D on a Q2W dosing schedule:  
 Basket Cohort: A basket cohort of KRAS  WT, 
advanced solid tumor  malignancy patients with 
MET -amplification will be evaluated. Patients must 
be MET -targeting TKI -naïve; an exception will be 
a subset of approximately 6 patients entered who 
have received prior therapy with a MET -targeting 
TKI.  
 NSCLC Cohort: A cohort of KRAS WT advanced 
NSCLC patients with METex14  mutation will be 
evaluated. Patients need not be MET -amplified and 
may have received prior therapy with a MET -
targeting TKI.  
The number of investigational trial sites…15 to 25 in 
Part 2.  
5.2.1 Rationale for 
Trial Design  Part 2 of this trial is designed: to evaluate the antitumor 
activity of Sym015 administered at the selected Q2W 
RP2D on a Q2W schedule and to further explore 
safety, tolerability and preliminary antitumor effect of 
the highest safe dose tested in Part 1 on a Q3W 
schedule.  
 
The choice of basket cohorts…  Part 2 of this trial is designed to evaluate the antitumor 
activity of Sym015 administered at the selected Q2W 
RP2D on a Q2W schedule.  
 
 
 
 
The choice of a basket cohort…  
 
5.2.2 Rationale for 
Trial  Population  Nonclinical studies have documented that the activity 
of Sym015 is greater in MET -amplified tumors, and 
similar findings have been observed in preliminary 
studies of other anti -MET mAbs in early clinical trials.  In addition, a cohort of KRAS  WT NSCLC patients 
with METex14  mutation will be entered to evaluate the 
antitumor activity of Sym015. Nonclinical studies have 
documented that the activity of Sym015 is greater in 
tumors with MET -amplification and/or METex14  
mutation, suggesting that Sym015 may provide a 
clinically relevant effect in these patient populations.  
Similar findings have been observed in preliminary 
studies in patients with MET -amplified tumors of other 
anti-MET mAbs in early clinical trials.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 147 of 164 Table 21 Protocol Amendment 6  
SECTION  ORIGINAL TEXT  NEW TEXT  
 
5.3.1 Prescreening 
for MET -
amplifica tion, 
METex14 , and 
KRAS  Mutational 
Status  The trial site may choose to prescreen patients utilizing 
archival tumor tissue to confirm MET -amplification 
status* and/or KRAS  mutational status*...   
*Part 2 ONLY:  Peripheral blood collection for MET -
amplifica tion assessment and for KRAS -mutation 
assessment… Other liquid biopsy methodologies will only 
be allowed if previously approved by the Sponsor…  The trial site may choose to prescreen patients utilizing 
archival tumor tissue to confirm MET -amplification 
status*, METex14  mutation status*, and/or KRAS  
mutational status*...   
*Part 2 ONLY:  Peripheral blood collection for MET -
amplification assessment, METex14  assessment, and 
KRAS -mutation assessment… Other liquid biopsy 
methodologies, except if used to detect METex14  
mutation, will only be allowed if previously approved by 
the Sponsor…  
5.3.2 Screening  Furthermore, once eligibility is confirmed:  
 All patients in Part 2 will have a tumor biopsy 
performed…  Furthermore, once eligibility is confirmed:  
 All patients in  the Part 2 Basket Cohort will have a 
tumor biopsy performed…  
 For patients in the Part 2 NSCLC Cohort, biopsy 
for biomarker analysis is optional; archival tissue to 
be submitted, if available   
 
5.3.4 Treatment  Sym015 will be administered on a Q2W or Q3W 
schedule by IV infusion:  
 Q2W dosing: Day 1 and Day 15 of each 28 -day 
cycle (± 2 days)  
 Q3W dosing: Day 1 and Day 22 of each 42 -day 
cycle (± 2 days) (Q3W Basket Cohort only)  
 Sym015 will be administered on a Q2W schedule by 
IV infusion:  
 Q2W dosing: Day 1 and  Day 15 of each 28 -day 
cycle (± 2 days)  
5.3.5 End of 
Treatment and 
Follow -up Visits  After the 1M FUP Visit, the Investigator will make 
every effort… every 2 months… Survival follow -up is 
required until death, withdrawal of consent, or 
termination of the t rial…  After the 1M FUP Visit, the Investigator will make 
every effort… about once every 2 months… Survival 
follow -up is required until death, withdrawal of 
consent, trial site closure, or termination/end of the 
trial.  Occurrence of one of these events con stitutes the 
EOS for the patient…  
 
5.3.6 Flow Chart – 
Schedule of 
Assessments  Schedules of assessments are provided in the trial flow 
charts in Table 3 (Q2W dosing) and Table 4 (Q3W 
dosing, Q3W Basket Cohort only), respectively.  
 
Furthermore, each new cy cle must be initiated as soon 
as possible after completion of the previous cycle in 
order to achieve the Q2W/Q3W dosing schedule as 
applicable for the individual patient.  
 Schedules of assessments are provided in the trial flow 
chart in Table 3 (Q2W dosing ). 
 
 
Furthermore, each new cycle must be initiated as soon 
as possible after completion of the previous cycle in 
order to achieve the Q2W dosing schedule.  
5.5 Number of 
Patients  During Part 2, it is planned to enroll and treat 
approximately 45 patients in  the Q2W Basket Cohort 
and 6 -12 patients in the Q3W Basket Cohort; i.e. a 
total of 51 -57 patients with documented and confirmed 
MET -amplified and KRAS  WT advanced solid tumor 
malignancies.  It is estimated that approximately 51 -57 patients will 
be enrolled to receive Sym015 at the RP2D on a Q2W 
schedule during Part 2. Two cohorts will be included:  
 Basket Cohort: Approximately 45 patients with 
KRAS  WT, advanced solid tumor malignancies 
with documented and confirmed MET -
amplification will be enrolled and treat ed. A subset 
of 6 patients will have received prior therapy with a 
MET -targeting TKI.  
 NSCLC Cohort: 6 -12 patients with KRAS  WT, 
advanced NSCLC with documented METex14  
mutation will be enrolled and treated. Patients need 
not be MET -amplified and may have r eceived prior 
therapy with a MET -targeting TKI.   
5.6 End of Trial  The end of trial will be reached at the latest 1 month The end of trial will be reached at the latest 1 month 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 148 of 164 Table 21 Protocol Amendment 6  
SECTION  ORIGINAL TEXT  NEW TEXT  
(30 +7 days) after the last patient has been withdrawn 
from Sym015. Patients will continue to be followed to 
assess duration of disea se stabilization, response and/or 
overall survival.  
 (30 +7 days) after the last patient has been withdrawn 
from Sym015.  
6.1 Inclusion 
Criteria  Part 2 ONLY : 
b. Tumor documented to be KRAS  WT…  
Note:  … Other liquid biopsy methodologies will only 
be allowed if previously approved by the Sponsor.  
 
 
c. Confirmed MET -amplification by local…  
 
d. No prior therapy with MET -targeting agents  
Note:  An exception will be a subset of approximately 6 
patients entered  to the Q2W Basket Cohort…  Part 2 ONLY : 
b. Tumor documented to be KRAS  WT…  
Note:  …Other liquid biopsy methodologies, except if 
used to detect METex14  mutation, will only be allowed 
if previously approved by the Sponsor.  
 
c. Basket Cohort ONLY:  
 Confirmed MET -amplification by local…  
 No prior therapy with MET -targeting agents  
Note:  An exception will be a subset of approximately 
6 patients entered to the Basket Cohort…   
 
d. NSCLC Cohort ONLY:  
 Documented METex14  mutations (patients need 
not be MET -amplified and may have received 
prior therapy with a MET -targeting TKI)  
Note: Patients with malignancies other than NSCLC and with 
documented METex14  mutation may be considered for entry 
to this cohort following discussion with the Sponsor’s 
Medical Monitor(s).  
Note : METex14  mutation status to be documented according 
to local institutional standards.  Assessment in ctDNA by 
Guardant360 technology or equivalent is allowed.  
Subsequent confirmation in tumor tissue is preferred but not 
required.  
 
6.2 Exclusion 
Criteria  1. Any antineoplastic agent (standard or 
investigational) within 4 weeks prior to C1/D1  
 
 
 
 
 
2. Part 2 ONLY :  
a. Prior therapy with MET -inhibiting agents  
Note:  An exception will be a subset of approximately 
6 patients entered to the Q2W Basket Cohort af ter 
having received prior therapy with a MET -targeting 
TKI.  
 
 
c. Tumor status demonstrating MET -polysomy  
 
 
 
 
 
3. Immunosuppressive or systemic hormonal therapy 
within 2 weeks prior to C1/D1 with the exception of 
the following allowed therapies:  
e. Hormona l contraceptive therapy  
f. GnRH analogs in patients with prostate cancer  
 
 1. Any antineoplastic agent for the primary malignancy 
(standard or investigational) without delayed toxicity 
within 4 weeks or 5 plasma half -lives, whichever is 
shortest, prior to C1/D1 except:  
 Nitrosoureas and mitomycin C within 6 weeks 
prior to C1/D1  
2. Part 2 ONLY :  
a. Prior therapy with MET -inhibiting agents  
Note:  Exceptions will be a subset of approximately 6 
patients entered to the Basket Cohort after having 
received prior therapy with a MET -targeting TKI, and 
patients entered to the N SCLC Cohort who may have 
received prior therapy with a MET -targeting TKI.  
 
c. Basket Cohort ONLY: Tumor status 
demonstrating MET -polysomy in the absence of 
MET -amplification, as specified  
Note: Patients in the NSCLC Cohort with polysomy are 
eligible  
 
3. Immunosuppressive or systemic hormonal therapy 
(> 10 mg daily prednisone equivalent) within 2 
weeks prior to C1/D1 with the exception of the 
following allowed therapies:  
e. Steroid therapy for contrast reaction 
prophylaxis  
f. Stable hormonal therapy for ova rian suppression 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 149 of 164 Table 21 Protocol Amendment 6  
SECTION  ORIGINAL TEXT  NEW TEXT  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Central nervous system (CNS) malignancy 
including:  
b. Known CNS or leptomeningeal metastases not 
controlled by prior surgery…  
Note: Patients with treated CNS metastases…  for non -malignant conditions, hormonal 
contraceptive therapy, or post -menopausal 
hormone replacement therapy (HRT)*  
g. GnRH analogs in patients with prostate cancer  
h. Intra -articular steroid injections  
i. Higher dose steroid therapy for treatment of an 
acute intercurrent illness in patients with stable 
disease or an ongoing response. In such 
situations, protocol therapy treatment should be 
interrupted.  
*Prior or concomitant therapies are permitted; 
however, patients must have been on a st able 
dose for at least 6 months prior to study start, and 
if continuing must remain on the stable dose 
while receiving study treatment (i.e. such 
treatment will not be considered as systemic 
hormonal therapy for the purpose of study 
eligibility).  
 
6. Centr al nervous system (CNS) malignancy 
including:  
b. Known, untreated CNS or leptomeningeal 
metastases, or spinal cord compression; patients 
with any of these not controlled by prior 
surgery…  
Note: Patients with treated CNS metastases…  
Patients with newly iden tified CNS metastases during 
study treatment will be considered to have PD and 
will be discontinued from treatment  
 
6.3.1 Withdrawal 
from Treatment 
with Sym015   Results from archival tumor tissue or a tumor biopsy 
submitted to confirm MET -amplification sta tus that 
do not meet study eligibility criteria.    Basket Cohort ONLY: Results from archival tumor 
tissue or a tumor biopsy submitted to confirm MET -
amplification status that do not meet study eligibility 
criteria.   
6.4.2 Part 2  Patients enrolled to the study…  Basket Cohort ONLY: Patients enrolled to the study…  
 
7.1.3.1 Treatment 
Schedule  Sym015 will be administered Q2W (Day 1 and Day 15 
of each 28 -day cycle [±2 days]) or Q3W (Day 1 and 
Day 22 of each 42 -day cycle [±2 days]).   
 Sym015 will be administer ed Q2W (Day 1 and Day 15 
of each 28 -day cycle [±2 days]).   
7.1.3.2 Part 1, 
Dose -Escalation  The SMC will review safety data… and the doses to be 
used in Part 2 (i.e. Q2W RP2D to be evaluated in the 
Q2W Basket Cohort and the highest safe dose in Part 1 
to be evaluated in the Q3W Basket Cohort).  
 The SMC will review safety data… and the dose(s) to 
be used in Part 2 (i.e. Q2W RP2D to be evaluated).  
7.1.3.3 Part 2  During Part 2 of this trial, patients included in the 
Q2W Basket Cohort will receive the Q2W RP2 D of 
Sym015 on a Q2W dosing schedule. Patients included 
in the Q3W Basket Cohort will receive the highest safe 
dose tested in Part 1 on a Q3W dosing schedule.  
 During Part 2 of this trial, patients will receive the 
RP2D of Sym015 on a Q2W dosing schedule.  
7.1.4 Dose -
Adjustment and 
Delays of Sym015  The dose of Sym015 in mg/kg and the dosing schedule, 
Q2W or Q3W, assigned to the individual patient, will 
be confirmed by the Sponsor…  
 The dose of Sym015 in mg/kg assigned to the 
individual patient will be conf irmed by the Sponsor…  
7.5.2 Prohibited 
Medication/ 
Therapy and  Systemic immunosuppressive or systemic hormonal 
therapy with the exception of the following allowed  Systemic immunosuppres sive or systemic hormonal 
therapy with the exception of the following allowed 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 150 of 164 Table 21 Protocol Amendment 6  
SECTION  ORIGINAL TEXT  NEW TEXT  
Procedures During 
the Trial  therapies:  
o Hormonal contraceptive therapy  therapies:  
o Stable hormonal therapy for ovarian 
suppression for non -malignant conditions, 
hormonal contraceptive therapy, or post -
menopausal HRT*  
o Intra -articular steroid injectio ns 
o Higher dose steroid therapy for treatment of an 
acute intercurrent illness in patients with stable 
disease or an ongoing response. In such 
situations, protocol therapy treatment should be 
interrupted.  
*Prior or concomitant therapies are permitted; 
howev er, patients must have been on a stable dose 
for at least 6 months prior to study start, and if 
continuing must remain on the stable dose while 
receiving study treatment (i.e. such treatment will 
not be considered as systemic hormonal therapy for 
the purpo se of study eligibility).  
 
8.3.1 Disease 
Status Evaluation 
by CT or MRI   For Q2W dosing schedule only:  
o End of Cycle 2 and end of every second cycle 
thereafter, i.e. end of Cycle 4, 6, 8, etc.  
Note: May be performed at any time during the week 
prior to Day 1 of the next cycle  
 
 For Q3W Basket Cohort only:  
o At the end of the follow -up period following 
every third dose, i.e. end of the follow -up 
period following C2/D1, C3/D22, C5/D1 etc.  
Note: May be performed at any time during the week 
prior to the next schedu led dose  
  End of Cycle 2 and end of every second cycle 
thereafter, i.e. end of Cycle 4, 6, 8, etc.  
Note: May be performed at any time during the week prior 
to Day 1 of the next cycle  
 
 
 
Removed  
8.3.3 Archival 
Tumor Tissue for 
MET  and KRAS  
Assessment   Scree ning 
o Part 2…  
It is preferred that the eligibility assessment for 
MET -amplification will be done using…  
During Part 2 ONLY… Other liquid biopsy 
methodologies will only be allowed if previously 
approved by the Sponsor…   Screening  
o Part 2…  
Basket Cohort: It is preferred that the eligibility 
assessment for MET -amplification be done 
using…  
During Part 2 ONLY… Other liquid biopsy 
methodologies, except if used to detect METex14  
mutation, will only be allowed if previously approved 
by the Sponsor…   
 
NSCLC Cohort: El igibility assessment for 
METex14  mutation status will be done 
according to local institutional standards.  
Assessment in ctDNA by Guardant360 
technology or equivalent is allowed.  
Subsequent confirmation in tumor tissue is 
preferred but not required, howev er, archival 
tissue to be submitted, if available.  
 
8.3.4 Tumor 
Biopsy for 
Eligibility  Screening  
o Part 2: Required, if archival tissue…  
  Screening  
o Part 2:  
Basket Cohort: Required, if archival tissue…  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 151 of 164 Table 21 Protocol Amendment 6  
SECTION  ORIGINAL TEXT  NEW TEXT  
Assessment and 
Biomarker 
Analysis   
 
 
 Post-dosing  
o Part 2: Required  
 For Q2W dosing schedule only: End of Cycle 
2… 
 For Q3W  Basket Cohort only: At the end of the 
follow -up period following the third dose (i.e. 
coinciding with time of first response 
assessment) or upon PD, whichever occurs first  
Note: May be performed at any time during the week 
prior to the next scheduled dose   
NSCLC Cohort: Optional  
 
 Post-dosing  
o Part 2:  
Basket Cohort: Required; End of Cycle 2…  
 
NSCLC Cohort: Optional, at the timepoint 
specified above  
8.7 Biomarker 
Blood Sample   Screening, after c onfirmation of eligibility  
 For Q2W dosing schedule only: End of Cycle 2…  
 For Q3W Basket Cohort only: At the end of the 
follow -up period following the third dose 
(coinciding with time of first response assessment) 
or upon PD, whichever occurs first  
Note: Ma y be performed at any time during the week prior 
to the next scheduled dose  
 EOT   Screening, after confirmation of eligibility  
 End of Cycle 2…  
Removed  
 
 
 
 
 EOT  
 
Note:  If a tumor biopsy is collected at the same time point as 
the biomarker blood sample, the bi omarker blood sample 
should be collected prior to collecting the tumor biopsy.  
 
10.1 Sample Size 
Determination  In Part 2 of the trial, the primary endpoint is 
documented OR in the Q2W Basket Cohort…  
 
For the Q3W Basket Cohort, assuming the response … 
 In Part 2 of the trial, the primary endpoint is 
documented OR in the Basket Cohort…  
 
For the NSCLC Cohort, assuming the response…  
10.3.2 Part 2  This will be assessed by the primary endpoint for Part 
2, documented OR in the Q2W Basket Cohort…  
 This will be ass essed by the primary endpoint for Part 
2, documented OR in the Basket Cohort…  
10.4.1 Efficacy 
Endpoints and 
Analyses  The following anti -tumor response endpoints will be 
measured in Part 1 and in the Q3W Basket Cohort…  The following anti -tumor response end points will be 
measured in Part 1…  
10.4.5 Additional 
Endpoints and 
Analyses   Part 1 only: MET -receptor down -regulation 
measured by percentage and nominal change in 
target expression from baseline to end of Cycle 
2/end of follow -up period following the thir d dose 
(Q2W/Q3W) or PD (whichever comes first) in skin 
biopsy samples   Part 1 only: MET -receptor down -regulation 
measured by percentage and nominal change in 
target expression from baseline to end of Cycle 2 or 
PD (whichever comes first) in skin biopsy samp les 
10.5 Interim 
Analysis  In Part 2 an assessment of futility will be performed … 
in the Q2W Basket Cohort.  
 In Part 2 an assessment of futility will be performed … 
in the Basket Cohort.  
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 152 of 164 21.7 Protocol Amendment 7 dated 07-Dec-2018  
1. Effective with this protocol  amendment, accrual to the Basket Cohort is suspended . 
Emerging literature allowed for the identification of specific tumor types that are more 
likely to respond to Sym015 treatment (e.g., NSCLC). With this change, a new cohort of 
NSCLC MET -amplified patie nts has been added to Part 2 of the trial design , for a total of 
three cohorts.  
2. With the suspension of the Basket Cohort, NSCLC MET -amplified patients entered to the 
Basket Cohort will be counted toward the NSCLC MET -Amplified Cohort; NSCLC 
METEx14Del patients entered to the Basket Cohort will be counted toward the NSCLC 
METEx14Del Cohort; patients with both will be counted as MET -Amplified.   
3. Updated clinical experience information ha ve been added to the scientific background . 
4. According to the ASCO/CAP gui delines for testing of HER2 amplification, MET -
amplification may be defined as positive with a MET/CEP7 ratio  of >2.2 (occasionally 
2.0). Symphogen has opted  to change the cutoff to > 3.0 based on emerging data that 
suggest higher degrees of MET -amplificat ion are associated with higher degree of 
response . 
5. Specified that concomitant therapy with bisphosphonates and denosumab are allowed 
during the dosing portion of the trial . 
6. Clarified that  after the Screening assessments, targeted physical examination may b e 
performed as indicated.  
7. The number of pharmacokinetic timepoints have been reduced for patients entered to the 
NSCLC cohorts.  
8. The mandatory post -dosing tumor biopsy scheduled to be performed at the EOC 2 or upon 
disease progression is now optional.  
9. Clarif ied that a ll analyses will be related to and used only in connection with the data 
collected in the present trial as well as  future development of Sym015.  
10. Clarified that EOC assessments may be performed at any time during the week prior to 
Day 1 of the nex t cycle, including Day 1 of the next cycle, prior to dosing . 
11. Clarified that initial SAE and follow -up SAE information are to be submitted within 24 
hours of awareness.  
12. Due to the new cohort sample sizes, an initially planned interim analysis becomes 
obsole te and will no longer be performed.  
13. Guidelines pertaining to the General Data Protection Regulation have been added.  
14. Formatting adjustments, typographical corrections, outline modifications, and 
wording/abbreviation changes are included.  
15. The synopsis, figu re, tables , and references  have been updated based on changes 
described, where applicable.  
 
Refer to Table 22 for the changes in Protocol Amendment 7.   
 
 
 
 
 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 153 of 164  
Table 22 Protocol Amendment 7  
SECTION  ORIGINAL TEXT  NEW TEXT  
3.1.1 Solid Tumor 
Malignancies  Not applicable  Non-small cell lung cancer (NSCLC) is the leading 
cause of death due to malignancy globally.  
3.1.2 MET -
Amplified Solid 
Tumor 
Malignancies  Mutations leading to skipping of MET e xon 14 
(METex14 ) result in the deletion of the juxtamembrane 
domain of MET, …  
 
Although this molecular alteration is rare, testing of 
KRAS  status in clinical trials involving anti -MET 
therapy may be warranted to avoid treating patients 
that may not experie nce clinical benefit from these 
agents  (10,19) . Mutations leading to skipping of MET exon 14 
(METEx14Del) result in the deletion of the 
juxtamembrane domain of MET, …  
Because these two molecular alterations are rare in 
NSCLC patients, testing of KRAS  statu s in clinical 
trials involving anti -MET therapy may not be 
warranted  (10,19) . 
NSCLC patients with either MET -amplification or 
METEx14Del have been documented to have a poor 
prognosis  (32). MET -amplification was observed in 
0.7% of all patients with NSCLC a nd MET  mutations 
were observed in 2.6% of patients in this population.  
3.1.3 Current 
Treatment of MET -
Amplified Solid 
Tumor 
Malignancies  These include both small -molecule tyrosine -kinase 
inhibitors, such as crizotinib, cabozantinib and 
tivantinib, as well  as monoclonal antibodies (mAbs). 
The small -molecule inhibitors are generally 
promiscuous in their target specificity and thus have 
activity on additional RTKs besides MET.  These include both small -molecule tyrosine -kinase 
inhibitors, such as crizotinib, c abozantinib, tivantinib, 
tepotinib, and capmatinib as well as single monoclonal 
antibodies (mAbs). The small -molecule inhibitors are 
generally promiscuous in their target specificity and 
may have activity on additional RTKs besides MET. 
The activity of MET  inhibitors in patients with 
NSCLC has recently been reviewed (33), and more 
recent data are cited below with respect to additional 
inhibitors.  
Not applicable  Tepotinib is another MET tyrosine kinase inhibitor 
(TKI) that has been studied in Phase 1 and P hase 2 
clinical studies …. (34).  
Capmatinib (INC280), a MET TKI, is also in Phase 2 
studies enrolling NSCLC patients with METEx14Del as 
well as in combination with gefitinib in patients with 
epidermal growth factor receptor ( EGFR )-mutated 
MET dysregulated N SCLC ... (35).  
3.2.4.1 Protocol 
Sym015 -01 As of Amendment 6, a total of 7 MET -amplified 
patients have been enrolled in the ongoing Part 2 
Basket Cohort of this trial to receive Sym015 at a 
loading dose of 18 mg/kg delivered over 1.5 hours, 
followed by Q2W maintenance doses of 12 mg/kg 
delivered over 1 hour … Other study drug -related AEs 
have been limited to fatigue (Grade 2) and prolonged  
prothrombin time (Grade 1).  Accrual to this portion of 
the trial continues.  As of September 2018, a total of 21 MET -ampl ified 
patients and 2 METEx14Del patients have been enrolled 
in the ongoing Part 2 portion of this trial to receive 
Sym015 at a loading dose of 18 mg/kg delivered over 
1.5 hours, followed by Q2W maintenance doses of 12 
mg/kg delivered over 1 hour …  In anoth er patient, the 
SAEs of Grade 3 anasarca and Grade 3 
hypoalbuminemia (both possibly related) have been 
reported. Other study drug -related AEs have been 
limited to Grade 2 fatigue and mouth sores, and Grade 
1 asthenia, anorexia, gastric pain, abdominal cram ping, 
abdominal gas, nausea, diarrhea, constipation, xerosis, 
pruritus, and voice change … Accrual to the Part 2 
portion of the trial continues.  
Note:  Effective with protocol version 8.0 (December 2018), 
accrual to the Part 2 Basket Cohort comprised of pat ients with 
MET -amplified solid tumor malignancies is suspended; 
accrual will continue to cohorts of patients with MET -
amplified NSCLC or METEx14Del NSCLC.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 154 of 164 Table 22 Protocol Amendment 7  
SECTION  ORIGINAL TEXT  NEW TEXT  
4.2.1 Primary 
Objective  To evaluate the antitumor activity of Sym015 when 
administered at the Q2W RP 2D to patients with MET -
amplified, KRAS  WT solid tumor malignancies without 
available therapeutic options.   To evaluate the antitumor activity of Sym015 when 
administered at the Q2W RP2D to patients in the 
following cohorts:  
1. Basket Cohort: MET -amplifi ed, KRAS WT solid 
tumor malignancies without available therapeutic 
options; patients may not have received prior therapy 
with a MET -targeting TKI  
2. NSCLC MET -Amplified Cohort: MET -amplified 
advanced NSCLC without available therapeutic 
options; patients m ay have received prior therapy with 
MET -targeting and/or EGFR -targeting agents   
3. NSCLC METEx14Del Cohort: METEx14Del NSCLC 
without available therapeutic options; patients may 
have received prior therapy with MET -targeting and/or 
EGFR -targeting agents  
4.2.2 Secondary 
Objectives  5. To make a preliminary evaluation of the antitumor 
activity of Sym015, and to evaluate all of the above 
secondary objectives, in a subset of approximately 6 
patients administered Sym015 at the Q2W RP2D after 
having received prio r therapy with a MET -targeting 
tyrosine kinase inhibitor (TKI)  5. Basket Cohort: To make a preliminary assessment of 
the antitumor activity of Sym015, and to evaluate all of 
the above secondary objectives, in a subset of 
approximately 6 patients with solid  tumor 
malignancies administered Sym015 at the Q2W RP2D 
after having received prior therapy with a MET -
targeting TKI  
6. To make a preliminary evaluation of the antitumor 
activity of Sym015, and to evaluate all the above 
secondary objectives, in a subset of approximately 6 -
12 KRAS WT NSCLC patients with METex14 
mutations administered Sym015 at the Q2W RP2D.  
Patients need not be MET -amplified and may have 
received prior therapy with a MET -targeting TKI.  
Note:  Patients with malignancies other than NSCLC ma y be 
considered for entry to this cohort following discussion with 
the Sponsor’s Medical Monitor(s).  Text removed  
5.1 Overall Design 
and Plan   Part 2 is a Phase 2a dose -expansion in which dosing 
will be at the recommended phase 2 dose (RP2D) on 
an every se cond week (Q2W) schedule, in the 
following referred to as the Q2W RP2D.  Two 
cohorts will be included:  
o Basket* Cohort : A cohort of approximately 45 
patients with KRAS  WT advanced solid tumor 
malignancies with MET -amplification, and 
without therapeutic opti ons. Included in this 
group will be a subset of approximately 6 
patients who have received prior therapy with a 
MET -targeting TKI.   
 
o NSCLC Cohort : A cohort of 6 -12 patients with 
KRAS  WT NSCLC with METex14  mutation, 
and without therapeutic options.  Patien ts need 
not be MET -amplified and may have received 
prior therapy with a MET -targeting TKI.  
  Part 2 is a Phase 2a dose -expansion in which dosing 
will be at the RP2D on an every second week (Q2W) 
schedule . Three c ohorts will be included:  
o Basket* Cohort : A co hort of approximately 25 
patients with KRAS  WT advanced solid tumor 
malignancies with MET -amplification, and 
without available therapeutic options. Included 
in this group will be a subset of approximately 6 
patients who have received prior therapy with a 
MET-targeting TKI.   
Note:  Effective with protocol version 8.0 (December 
2018), accrual to the Basket Cohort is suspended.  
 
o NSCLC MET -Amplified Cohort : A cohort of  
approximately  20 patients with advanced 
NSCLC with MET -amplification , and without 
available therapeutic options.  Patients may 
have received prior therapy with MET -targeting 
and/or EGFR -targeting agents . 
 
o NSCLC METEx14Del Cohort : A cohort of 
approximately 6 -12 patients with advanced 
NSCLC with METEx14Del, and without available 
therapeutic options .  Tumors need not be MET -
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 155 of 164 Table 22 Protocol Amendment 7  
SECTION  ORIGINAL TEXT  NEW TEXT  
amplified, and patients may have received prior 
therapy with MET -targeting and/or EGFR -
targeting agents.  
5.1 Overall Design 
and Plan  
(continued)  During Part 2, two cohorts will receive Sym015 at the 
RP2D on a Q2W dosing schedule:  
 Basket Cohort : A basket cohort of KRAS  WT, 
advanced solid tumor malignancy patients with 
MET -amplification will be evaluated. Patients must 
be MET -targeting TKI -naïve; an exception will be 
a subset of approximately 6 patients entered who 
have received pri or therapy with a MET -targeting 
TKI.  
 
 NSCLC Cohort : A cohort of KRAS  WT advanced 
NSCLC patients with METex14  mutation will be 
evaluated. Patients need not be MET -amplified and 
may have received prior therapy with a MET -
targeting TKI.  During Part 2, three  cohorts will receive Sym015 at the 
RP2D on a Q2W dosing schedule:  
 Basket Cohort: A basket cohort of KRAS  WT, 
advanced solid tumor malignancy patients with 
MET -amplification will be evaluated. Patients must 
be MET -targeting TKI -naïve; an exception will be 
a subset of approximately 6 patients entered who 
have received prior therapy with a MET -targeting 
TKI. 
Note:  Effective with protocol version 8.0 (December 
2018), accrual to the Basket Cohort is suspended.  
 
 NSCLC MET -Amplified Cohort : A cohort of 
advanced NS CLC patients with MET -amplification 
will be evaluated. Patients may have received prior 
therapy with MET -targeting and/or EGFR -targeting 
agents.  
 NSCLC METEx14Del Cohort : A cohort of advanced 
NSCLC  patients with METEx14Del will be evaluated .  
Tumors need n ot be MET -amplified, and patients 
may have received prior therapy with MET -
targeting and/or EGFR -targeting agents.  
The number of investigational trial sites …15 to 25 in 
Part 2 . The number of investigational trial sites …15 to 2 7 in 
Part 2 . 
5.2.1 Rational e for 
Trial Design  Additionally, this trial design may also allow for the 
identification of specific tumor types that are more 
likely to respond to Sym015 treatment.  Emerging literature allowed for the identification of 
specific tumor types that are more l ikely to respond to 
Sym015 treatment (e.g., NSCLC).  
Note:  Effective with protocol version 8.0 (December 2018), 
accrual to the Basket Cohort is suspended.  
5.2.2 Rationale for 
Trial Population  In Part 2, patients with MET -amplified, KRAS  WT, 
advanced soli d tumor malignancies of any tissue origin 
will be entered to evaluate the antitumor activity of 
Sym015. In addition, a cohort of KRAS  WT NSCLC 
patients with MET ex14 mutation will be entered to 
evaluate the antitumor activity of Sym015.  
 
Nonclinical studie s have documented that the activity 
of Sym015 is greater in tumors with MET -
amplification and/or MET ex14 mutation, suggesting 
that Sym015 may provide a clinically relevant effect in 
these patient populations.  Similar findings have been 
observed in prelimi nary studies in patients with MET -
amplified tumors of other anti -MET mAbs in early 
clinical trials.  In Part 2, patients with MET -amplified, KRAS  WT, 
advanced solid tumor malignancies of any tissue origin 
will be entered to evaluate the antitumor activity o f 
Sym015 in the Basket Cohort. In addition, a cohort of 
NSCLC patients with MET -amplification and a cohort 
of NSCLC patients with METEx14Del will be entered to 
evaluate the antitumor activity of Sym015 in these 
populations.  
 
Nonclinical studies have docum ented that the activity 
of Sym015 is greater in tumors with MET -
amplification and/or METEx14Del, suggesting that 
Sym015 may provide a clinically relevant effect in 
these patient populations.  Similar findings have been 
observed in preliminary studies in pa tients with MET -
amplified tumors with other anti -MET mAbs in early 
clinical trials.  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 156 of 164 Table 22 Protocol Amendment 7  
SECTION  ORIGINAL TEXT  NEW TEXT  
5.3.1 Prescreening 
for MET -
amplification and 
METEx14Del Status  
 5.3.1 Prescreening for MET -amplification, METex14 , 
and KRAS  Mutational Status  
The trial site may choose to prescreen patients utilizing 
archival tumor tissue to confirm MET -amplification 
status*, METex14  mutation status*, and/or KRAS  
mutational status* ...   
*Part 2 ONLY:  Peripheral blood collection for MET -
amplification assessment, METex14  assessment, and 
KRAS -mutation assessment … Other liquid biopsy 
methodologies, except if used to detect METex14  
mutation, will only be allowed if previously approved by 
the Sponsor … 5.3.1 Prescreening for MET -amplification and 
METEx14Del Status  
The trial site may choose to pres creen patients utilizing 
genomic analysis (e.g., Guardant360 or other similar 
liquid biopsy methodology) or tumor tissue (archival, 
or recently obtained if acquired outside of the 
screening process as part of the site’s usual practice) to 
assess MET -amplif ication status and METEx14Del 
status…  
Peripheral blood collection for assessment in 
circulating tumor deoxyribonucleic acid (ctDNA) (also 
referred to as “liquid biopsy”) may be used as a local 
pre-screening methodology by Guardant360 analysis 
(http://guard anthealth.com/guardant360/).  Other liquid 
biopsy methodologies, if used to detect METEx14Del, are 
acceptable alternatives.      
5.3.2 Screening  When the trial site identifies a patient suitable for 
screening, the Sponsor or designee should be contacted 
to ensure that a cohort is open for inclusion. Once 
confirmed, the patient may be approached for informed 
consent.  When the trial site identifies a patient suitable for 
screening, the Sponsor or designee should be contacted 
to ensure that a cohort is open fo r inclusion (applies to 
Part 1 only). With this assurance, the patient may be 
approached for informed consent.  
The trial site staff must complete a Screening and 
Allocation Form , stating the allocated patient number 
along with the planned dates of screen ing and the day 
of first scheduled Sym015 administration (C1/D1), and 
whether the patient has received prior therapy with 
MET -inhibiting agents. The planned date of C1/D1 
will be agreed upon in collaboration with Sponsor or 
designee for the dose -escalation  cohorts in order to 
ensure adequate time between dosing of the first 
patient and dosing of subsequent patients within each 
cohort.  The trial site staff must complete a Screening and 
Allocation Form , stating the allocated patient number 
along with the pla nned dates of screening and the day 
of first scheduled Sym015 administration (C1/D1). The 
planned date of C1/D1 will be agreed upon in 
collaboration with Sponsor or designee for the dose -
escalation cohorts in order to ensure adequate time 
between dosing of  the first patient and dosing of 
subsequent patients within each cohort (applies to Part 
1 only).  
Furthermore, once eligibility is confirmed:  
• Patients in Part 1 … 
• All patients in the Part 2 Basket Cohort …  
• For patients in the Part 2 NSCLC Cohort, b iopsy for 
biomarker analysis is optional; archival tissue to be 
submitted, if available   
 
 
 • Part 1: Patients in Part 1 … 
• Basket Cohort: All patients in the Part 2 Basket 
Cohort …   
• NSCLC MET -Amplified Cohort: All patients in the 
Part 2 NSCLC MET -Ampli fied Cohort will have a 
tumor biopsy performed and submitted for central 
confirmation of MET -amplification status, and for 
biomarker analysis.   
 
Note: Peripheral blood for ctDNA analysis by Guardant 360 
will be obtained for assessment of MET -amplification  status. 
If central confirmation of MET -amplification status cannot be 
assessed in tumor due to assay failure/technical error, the 
Sponsor may decide to enroll based on MET -amplification 
detected by Guardant360 on a case per case basis. As data are 
acquire d on concordance between findings in tumor tissue 
versus ctDNA, the Sponsor may decide to transition to 
screening for MET -amplification using Guardant360 analysis 
only (e.g., 2+ or 3+ amplification score) without requiring 
confirmation in a recent or newly  performed tumor biopsy.  
Not applicable  • NSCLC METEx14Del Cohort: All patients in the Part 2 
NSCLC METEx14Del Cohort will have a tumor biopsy 
performed and submitted for central assessment of 
METEx14Del status, and for biomarker analysis.   
5.3.6 Flow Chart – 
Schedule of 
Assessments  Schedules of assessments are provided in the trial flow 
chart in Table 3 (Q2W dosing).  Schedules of assessments are provided in the trial flow 
charts in Table 3 (Part 1 and Part 2 Basket Cohort) and 
Table 4 (Part 2 NSCLC Coh orts).  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 157 of 164 Table 22 Protocol Amendment 7  
SECTION  ORIGINAL TEXT  NEW TEXT  
5.4 Recruitment 
Period  Enrollment is expected to complete by Q3 2018.  Enrollment is expected to complete by Q 4 2019. 
5.5 Number of 
Patients  It is estimated that approximately 51 -57 patients will 
be enrolled to receive Sym015 at the RP2D on a Q2W 
schedule during Part 2. Two cohorts will be included:  
 Basket Cohort : Approximately 45 patients with 
KRAS  WT, advanced solid tumor malignancies 
with documented and confirmed MET -
amplification will be enrolled and treated. A subset 
of 6 patients will have rec eived prior therapy with a 
MET -targeting TKI.  It is estimated that approximately 51 -57 patients will 
be enrolled to receive Sym015 at the RP2D on a Q2W 
schedule during Part 2. Three  cohorts will be included:  
 Basket Cohort : Approximately 25 patients with 
KRAS WT, advanced solid tumor malignancies 
with documented MET -amplification will be 
enrolled and treated. A subset of approximately 6 
patients will have received prior therapy with a 
MET -targeting TKI.  
Note:  Effective with protocol version 8.0 (December 
2018), accrual to the Basket Cohort is suspended.  
NSCLC MET -Amplified patients entered to the Basket 
Cohort will be counted toward the NSCLC MET -
Amplified Cohort; NSCLC METEx14Del patients entered to 
the Basket Cohort will be counted toward the NSCLC 
METEx14Del Cohort; patients with both will be counted as 
MET -Amplified.  
 NSCLC Cohort : 6-12 patients with KRAS  WT, 
advanced NSCLC with documented METex14  
mutation will be enrolled and treated. Patients need 
not be MET -amplified and may have received prior 
therapy with a MET -targeting TKI.    NSCLC MET -Amplified Cohort : approximately 20 
patients with advanced NSCLC with documented 
MET -amplification will be enrolled and treated. 
Patients may have received prior therapy with 
MET -targeting agents and/or EGFR -targeti ng 
agents.  
Not applicable   NSCLC METEx14Del Cohort : approximately 6 -12 
patients with advanced NSCLC with documented 
METEx14Del will be enrolled and treated. Tumors 
need not be MET -amplified, and patients may have 
received prior therapy with MET -targeting and/or 
EGFR -targeting agents.   
Note:  NSCLC patients with tumors identified as both 
MET -Amplified and METEx14Del will be enrolled to the 
MET -Amplified cohort.  
6.1 Inclusion 
Criteria  Part 2 ONLY : 
b. Tumor documented to be KRAS WT by local 
assessment accor ding to institutional standards.  
Note:  Peripheral blood collection for KRAS -mutation 
assessment in ctDNA will be allowed as a local pre -screening 
methodology by Guardant360* analysis.  Other liquid biopsy 
methodologies, except if used to detect MET ex14 mu tation, 
will only be allowed  if previously approved by the Sponsor.  
 
c. Basket Cohort ONLY : 
 Confirmed MET -amplification by local…  
 No prior therapy with MET -targeting agents … 
 Willingness to undergo a pre - and post -dosing 
biopsy…  
 
 Part 2 ONLY : 
b. Basket Coh ort ONLY : 
 Tumor documented to be KRAS  WT by local 
assessment according to institutional standards. 
If KRAS  WT is not previously documented and if 
archival tissue is not available for pretrial 
assessment, patient must be willing to undergo a 
tumor biopsy to  confirm eligibility.   
Note:  Peripheral blood collection for KRAS -mutation 
assessment in ctDNA will be allowed as a local pre -
screening methodology by Guardant360* analysis.  
Other liquid biopsy methodologies, if used to detect 
METEx14Del, are acceptable  alternatives.  
 
 Confirmed MET -amplification by local…  
 No prior therapy with MET -targeting agents…  
 Willingness to undergo a pre - and post -dosing 
biopsy…  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 158 of 164 Table 22 Protocol Amendment 7  
SECTION  ORIGINAL TEXT  NEW TEXT  
6.1 Inclusion 
Criteria  
(continued)  d. NSCLC Cohort ONLY :  
 Documented METex14  mutations (patients need 
not be MET -amplified and may have received 
prior therapy with a MET -targeting TKI)  
Note: Patients with malignancies other than NSCLC and with 
documented METex14  mutation may be considered for entry 
to this cohort following discussion with the Sponsor’s 
Medi cal Monitor(s).  
Note: METex14  mutation status to be documented according 
to local institutional standards.  Assessment in ctDNA by 
Guardant360 technology or equivalent is allowed.  
Subsequent confirmation in tumor tissue is preferred but not 
required.  c. NSCLC MET -Amplified Cohort ONLY :  
 Documented NSCLC meeting disease criteria as 
defined above   
 Documented MET -amplification by either:  
o Local assessment in a recent* tumor biopsy; 
i.e.,  G:CN ≥3.0 scored in 50 tumor nuclei 
by FISH, CISH, SISH or similar assa y, or a 
copy number >5 by NGS or qPCR 
(subsequent central confirmation required, 
however patient may be enrolled and treated 
based on local assessment, before central 
confirmation results have been obtained)  
*Tissue for local assessment may be from a 
recen t tumor biopsy, defined as one 
performed since last documented disease 
progression as part of the site’s usual 
practice, and where no intervening 
antineoplastic therapy has been 
administered; otherwise tissue from a newly 
performed biopsy must be obtained and 
submitted.       
o Central confirmation** in a newly performed 
pre-dosing tumor biopsy; i.e.,  G:CN ≥3.0 
scored in 50 tumor nuclei by FISH  
o **If central confirmation of MET -
amplification status cannot be assessed in 
tumor due to assay failure/technical er ror, 
the Sponsor may decide to enroll based on 
MET -amplification detected by 
Guardant360 on a case per case basis (see 
Note below regarding Guardant360 
analysis).  
 May have received prior therapy with MET -
targeting and/or EGFR -targeting agents 
(antibodies o r TKIs)  
 Willingness to undergo a pre -dosing biopsy 
(mandatory unless a recent* tumor biopsy as 
defined above is available), and potentially a 
biopsy at the End of Cycle 2 (EOC2) (optional), 
from a primary or metastatic tumor site 
considered safely accessib le for biopsy  
Note: Peripheral blood for ctDNA analysis by Guardant 360 
will be obtained for assessment of MET -amplification status. 
As data are acquired on concordance between findings in 
tumor tissue versus ctDNA, the Sponsor may decide to 
transition to  screening for MET -amplification using 
Guardant360 analysis only (e.g., 2+ or 3+ amplification score) 
without requiring confirmation in a recent or newly performed 
tumor biopsy.  
6.1 Inclusion 
Criteria 
(continued)  Not applicable  d. NSCLC METEx14Del Cohort ONLY :  
 Documented NSCLC meeting disease criteria as 
defined above   
 Documented METEx14Del (tumors need not be 
MET -amplified)  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 159 of 164 Table 22 Protocol Amendment 7  
SECTION  ORIGINAL TEXT  NEW TEXT  
 Note: METEx14Del status to be documented 
according to local institutional standards.  
Assessment in ctDNA by Guardant360 
technology  or equivalent is allowed. Tissue from 
a recent* or newly performed pre -dosing tumor 
biopsy must be submitted for central assessment.  
*Recent tumor biopsy, defined as one performed 
since last documented disease progression as part 
of the site’s usual pract ice, and where no 
intervening antineoplastic therapy has been 
administered; otherwise tissue from a newly 
performed biopsy must be obtained and 
submitted.  
 
 May have received prior therapy with MET -
targeting and/or EGFR -targeting agents 
(antibodies or TKIs)  
 Willingness to undergo a pre -dosing biopsy 
(mandatory unless a recent* tumor biopsy as 
defined above is available), and potentially a 
biopsy at the EOC2 (optional), from a primary or 
metastatic tumor site considered safely accessible 
for biopsy  
Note: Peri pheral blood for ctDNA analysis by Guardant 
360 will be obtained for assessment of METEX14Del 
status.   
6.2 Exclusion 
Criteria  2. Part 2 ONLY :  
a. Prior therapy with MET -inhibiting agents  
Note:  Exceptions will be a subset of approximately 6 
patients ente red to the Basket Cohort after having 
received prior therapy with a MET -targeting TKI, and 
patients entered to the NSCLC Cohort who may have 
received prior therapy with a MET -targeting TKI.  
b. Prior therapy with antibody to HGF  
c. Basket Cohort ONLY : Tumor  status  demonstrating 
MET -polysomy in the absence of MET -
amplification, as specified  
Note: Patients in the NSCLC Cohort with polysomy are 
eligible  
d. Radiotherapy against target lesions within 4 weeks 
prior to C1/D1, unless there is documented 
progression  of the lesion following the radiotherapy  
Note: Radiotherapy for pain control against non -target 
lesions is allowed, as long as it does not influence bone 
marrow function  2. Part 2 ONLY :  
a. Basket Cohort :  
 Prior therapy with MET -inhibiting agents Note:  
Exceptions will be a subset of approximately 6 patients 
entered to the Basket Cohort after having received prior 
therapy with a MET -targeting TKI  
 
 Prior therapy with antibody to HGF  
b. Basket Cohort and NSCLC MET -Amplified Cohort : 
Tumor status demonstrating  MET -polysomy in the 
absence of MET -amplification, as specified  
Note: Patients in the NSCLC METEx14Del Cohort with 
polysomy are eligible.   
c. Radiotherapy against target lesions within 4 weeks 
prior to C1/D1, unless there is documented 
progression of the lesion following the radiotherapy  
Note: Radiotherapy for pain control against non -target 
lesions is allowed, as long as it does not influence bone 
marrow function  
3. Immunosuppressive or systemic hormonal therapy 
(> 10 mg daily prednisone equivalent) wit hin 2 weeks 
prior to C1/D1 with the exception of the following 
allowed therapies:  
a. Hormonal therapy … 
b. Nasal, ophthalmic, inhaled … 
c. Oral replacement glucocorticoid … 
d. Low-dose maintenance steroid therapy … 3. Immunosuppressive or systemic hormonal the rapy 
(> 10 mg daily prednisone equivalent) within 2 weeks 
prior to C1/D1 (for exceptions, see Section 7.5.2)  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 160 of 164 Table 22 Protocol Amendment 7  
SECTION  ORIGINAL TEXT  NEW TEXT  
7.5.1 Allowed 
Medication/ 
Therapy and 
Procedures During 
the Trial  Not applicable  Bisphosphonates and denosumab:  Bisphosphonates 
and denosumab for  bone metastases and other skeletal 
conditions provided the patient is on a stable dose for 
at least 2 months prior to study start and remains on the 
stable dose while receiving study treatment  
7.5.2 Prohibited 
Medication/ 
Therapy and 
Procedures During 
the Trial  Not applicable  Basket Cohort ONLY: MET -targeting therapies, 
except in subset of approximately 6 patients  
8.1.2  
Demographics  To include date of birth, sex, race and ethnicity.  To include date of birth, sex,  race and ethnicity (as 
allowed by country)  
8.2.6  Physical 
Examination  To include evaluation of the following: General 
appearance, skin, head, ears, eyes, nose, throat, 
neck/thyroid, chest, cardiovascular system, abdomen, 
musculoskeletal system, lymph nod es, neurologic 
status, and mental status. At Screening, include height 
(without shoes, rounded to nearest centimeter).  To include evaluation of the following at Screening: 
General appearance, skin, head, ears, eyes, nose, 
throat, neck/thyroid, chest, cardi ovascular system, 
abdomen, musculoskeletal system, lymph nodes, 
neurologic status, and mental status; include height 
(without shoes, rounded to nearest centimeter). 
Thereafter, a targeted physical examination may be 
performed as indicated.  
8.3.3 Archival 
Tumor Tissue for 
MET  and KRAS  
Assessment (Part 1 
and Part 2 Basket 
Cohort)  8.3.3 Archival Tumor Tissue for MET  and KRAS  
Assessment  
 
o Part 2: Eligibility assessment for KRAS  mutational  
status…  
Basket Cohort : It is preferred that the eligibility 
assessment for MET -amplification be done … 
 
NSCLC Cohort : Eligibility assessment for METex14  
mutation status … 8.3.3 Archival Tumor Tissue for MET  and KRAS  
Assessment (Part 1 and Part 2 Basket Cohort)  
 
o Part 2:  
Eligibility assessment for KRAS mutational status … 
It is preferred that the eligibility assessment for MET -
amplification be done … 
 
NSCLC METEx14Del Cohort ( pre-protocol v8.0 ): 
Eligibility assessment for METEx14Del status … (applies 
only to patients with METEx14Del tumors entered prior 
to suspension of the Basket  Cohort and establishment 
of NSCLC METEx14Del Cohort).  
8.3.5  Tumor 
Biopsy for MET  
Status and 
Biomarker 
Analysis (Part 2 
NSCLC MET -
Amplified Cohort 
and NSCLC 
METEx14Del Cohort)  Not applicable  To be assessed centrally:  
 Screening (Mandatory)  
Note: It will b e permissible to perform this procedure 
outside the 14 -day screening period, provided informed 
consent for the trial has been obtained  
 
o NSCLC MET -Amplified Cohort : Required; 
tissue from a newly performed pre -dosing 
tumor biopsy must be submitted for centra l 
confirmation of MET -amplification  
(Patients may be entered and treated based on 
local assessment of a recent tumor biopsy [if 
available and performed outside of the 
screening process as part of the site’s usual 
practice] provided no intervening antineop lastic 
therapy has been administered; otherwise tissue 
from a newly performed biopsy must be 
obtained and submitted)  
 
o NSCLC METEx14Del Cohort :  Required; tissue 
from a recent or newly performed pre -dosing 
tumor biopsy must be submitted for central 
assessme nt of METEx14Del  
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 161 of 164 Table 22 Protocol Amendment 7  
SECTION  ORIGINAL TEXT  NEW TEXT  
(Patients may be entered and treated based on 
local institutional standards; alternatively, 
assessment in ctDNA by Guardant360 
technology or equivalent is allowed; a recent [as 
defined above] or newly performed pre -dosing 
biopsy must stil l be submitted ) 
 
 Post-dosing (Optional)  
EOC2 (i.e., coinciding with time of first 
response assessment) or upon PD, whichever 
occurs firs t 
Note: EOC assessments may be performed at any 
time during the week prior to Day 1 of the next cycle, 
including Day 1 o f the next cycle, prior to dosing   
8.7 Blood Sample 
for Genomic and 
Biomarker 
Analyses  8.7 Biomarker Blood Sample  
 
To be performed only after eligibility has been 
confirmed.  
Analysis of all samples taken for pharmacodynamic 
assessments will be performed at a central laboratory. 
A detailed laboratory manual specifying sample 
collection, handling, storage, and shipment will be 
provided to the trial sites.  
 Screening, after confirmation of eligibility  
 End of Cycle 2 (coinciding with time of first 
response as sessment) or upon PD, whichever 
occurs first  
Note: End of cycle assessments may be performed at 
any time during the week prior to Day 1 of the next 
cycle  
 EOT  8.7 Blood Sample for Genomic and Biomarker 
Analyses  
 
To include assessment of MET -amplification a nd 
METEx14Del status; analysis of all samples taken will be 
performed at a central laboratory. A detailed laboratory 
manual specifying sample collection, handling, 
storage, and shipment will be provided to the trial sites.  
 Screening (it will be permissibl e to perform this 
procedure outside the 14 -day screening period, 
provided informed consent for the trial has been 
obtained)  
 EOC2 (coinciding with time of first response 
assessment or upon PD, whichever occurs first)  
 Note: EOC assessments may be performed at any 
time during the week prior to Day 1 of the next 
cycle, including Day 1 of the next cycle, prior to 
dosing  
 EOT (if after EOC2; need not repeat if patient is 
discontinuing at the EOC2 or if a sample was 
obtained upon PD)  
9.3 Serious 
Adverse Event 
Recording and 
Reporting  
 In case of an SAE, the Investigator must, within 24 
hours of first awareness of the event, report the SAE to 
the Sponsor or designee by fax or e -mail. Fax 
number(s) and e -mail address will be stated in the SAE 
report form and the SAE  report form instructions.  In case of an SAE, the Investigator must, within 24 
hours of first awareness of the event, report the SAE to 
the Sponsor (or designee) by fax or e -mail. Fax 
number(s) and e -mail address(es) will be stated on the 
SAE Report Form a nd the SAE Report Form 
Completion Instructions. SAE follow -up information 
must also be reported to the Sponsor (or designee) 
within 24 hours of awareness.  
10.1 Statistical 
Considerations and 
Analysis Plan  
 Not applicable  No formal hypothesis testing is pl anned.  Descriptive 
statistics will be used to summarize the safety, 
tolerability, pharmacokinetics, and clinical activity of 
Sym015 in all patient cohorts.  
Data will be described and summarized as warranted 
by sample sizes.  Listings will be used in place  of 
tables in the event of small sample sizes.  Dose -
escalation assessment will be based on the DLT -
evaluable population, defined as patients who complete 
the DLT assessment window.  All other analyses will 
be based on the safety -evaluable population, defi ned as 
all patients who receive any amount of the study drug.  
Continuous variables will be summarized with the use 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 162 of 164 Table 22 Protocol Amendment 7  
SECTION  ORIGINAL TEXT  NEW TEXT  
of means, standard deviations, medians, and ranges; 
categorical variables will be summarized using counts 
and percentages.  All summaries wil l be presented 
separately by cohort, in both Part 1 and Part 2 of the 
study.  
All details of the data analyses will be described in the 
Statistical Analysis Plan.  
10.2 Sample Size 
Determination  In Part 2 of the trial, the primary endpoint is 
documented OR in the Basket Cohort, assessed by 
RECIST v1.1, at any time during trial participation by 
Investigator assessment. It is planned to include 45 
patients with various advanced solid tumor 
malignancies, documented and confirmed as MET -
amplified and KRAS WT in this cohort. It is expected 
to see a meaningful number of patients with OR, based 
on preclinical data as well as data from other MET -
targeting mAbs presently in clinical development. The 
expected range of OR is in the range of 25 -50%, 
depending on histolog y, previous therapies and other 
prognostic factors defining the enrolled patient 
population. Sample size considerations are based on a 
Simon’s Optimal 2 -stage design (31), testing a null 
hypothesis (poor response) of 11% OR versus an 
alternative hypothesis  (promising response) of 25% 
OR at an approximate 10% 1 -sided significance level 
and 85% power. In Stage 1 (futility assessment) 
enrollment will include 20 evaluable patients for OR 
assessment and accrual will continue to Stage 2, if at 
least 3 of 20 (15%)  patients respond (PR or CR). The 
probability of early stopping assuming poor response is 
about 62%.  In stage 2, if the futility boundary is 
exceeded, an additional 25 patients evaluable for OR 
assessment will be enrolled for a total of 45 patients. 
Furth er development will be considered warranted if at 
least 8 of 45 (18%) patients respond.    
For the NSCLC Cohort, assuming the response rate is 
at least 20%, there is a 74 93% probability of 
observing 1 or more responses in 6 -12 patients.  In Part 2 of the t rial, the primary endpoint is 
documented, confirmed OR assessed by RECIST v1.1, 
at any time during trial participation by Investigator 
assessment. It is planned to include 25 patients with 
various advanced solid tumor malignancies, 
documented and confirmed  as MET -amplified in the 
Basket Cohort, 20 patients in the NSCLC MET -
Amplified Cohort, and 6 -12 patients in the NSCLC 
METEx14Del Cohort, for the total of approximately 51 -
57 patients in Part 2.  
 
No power and type I error considerations were used to 
determ ine the sample size in each cohort. Proposed 
sample sizes in Basket and NSCLC Cohorts should 
allow to obtain preliminary safety, PK, response, and 
pharmacodynamic information of Sym015 in the 
respective patient populations (Table 10).  
The expected (target)  range of OR in any of these three 
cohorts is in the range of 20% -50%, depending on 
histology, previous therapies, and other prognostic 
factors defining the enrolled patient population.  
10.4.2 Part 2  The primary objective of Part 2 is to evaluate the 
antitumor activity of Sym015 when administered at the 
Q2W RP2D. This will be assessed by the primary 
endpoint for Part 2, documented OR in the Basket 
Cohort, defined as documented PR or CR and assessed 
by RECIST v1.1 at any time during trial participation 
by Investigator assessment. The assessment will be 
performed after completion of Part 2 of the trial.  
 
Number and percentages of patients with documented 
OR will be presented including corresponding 95% 
exact Confidence Intervals (CI).  The primary objective of  Part 2 is to evaluate the 
antitumor activity of Sym015 when administered at the 
Q2W RP2D. The primary endpoint is documented, 
confirmed OR, defined as documented PR or CR and 
assessed by RECIST v1.1 at any time during trial 
participation by Investigator a ssessment. The 
assessment will be performed after completion of Part 
2 of the trial.  
 
Number and percentages of patients with documented 
OR will be presented including corresponding 90% 
exact Confidence Intervals (CI), separately for each 
cohort.  
10.5.1  Efficacy 
Endpoints and 
Analyses  Number and percentages of patients with documented 
OR in the dose -escalation part will be presented 
including corresponding 95% exact CI. All 
documented ORs (Part 1 and 2) will be listed including 
duration (in days) of OR, me asured from time of first 
PR or CR to PD.  
 
Time to disease progression (TTP), PFS, and OS will Number and percentages of  patients with documented 
OR in the dose -escalation part will be presented 
including corresponding 90% exact CI. All 
documented ORs (Part 1 and Part 2) will be listed 
including duration (in days) of OR, measured from 
time of first PR or CR to PD.  
 
Time to disease progression (TTP), PFS, and OS will 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 163 of 164 Table 22 Protocol Amendment 7  
SECTION  ORIGINAL TEXT  NEW TEXT  
be summarized using the product -limit method and 
Kaplan -Meier plots. The median TTP, PFS, and OS, 
including 95% CI, will be calculated.  be summarized using the product -limit method and 
Kaplan -Meier plots. The median TTP, PFS, and OS, 
including 90% CI, will be calculated.  
10.6 Interim 
Analysis  All relevant safety and toxicity data will be reviewe d 
on an ongoing base throughout the trial. Refer to 
Section 12.  
During Part 1, clinical and laboratory safety data will 
be assessed when the first patient in a 3 -patient cohort 
has completed the first dose of Sym015, when 3 
patients have completed Cycle 1,  and if the cohort is 
expanded, when 6 patients have completed Cycle 1.  
Based on an overall evaluation of Part 1 of the trial, the 
Q2W RP2D and highest safe dose tested will be 
determined.  
In Part 2 an assessment of futility will be performed 
when 20 patie nts evaluable for OR have been included 
in the Basket Cohort. The trial will be stopped for 
futility if less than 3 of the evaluable patients have 
documented OR.  No interim analysis is planned.  
14. Data Handling 
and Record 
Keeping  Data will be handled acc ording to good data 
management practices and comply with Federal 
regulations including, but not limited to, 21 CFR Part 
11 and ICH GCP E6(R2).  Study data collection, processing, transfer, and 
reporting, as well as handling of study personnel 
information, w ill be done in compliance with ICH 
E6(R2) GCP and all applicable data protection 
regulations, including Regulation (EU) 2016/679 of the 
European Parliament and of the Council of 27 April 
2016 on the protection of natural persons with regard 
to the processi ng of personal data and on the free 
movement of such data (General Data Protection 
Regulation; GDPR).  
14.3 Case Report 
Form  
 The Investigator or designee will be responsible for 
entering trial data in the CRF provided. It is the 
responsibility of the Inve stigator to ensure the accuracy 
of the data entered in the CRF.  
All collected data will be entered into a validated 
database.  Text removed ; section replaced (see below)  
14.3 Data 
Processing  The process of entering or uploading of data from trial 
sites wil l assure the accuracy of data entry into the 
database and include a validation at data entry time 
(real time validation). Entry or electronic transfer of 
other data than those directly from trial sites (e.g. 
imports of laboratory results) will follow the S ponsor 
requirements for data flow and transfer.  
 
The Sponsor or designee will be responsible for data 
processing in accordance with the applicable data 
management SOPs. A Data Management Plan will be 
generated for this trial.  
 
Database lock will occur once  quality control 
procedure, and quality assurance procedures (if 
applicable) have been completed.  
 
The PDF files of the CRFs will be provided to the 
Investigator before access to the CRF is revoked.  A Data Management Plan (DMP) will be prepared for 
this t rial. The Sponsor (or designee) will be responsible 
for data processing in accordance with applicable Data 
Management SOPs and the trial DMP.  
 
Once recorded within the electronic CRF, study data 
will pass through a set of preprogrammed data 
validation chec ks designed to identify inconsistencies 
and other data errors, and will undergo an additional 
study -specific data review process.  Data issues will be 
queried via the electronic data capture (EDC) system 
and query resolutions will be documented.  
 
Entry an d processing of data other than those directly 
recorded on electronic CRFs by trial sites (e.g., imports 
of laboratory results) will follow vendors’ SOPs. 
Transfer of such data from vendors to Sponsor (or 
designee) will be handled according to vendors’ dat a 
transfer SOPs and the Sponsor data transfer 
requirements with full compliance to applicable 
regulations.  
 
Database Lock will occur upon reaching the predefined 
Symphogen  Clinical Trial Protocol  
Trial ID: Sym015 -01 Version 8.0 
 
 
Confidential   Page 164 of 164 Table 22 Protocol Amendment 7  
SECTION  ORIGINAL TEXT  NEW TEXT  
data cut -off for primary analysis and completion of 
Sponsor’s (or designee’s) quality control and quality 
assurance procedures.  
 
Portable Document Format (PDF) files of the 
electronic CRFs will be provided to the Investigator 
upon removal of access to the electronic CRFs.  
14.4 Clinical Trial 
Report  Not applicable  Following study completion, a fina l integrated 
clinical/statistical CTR will be prepared.  
14.5 Compliance 
with the General 
Data Protection 
Regulation  Not applicable  The applicable EU data protection legislation requires 
that parties enter into a written contract if one party 
(data process or) processes personal data on behalf of 
the other party (data controller). This written contract 
must regulate the subject -matter and duration of the 
processing, the nature and purpose of the processing, 
the types of personal data and categories of data 
subjects, as well as the obligations and rights of the 
data controller …  
17 Changes to the 
Final Clinical Trial 
Protocol  Changes to the CTP will not be implemented without 
agreement from the Sponsor and prior review and 
written approval from the HA and IRB /EC, except 
where necessary to eliminate an immediate hazard to 
the patient. No protocol waivers will be allowed.  Changes to the protocol will not be implemented 
without agreement from the Sponsor and prior review 
and written approval from the appropriate Health 
Authority (as indicated) and the IRB/EC, except where 
necessary to eliminate an immediate hazard to the 
patients. No protocol waivers will be allowed.  
Protocol changes to eliminate an apparent hazard to 
trial patients may be implemented by the Inve stigator 
immediately. The Investigator must then, without 
delay, inform the local IRB/EC, and the Sponsor (or 
designee) will immediately notify local governing 
Health Authorities.  
 
 